Apoptotic Anti-IgE Antibodies

ABSTRACT

The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.

RELATION BACK

The invention claims priority under 35 U.S.C. § 119 (e) to U.S. Ser. No.60/896,339, filed Mar. 22, 2007.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to apoptotic anti-IgE antibodies, nucleic acidencoding the same, therapeutic compositions thereof, and their use inthe treatment of IgE-mediated disorders.

2. Description of the Related Art

Allergy refers to certain diseases in which immune responses toenvironmental antigens cause tissue inflammation and organ dysfunction.The clinical features of each allergic disease reflect theimmunologically induced inflammatory response in the organ or tissueinvolved. These features are generally independent of the chemical orphysical properties of the antigen. The diversity of allergic responsesarises from the involvement of different immunological effectorpathways, each of which generates a unique pattern of inflammation.

Allergy is common throughout the world. The predilection for specificdiseases, however, varies among different age groups, sexes and races.The prevalence of sensitivity to specific allergens is determined bothby genetic predilection and by the geographic and cultural factors thatare responsible for exposure to the allergen. A clinical state ofallergy affects only some individuals who encounter each allergen. Theoccurrence of allergic disease on exposure to an allergen requires notonly prior “sensitization” but also other factors that determine thelocalization of the reaction to a particular organ.

A biological process that precedes the disease of allergy upon allergenexposure allergen is induces an immune response known as “sensitization”or the sensitization phase. Once sensitization occurs, an individualdoes not become symptomatic until there is a subsequent exposure to theallergen. The effect of sensitization is also known as immune memory.

One of the primary pathways by which in inflammation is induced isthrough the immunoglobulin E (IgE). IgE plays a central role inallergies by virtue of their role as allergen receptors on the surfaceof mast cells and basophils. IgE antibodies are fixed to the surface ofmast cells and basophils at the Fc portion of the molecule to a highaffinity cell surface receptor, called FcεRI. The allergic reaction isinitiated when the polyvalent allergen molecule binds to antibodies thatare occupying these receptors. The result is a bridging of the FcεRI,which in turn signals intracellularly causing the release and activationof mediators of inflammation: histamine, leukotrienes, chemotacticfactors, platelet-activating factor, and proteinases. These activatedmediators act locally and cause increased vascular permeability,vasodilation, smooth muscle contraction and mucous gland secretion. Suchevents are termed clinically the immediate or early phase, and occurwithin the first 15-30 minutes following allergen exposure. Over thesucceeding 12 hours there is progressive tissue infiltration ofinflammatory cells, proceeding from neutrophils to eosinophils tomononuclear cells in response to other chemical mediators not quitefully understood. This period of time 6-12 hours after allergen exposureis designated the late phase and is characterized by clinicalmanifestations of cellular inflammation. Given that late phasereactions, especially in the lung, occur in the absence of early phasereactions, it is still not entirely understood if the late phasereaction is necessarily IgE mediated.

IgE exists in a membrane bound form and in a secreted form. Thesedistinct forms appear to be splice variants. Previous approaches toachieve therapeutic effect by down regulating IgE targeting primarilythe secreted form (e.g., XOLAIR® omalizumab), so as prevent or disarmfurther “arming” of the immune system. The secreted form of IgE is ashorter form, essentially the Fc region ends at the CH4 domain (FIG. 1),whereas the longer form includes additional C-terminal residuesincluding the peptides encoded by the exons known as M1/M1′ and M2.While some have reported two distinct forms of membrane bound IgE, bothwith and without a 52 amino acid segment known as M1′ [Batista et al.,J. Exp. Med. 184: 2197-2205 (1996)], Applicants were unable to verifythat any membrane bound form lacks this M1′ segment. Conventionaltherapy with anti-IgE antibodies, which bind to the secreted form ofIgE, results in reduction of free serum, but not total serum IgE. Casaleet al., J. Allergy Clin. Immunol 100 (1): 110-121 (1997).

It has further been noted that in the absence of antigen signal, B-cellreceptors (i.e., immunoglobulins) that are cross-linked are prone toapoptosis. Surprisingly, Applicants have found that targeting the M1′segment of IgE with anti-IgE antibodies can result in inducing apoptosisof the B-cell. As the progeny of activated B-cells can result in plasmacells that make and secrete the secreted form of IgE, the depletion ofthe IgE-producing B-cell through apoptosis offers a novel therapeuticapproach to the treatment of allergy.

SUMMARY OF THE INVENTION

The present invention provides for apoptotic anti-IgE antibodies, orfunctional fragments thereof, and for their use in the treatment ofIgE-mediated disorders. The invention further provides for compositionsand methods of inhibiting IgE production and secretion from B-cells. Theinvention further provides compositions and methods of specificallydepleting IgE-producing B-cells, and lowering total serum IgE.

In one embodiment, the invention provides for an anti-IgE/M1′ antibodythat specifically binds the M1′ segment of IgE and which inducesapoptosis in IgE-expressing B-cells. In a specific aspect, the antibodyspecifically depletes IgE-producing B-cells. In another specific aspect,the antibody reduces total serum IgE. In yet another specific aspect,the antibody reduces both total serum and free serum IgE. In a furtherspecific aspect, the serum IgE is allergen-specific. In a still furtherspecific aspect, the antibody binds to IgE that is human, rhesus monkeyand cynomolgus monkey in origin. In a still further specific aspect, theantibody is chimeric. In a still further specific aspect, the antibodyis humanized. In a still further aspect, the antibody is human.

In another embodiment, the invention provides for an anti-IgE/M1′antibody that specifically binds to any one of the M1′ epitopescorresponding to the peptides identified in FIG. 5. In a specificaspect, the antibody specifically binds to the same epitope as the onebound by an antibody selected from the group consisting of: 47H4, 7A6,26A11, 47H4v5, 7A6v1 and 26A11v6. In another specific aspect, theantibody binds to an epitope corresponding to a peptide selected fromthe group consisting of: peptide 4 (SEQ ID NO:8), peptide 5 (SEQ IDNO:9), peptide 7 (SEQ ID NO:11) or peptide 8 (SEQ ID NO:12). In yetanother specific aspect, the antibody binds to peptide 4 (SEQ ID NO:8).

In yet another embodiment, the invention provides for an M1′ epitope ofIgE selected from the group consisting of: peptide 4 (SEQ ID NO:8),peptide 5 (SEQ ID NO:9), peptide 7 (SEQ ID NO:11) or peptide 8 (SEQ IDNO:12). In a specific aspect, the M1′ peptide is peptide 4 (SEQ IDNO:8).

In a further embodiment, the invention provides for an anti-IgE antibodythat specifically binds to an M1′ segment of IgE with a Scatchardbinding affinity to human IgE is equivalent to that of the murineanti-IgE/M1′ antibody 47H4 or humanized variant thereof. In a specificaspect, the affinity is equivalent to the binding affinity of 47H5. Inanother specific aspect, the affinity is between 0.30 and 0.83 nm. Inyet another specific aspect, the affinity is equivalent to the bindingaffinity of 47H4v5. In a further specific aspect, the affinity is about1.5 nm.

In a still further embodiment, the invention provides for ananti-IgE/M1′ antibody comprising the heavy chain and light chain HVRs ofthe antibody appearing in any of FIGS. 6A-6F and FIGS. 20-25. In aspecific aspect, the antibody further comprises the variable regions ofthe heavy and light chains of the antibody sequences appearing in any ofFIGS. 6A-6F and FIGS. 20-25. In another specific aspect, the antibodycomprises the full length heavy and light chains of the antibodiesappearing in any of FIGS. 6A-6F. In yet another specific aspect, theheavy and light chains of the antibody sequences appear in any of FIGS.6A-6F. In a further specific aspect, the antibody is selected from groupconsisting of: 26A11, 26A11 v1-16, 7A6, 7A6v1, 47H4, 47H4v1-6. In astill further specific aspect, the antibody is 47H4v5. In a stillfurther specific aspect, the antibody is afucosylated.

In a still further embodiment, the invention provides for a compositioncomprising an anti-IgE/M1′ antibody comprising the heavy chain and lightchain HVRs of the antibody appearing in any of FIGS. 6A-6F incombination with at least one pharmaceutically acceptable carrier. In aspecific aspect, the antibody is selected from the group consisting of:26A11, 26A11v1-16, 7A6, 7A6v1, 47H4, 47H4v1-6. In another specificaspect, the antibody is 47H4v5. In yet another specific aspect, theantibody is afucosylated.

In a still further embodiment, the invention provides for a compositioncomprising an anti-IgE/M1′ antibody comprising the heavy chain and lightchain HVRs of the antibody appearing in any of FIGS. 8-13 in combinationwith one or more drugs selected from the group consisting of: anti-IgEantibody, antihistamine, bronchodilator, glucocorticoid, NSAID,TNF-antagonist, integrin antagonist, immunosuppressive agent, IL-4antagonist, IL-13 antagonist, dual IL-4/IL-13 antagonist, DMARD,antibody that binds to a B-cell surface marker and BAFF antagonist. In aspecific aspect, the composition further comprises at least onepharmaceutically acceptable carrier.

In a still further embodiment, the invention provides for isolatednucleic acid encoding the heavy chain HVRs of the anti-IgE/M1′ antibodyappearing in any of FIGS. 6A-6F. In a specific aspect, the isolatednucleic acid further comprises nucleic acid encoding the light chainHVRs of the antibody appearing in any of FIGS. 6A-6F. In anotherspecific aspect, the antibody is chimeric. In yet another specificaspect, the antibody is humanized. In a further aspect, the antibody ishuman. In a still further specific aspect, the antibody is selected fromgroup consisting of: 26A11, 26A11v1-16, 7A6, 7A6v1, 47H4, 47H4v1-6. In astill further specific aspect, the antibody is 47H4v5. In a stillfurther specific aspect, the antibody is afucosylated. In a stillfurther aspect, the nucleic acid further comprises a vector suitable forexpression of the nucleic acid. In a still further specific aspect, thevector further comprises a host cell suitable for expression of thenucleic acid. In a still further specific aspect, the host cell is aeukaryotic cell or a prokaryotic cell. In a still further specificaspect, the eukaryotic cell is a mammalian cell, such as Chinese HamsterOvary (CHO).

In a still further embodiment, the invention provides for a process ofmaking an anti-IgE/M1′ antibody, or functional fragment thereof, thatspecifically binds to an M1′ segment of IgE, comprising culturing a hostcell containing nucleic acid encoding such antibody or fragment in aform suitable for expression, under conditions suitable to produce suchantibody or fragment, and recovering the antibody or fragment.

In a still further embodiment, the invention provides an article ofmanufacture comprising a container enclosing a composition disclosedherein and a package insert indicating use for the treatment of anIgE-mediated disorder. In a specific aspect, the article of manufactureis a vial. In another specific aspect, the article of manufacture is apre-filled syringe. In yet another specific aspect, the pre-filledsyringe is further contained within an injection device. In a furtherspecific aspect, the injection device is an auto-injector.

In a still further embodiment, the invention provides for a method ofspecifically depleting IgE-producing B-cells comprising administering atherapeutically effective amount of an anti-IgE/M1′ antibody thatspecifically binds to the M1′ segment of IgE and induces apoptosis inIgE-expressing B-cells. In a specific aspect, the antibody comprises theheavy and light chain HVRs of the antibody appearing in any of FIGS.6A-6F. In another specific aspect, the method reduces total serum IgE.In yet another specific aspect, the method reduces both free serum andtotal serum IgE. In a further specific aspect, the serum IgE isallergen-specific. In a still further specific aspect, the antibody isselected from group consisting of: 26A11, 26A11v1-16, 7A6, 7A6v1, 47H4,47H4v1-6. In a still further specific aspect, the antibody is 47H4v5. Ina still further specific aspect, the antibody has ADCC activity.

In a still further embodiment, the invention provides for a method oftreating an IgE-mediated disorder comprising administering atherapeutically effective amount of an anti-IgE/M1′ antibody that thatspecifically binds to the M1′ segment of IgE and induces apoptosis inIgE-expressing B-cells. In a specific aspect, the antibody specificallydepletes IgE-producing B-cells. In another specific aspect, the antibodyreduces total serum IgE. In yet another specific aspect, the antibodyreduces both total and free IgE. In a further specific aspect, the serumIgE is allergen-specific. In a still further specific aspect, theantibody comprises the heavy and light chain HVRs of the antibodyappearing in any of FIGS. 6A-6F. In a still further specific aspect, theantibody is selected from the group consisting of: 26A11, 26A11v1-16,7A6, 7A6v1, 47H4, 47H4v1-6. In a further specific aspect, the antibodyis 47H4v5. In a still further specific aspect, the antibody has ADCCactivity. In a still further specific aspect, the IgE-mediated disorderis selected from the group consisting of: allergic rhinitis, asthma(e.g., allergic asthma and non-allergic asthma), atopic dermatitis,allergic gastroenteropathy, hypersensitivity (e.g., anaphylaxis,urticaria, food allergies etc.), allergic bronchopulmonaryaspergillosis, parasitic diseases, interstitial cystitis, hyper-IgEsyndrome, ataxia-telangiectasia, Wiskott-Aldrich syndrome, athymiclymphoplasia, IgE myeloma and graft-versus-host reaction. In yet a stillfurther specific aspect, the IgE-mediated disorder is food allergy,anaphylaxis, contact dermatitis and allergic purpura.

In a still further embodiment, the invention provides for a method oftreating an IgE-mediated disorder comprising administering a compositioncomprising a therapeutically effective amount of an anti-IgE/M1′antibody that specifically binds to the M1′ segment of IgE and inducesapoptosis in IgE-expressing B-cells in combination with atherapeutically effective amount of at least one drug selected from thegroup consisting of: anti-IgE antibody, antihistamine, bronchodilator,glucocorticoid, NSAID, decongestant, cough suppressant, analgesic,TNF-antagonist, integrin antagonist, immunosuppressive agent, IL-4antagonist, IL-13 antagonist, dual IL-4/IL-13 antagonist, DMARD,antibody that binds to a B-cell surface marker and BAFF antagonist. In aspecific aspect, the antibody specifically depletes IgE-producingB-cells. In another specific aspect, the antibody reduces total serumIgE. In yet another specific aspect, the antibody reduces both total andfree IgE. In a further specific aspect, the serum IgE isallergen-specific. In a still further specific aspect, the antibodycomprises the heavy and light chain HVRs of the antibody appearing inany of FIGS. 6A-6F. In a still further specific aspect, the antibody isselected from group consisting of: 26A11, 26A11v1-16, 7A6, 7A6v1, 47H4,47H4v1-6. In a still further specific aspect, the antibody is 47H4v5. Ina still further specific aspect, the antibody has ADCC activity.

In a still further embodiment, the invention provides for a method oftreating an IgE-mediated disorder comprising a combined treatmentregimen of administering a therapeutically effective amount of ananti-IgE/M1′ antibody that specifically binds to the M1′ segment of IgEand induces apoptosis in IgE-expressing B-cells, prior to, simultaneouswith or after the administration of a known method of treatment forallergic disorders. In a specific aspect, the combination comprises theadministration of an anti-IgE antibody, antihistamine, a bronchodilator,a glucocorticoid, a non-steroidal anti-inflammatory drug, animmunosuppressant, IL-4 antagonist, IL-13 antagonist, dual IL-4/IL-13antagonist, a decongestant, a cough suppressant or an analgesic. Inanother specific aspect, the anti-IgE/M1′ antibody is administered incombination with a treatment regimen of allergen densitization. In aspecific aspect, the antibody specifically depletes IgE-producingB-cells. In another specific aspect, the antibody reduces total serumIgE. In yet another specific aspect, the antibody reduces both total andfree IgE. In a further specific aspect, the serum IgE isallergen-specific. In a still further specific aspect, the antibodycomprises the heavy and light chain HVRs of the antibody appearing inany of FIGS. 6A-6F. In a still further specific aspect, the antibody isselected from group consisting of: 26A11, 26A11v1-16, 7A6, 7A6v1, 47H4,47H4v1-6. In a still further specific aspect, the antibody is 47H4v5. Ina still further specific aspect, the antibody has ADCC activity.

In a still further embodiment, the invention provides for a method ofpreventing allergen-induced IgE production, comprising administering atherapeutically effective amount of an anti-IgE/M1′ antibody thatspecifically binds to the M1′ segment of IgE and induces apoptosis inIgE-expressing B-cells. In a specific aspect, the antibody comprises theheavy and light chain HVRs of the antibody appearing in any of FIGS.6A-6F. In another specific aspect, the method specifically depletesIgE-producing B-cells. In yet another specific aspect, the methodreduces total serum IgE. In a further another specific aspect, themethod reduces both free serum and total serum IgE. In a still furtherspecific aspect, the serum IgE is allergen-specific. In a still furtherspecific aspect, the antibody is selected from group consisting of:26A11, 26A11v1-16, 7A6, 7A6v1, 47H4, 47H4v1-6. In a still furtherspecific aspect, the antibody is 47H4v5. In a still further specificaspect, the antibody has ADCC activity.

In a still further embodiment, the invention provides for a method ofreducing the allergen-induced IgE production, comprising administering atherapeutically effective amount of an anti-IgE/M1′ antibody thatspecifically binds to the M1′ segment of IgE and induces apoptosis inIgE-expressing B-cells. In a specific aspect, the antibody comprises theheavy and light chain HVRs of the antibody appearing in any of FIGS.6A-6F. In another specific aspect, the method specifically depletesIgE-producing B-cells. In yet another specific aspect, the methodreduces total serum IgE. In a further specific aspect, the methodreduces both free serum and total serum IgE. In a still further specificaspect, the serum IgE is allergen-specific. In a still further specificaspect, the antibody is selected from group consisting of: 26A11,26A11v1-16, 7A6, 7A6v1, 47H4, 47H4v1-6. In a still further specificaspect, the antibody is 47H4v5. In a still further specific aspect, theantibody has ADCC activity.

In a still further embodiment, the invention provides for a compositionuseful for any of the previously described methods.

In a still further embodiment, the invention provides for the use of acomposition for any of the previously described methods.

In a still further embodiment, the invention provides a murine hybridomadeposited at the ATCC on Mar. 21, 2007 with a designation selected fromthe group consisting of: 7A6.18, 1C11.10.20, 47G4.6.2, 47H4.12.10,42H4.6.9, 42A5.20.11, 26A11.6.5, 51D2.22.15, 45C1.6.14, 26B11.3.12,28E9.12.9. In a specific aspect, the invention provides for an antibodysecreted by the deposited hybridoma.

In a still further embodiment, the invention provides for a transgenicanimal that expresses the human M1′ segment of IgE.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-B is an alignment of selected constant chain regions of IgE ofthe human (SEQ ID NO:1, rhesus monkey (SEQ ID NO:2) and cynomolgousmonkey (SEQ ID NO:3). Shown are the approximate locations of the CH2,CH3, CH4, M1′, transmembrane and intracellular domains.

FIGS. 2A-2C are FACS Scatchard plots showing the specificity of thevarious anti-M1′ antibodies. FIG. 2A-1 to 2A-6 shows binding against theshort form of IgE (missing M1′), while FIGS. 2B-1 to 2B-6 show bindingagainst the long form (with M1′). FIGS. 2C-1 to 2C-6 show bindingagainst IgE expressed by U266 cell line. The shaded curve showsfluorescence intensive of control Ab, while unshaded curve showsrelative fluorescence of the tested antibody. FIGS. 2D-F show thebinding specificities of the murine anti-IgE/M1′ antibodies 47H4, 26A 11and 7A6. FIG. 2D shows that 47H4 binds to human, rhesus, and cynoIgE/M1′, but not to IgE lacking M1′. FIG. 2E shows that 47H4 bound toU266, while 26A 1 and 7A6 do not. FIG. 2F shows that 47H4 and 7A6 bindboth Rhesus and Cyno M1′, whereas 26A 11 binds only Rhesus. FIGS. 2G-Ishow the binding specificities of the humanized anti-IgE/M1′ antibodies47H5 v.5, 26A 11v6 and 7A6v1. FIG. 2G shows that all three humanizedvariants 47H4v5, 26A11v6 and 7A6v1 are specific for IgE-M1′, but not IgElacking M1′. FIG. 2H shows that variants 47H4v5 and 26A11v6 (but not7A6v1) bind U266. FIG. 2I shows that 47H4v5 and 7A6v1 bind rhesus andcyno M1′, whereas 26A11v6 only binds rhesus M1′.

FIGS. 3A-L are FACS plots showing the relative binding affinityaffinities of the various anti-M1′ antibodies using the serial dilutionsindicated in FIG. 3M. FIG. 3N shows the relative affinities for eachantibody. FIG. 3O summarizes the affinities of the murine antibodies47H4, 26A 11 and 7A6 as measured by Scatchard analysis against human,Rhesus and Cyno M1′. Unless otherwise indicated, numbers reported aremean averages. FIG. 3P summarizes the affinities of the indicatedhumanized variants of antibodies 47H4 and 26A 11 as measured byScatchard analysis against human, Rhesus and Cyno M1′.

FIGS. 4A-D show a relative binding/blocking study of the anti-M1′antibodies. FIGS. 4A-I to 4A-20 are FACS plots showing antibodies thatblocked or partially blocked binding. FIG. 4B is a two dimensional plotshowing the relative ability to block binding of the other antibodies(partially or fully using a 1:1 molar ratio). FIG. 4C is a twodimensional plot that is more focused on the specifically indicatedantibodies and in which the blocking study was repeated with a molarratio of 10:1. FIG. 4D is a schematic that shows the groupings resultingfrom epitope binding/blocking studies.

FIGS. 5A-C show epitope binding studies performed using 47H4, 7A6 and26A11. FIG. 5A shows the M1′ segment including adjacent N- andC-terminal residues (SEQ ID NO:3), and M1′ peptides 1-5, (SEQ IDNOS:5-19), respectively, used to determine epitope binding. FIGS. 5B and5D show that parent murine antibodies 47H4 binds peptide 4, 7A6 bindspeptides 4 and 5 and 26A11 binds peptides 7 and 8. FIGS. 5C and 5E showthat humanized variants 47H4v5 binds peptide 4, while 7A67v1 bindspeptides 4 and 5, and 26A 11v6 binds peptides 7 and 8, thereby retainingthe epitope specificities of the parent murine antibodies.

FIGS. 6A-F show the variable light and heavy chain sequences of murineantibody 26A11, 7A6 and 47H4 and various humanized variants thereof.Positions are numbered according to Kabat and hypervariable regions thatwere grafted to the variable consenus network (Kappa I for light,subgroup III for heavy chain) are boxed. FIG. 6A shows, relative tohuman kappa I light chain (SEQ ID NO:20), the variable light chain of26A11 (SEQ ID NO:21) and humanized variants 1,4 (SEQ ID NO:22), variants2,5 (SEQ ID NO:23), variants 3,6 (SEQ ID NO:24), variants 13,15 (SEQ IDNO:25) and variants 14,16 (SEQ ID NO:26). FIG. 6B shows, relative tohuman kappa I light chain (SEQ ID NO:20), the variable light chain of7A6 (SEQ ID NO:27) and humanized variant 1 (SEQ ID NO:28). FIG. 6Cshows, relative to human kappa I light chain (SEQ ID NO:20), thevariable light chain of 47H4 (SEQ ID NO:29) and humanized variants 1,3(SEQ ID NO:30) and variants 2, 4-6 (SEQ ID NO:31). FIG. 6D shows,relative to human III heavy chain (SEQ ID NO:32), the variable heavychain of 26A11 (SEQ ID NO:33) and humanized variants 1-3, 13, 14 (SEQ IDNO:34) and variants 4-6, 15, 16 (SEQ ID NO:35). FIG. 6E shows, relativeto human heavy chain (SEQ ID NO:34), the variable heavy chain of 7A6(SEQ ID NO:26) and humanized variant 1 (SEQ ID NO:37). FIG. 6F shows,relative to human III heavy chain (SEQ ID NO:32), the variable heavychain of 47H4 (SEQ ID NO:38), and humanized variants 1,2 (SEQ ID NO:39),variants 3-4 (SEQ ID NO:40), variant 5 (SEQ ID NO:41) and variant 6 (SEQID NO:41).

FIGS. 7A-G show the apoptotic activity of the parental anti-M1′antibodies in IgE-M1′ transfected Daudi cells. FIG. 7A is a FACS plotshowing essentially that IgM is expressed at a higher level than IgE.FIG. 7B shows the effect of crosslinking anti-IgM [F(ab′)₂] antibodiesand application of camptothecin, in inducing apoptosis, respectively.Cells staining positive for annexin, but negative for PI are dying,while cells staining positive for both annexin and PI are dead. FIG. 7Cis a graphical depiction of the total observed apoptosis, in which thelight bar shows the cells annexin-(+) and PI-(−), while the dark barshows annexin-(+) and PI-(+). FIGS. 7D-7G are graphical representationsof anti-M1′-induced apoptosis at concentrations of 25, 10, 1, 0.1, 0.01and 0.001 μg/ml. FIG. 7D shows the results of application of the M1′antibodies of the epitope group A1, including 7A6, 47H4, 47G4, 42A5,42H4 (along with controls MAE-11 and GP120) without crosslinking. FIG.7E shows the results of application of M1′ antibodies of the epitopegroup A2, including 1C11, 26A11, 51D2, 45C1) and epitope group B/C,including 26B11 and 28E9 without crosslinking. FIG. 7F shows epitopegroup A1 with crosslinking, and FIG. 7G shows epitope group A2 and B/Cwith crosslinking.

FIGS. 8A-B show the apoptotic activity of the humanized anti-M1′variants in Daudi cells transfected with IgE-M1′ treated with varioushumanized anti-M1′ antibody variants at concentrations of 25, 10, 1,0.1, 0.01 and 0.001 μg/ml. FIG. 8A shows that humanized variants 47H4v5,26A11v6 and 7A6v1 induce apoptosis in the range of 30-40% at the higherconcentration levels (i.e., 10-25 μg/ml 47H4 and 26A11 variants, 1, 10and 25 μg 7A6 variant). FIG. 8B shows the apoptotic activity of the sameantibody on IgE-M1′ transfected Daudi cells that that are treated in thepresence of goat anti-human IgG F(ab′)2 cross-linking antibody. Allantibodies induced maximum apoptotic levels of 70-90%, with somedecrease in apoptotic activity at high concentrations (e.g., 47H4-yl,-v2, 26A11-yl, -v14). FIG. 8C shows that both wildtype and afucosylated47H4v5 were able to induce apoptosis at similar levels.

FIGS. 9A-B1-2 shows the ability of the murine anti-M1′ antibodies toinduce calcium flux in Daudi-IgE/M1′ cells. FIG. 9A is the controlshowing the effect of anti-IgM and MAE11, while FIG. 9B1-B2 show theeffect of the application of the indicated murine anti-M1′ antibodies.

FIG. 10 shows the ability of humanized anti-IgE/M1′ antibody 47H4 v5 wtand afucosylted variant to induce ADCC. While the wt and afuscosylatedvariants induce similar maximal cytotoxicity, the afucosylated variant(“AF”) was more potent than the wildtype form (EC50 AF 0.83 nM, EC50 wt6.6 nM).

FIG. 11A-11F are full length sequences of the heavy and light chains ofmurine anti-IgE/M1′ antibodies. The variable regions are shown initalics, while the HVRs (hypervariable regions) are underlined. FIG. 11Ashows the heavy and light chains of the murine antibody 7A6 (SEQ ID NOS:43 and 44), respectively. FIG. 11B shows the heavy and light chains ofthe murine antibody 47H4 (SEQ ID NOS: 45 and 46), respectively. FIG. 11Cshows the heavy and light chains of the murine antibody 26A11 (SEQ IDNOS: 47 and 48), respectively. FIG. 11D shows the heavy and light chainsof the murine antibody 45C1 (SEQ ID NOS: 49 and 50), respectively. FIG.11E shows the heavy and light chains of the murine antibody 28E9 (SEQ IDNOS: 51 and 52), respectively. FIG. 11F shows the heavy and light chainsof the murine antibody 1C11 (SEQ ID NOS: 53 and 54), respectively.

FIGS. 12A-I demonstrate the ability of the murine anti-IgE/M1′antibodies to inhibit the production of serum IgE and IgE producingplasma cells in an atopic hu-SCID model. FIG. 12A is a graphicaldepiction of the experimental design. FIGS. 12B-C show that treatmentwith the murine anti-IgE/M1′ antibodies reduced IgE levels by 65-84%.FIGS. 12D-E show the reduction of IgE-producing cells in vivo was19-69%. FIGS. 12F-G show that the levels of other immunoglobulins (e.g.,IgG1-4, IgA, IgM) were relatively unaffected. FIGS. 12H-I show that noreduction in the total number of plasma cells of the spleen wasobserved.

FIGS. 13A-H show the effect of the humanized variant 47H4v5 onimmunoglobulin levels in the atopic hu-SCID model. FIG. 13A is agraphical depiction of the experimental design. FIGS. 13B-D show thatserum IgE was reduced by 79%, and that IgE-producing plama cells werereduced by 75%. FIGS. 13E-F show no reduction in levels of other serumimmunoglobulins. FIGS. 13G-H show no reduction in total plama celllevels, thus demonstrating that 47H4 specifically reduces IgE-producingplasma cells, which are a very small proportion of total plasma cells.

FIGS. 14A-D illustrate the generation of huM1′ knock-in mice. FIG. 14Ashows the location of the M1′ exon on the mouse IgE locus. FIG. 14Bshows a schematic of the recombination in the mouse IgE locus resultingin the creation of the target allele. FIG. 14C shows PCR genotyping of a668 bp band in wt mice and a 457 bp band in the M1′ knock-ins. FIG. 14Dshows a Southern Blot in which a 7.4 kB HindIII fragment in wt mice,becomes a 3 kB fragment in hu-M1′ knockins, and a 14.1 kB BamHIIIfragment becomes an 18.1 fragment in the hu-M1′ knockin allele. Bothwildtype and heterozygous mice are shown.

FIGS. 15A-I show the ability of the anti-IgE/M1′ antibodies to preventthe generation of IgE in a primary immune response. FIG. 15A isschematic showing the timeline of the experimental design, includingadministration of TNP/OVA and anti-IgE/M1′ antibodies. FIG. 15B is agraph of antigen-specific IgE levels over time and shows that whileantigen-specific IgE levels in control animals (i.e., gp120) reachedpeak levels between days 8 and 14, anti-IgE/M1′ prevented any increase,and measured antigen-specific IgE levels were not significantlydifferent from unimmunized mice. FIGS. 15C-D show that anti-IgE/M1′treatment prevented the increase in antigen-specific serum IgE on days 8and 14, respectively, and was not statistically different fromunimmunized mice (FIG. 15E). FIGS. 15F-I show that levels ofantigen-specific IgG1 were not significantly affected by anti-IgE/M1′through the 28 days of the experiment (except for a modest difference atday 14).

FIGS. 16A-K show the ability of the anti-IgE/M1′ antibodies to preventthe generation of antigen-specific IgE in a memory or secondary immuneresponse. FIG. 16A is a schematic showing the timelines of secondaryboost of TNP-OVA and administration of anti-IgE/M1′ antibodies, whichwas first administered on day 28. FIG. 16B is a graph ofantigen-specific IgE levels over time and shows that secondary IgEresponse to TNP-OVA boost on day 28 is more rapid, peaking after 4 daysrather than 8-9 days in the primary response. FIGS. 16C-D show thatantigen-specific IgE levels in anti-IgE/M1′ treated animals weresignificantly reduced compared to isotype control, 59-65% by day 32 and90-93%% by day 35. FIG. 16E shows that by day 42 (12 days initialadministration of anti-IgE), antigen-specific IgE levels were reduced toa level not statistically different from naïve control mice. FIGS. 16F-Hshow that between days 28 and 49, the administration of anti-IgE/M1′reduced serum IgE levels by 74-84%, and the average daily level ofantigen-specific IgE was also reduced by 74-83%. FIGS. 16I-K show thatlevels of antigen-specific IgG1 were not significantly affected byanti-IgE/M1′.

FIGS. 17A-D illustrate the ability of the anti-IgE/M1′ antibodies topreventatively reduce the production of IgE in response toNippostrongylus brasiliensis (“NB”) infection. FIG. 17A is a schematicshowing the experimental design. Animals were treated three times perweek starting on day 0 through day 21. FIG. 17B shows IgE levels overtime in response to NB infection with anti-IgE/M1′ and controlantibodies. FIGS. 17C-D show that at day 15, anti-IgE/M1′ treatedantimals had reduced serum IgE levels not statistically significant fromuninfected mice.

FIGS. 18A-I illustrate the ability of the anti-IgE/M1′ antibodies tothereby therapeutically treat peak IgE response to Nippostrongylusbrasiliensis (“NB”) infection. FIG. 18A is a schematic showing theexperimental design. Animals were treated three times per week betweendays 11 and 21. FIG. 18B shows IgE levels over time in response to NBinfection with anti-IgE/M1′ and control antibodies. FIG. 18C-D show thatanti-IgE/M1′ reduced serum IgE levels by 82-89% within four days oftreatment. FIG. 18E shows that by day 21 IgE levels in anti-IgE/M1′treated animals by 97-98%, and reached levels not statisticallysignificant from the uninfected control group. FIGS. 18F-G shows thatIgE-producing plasma cells (as quantitated by Elispot) in the lymphnodes and spleen were reduced by 88-94% and 57-66%, respectively. FIGS.18H-I show that total plasma cells (CD138⁺) in both lymph node andspleen increased in all treatment groups compared with uninfected mice,and that treatment with anti-IgE/M1′ did not significantly change thetotal number of plasma cells in either organ. These results demonstratethe ability of anti-IgE/M1′ antibodies to reduce serum IgE levels bydepleting IgE producing cells in vivo.

FIGS. 19A-G illustrate the ability of the anti-IgE/M1′ antibodies totherapeutically treat IgE response occurring late in an infection cycleto Nippostrongylus brasiliensis (“NB”) infection. FIG. 19A is aschematic showing the experimental design in which animals were treatedthree times per week starting at day 40. FIG. 19B shows that peak IgEproduction occurred around day 15 and that all anti-IgE/M1′ antibodiesreduced serum IgE. FIG. 19C-D shows that anti-IgE/M1′ antibody shows asignificant reduction in both absolute and normalized IgE levels,respectively, relative to commencement of treatment. FIGS. 19E-G showthat anti-IgE/M1′ treatment significantly reduced serum IgE levels,compared to the anti-gp120 mIgG1 isotype control between days 48 and 55.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

All references mentioned herein are specifically incorporated byreference.

General Techniques

The practice of the present invention will employ, unless otherwiseindicated, conventional techniques of molecular biology (includingrecombinant techniques), microbiology, cell biology, biochemistry andimmunology, which are within the skill of the art. Such techniques areexplained fully in the literature, such as, Molecular Cloning: ALaboratory Manual, second edition (Sambrook et al., 1989);Oligonucleotide Synthesis (M. J. Gait, ed., 1984); Animal Cell Culture(R. I. Freshney, ed., 1987); Methods in Enzymology (Academic Press,Inc.); Current Protocols in Molecular Biology (F. M. Ausubel et al., eds1987, and periodic updates); PCR: The Polymerase Chain Reaction, (Mulliset al., ed., 1994); A Practical Guide to Molecular Cloning (PerbalBernard V., 1988); Phage Display: A Laboratory Manual (Barbas et al.,2001).

Lymphocyte Development and Activation

The two major types of lymphocytes in humans are T (thymus-derived) andB (bone marrow derived. These cells are derived from hematopoietic stemcells in the bone marrow and fetal liver that have committed to thelymphoid development pathway. The progeny of these stem cells followdivergent pathways to mature into either B or T lymphocytes. HumanB-lymphocyte development takes place entirely within the bone marrow. Tcell, on the other hand, develop from immature precursors that leave themarrow and travel through bloodstream to the thymus, where theyproliferate and differentiate into mature T lymphocytes.

Mature lymphocytes that emerge from the thymus or bone marrow are in aquiescent, or “resting” state, i.e., they are mitotically inactive. Whendispersed into the bloodstream, these “naïve” or “virgin” lymphocytes,travel into various secondary or peripheral lymphoid organs, such as thespleen, lymph nodes or tonsils. Most virgin lymphocytes have aninherently short life span and die without a few days after leaving themarrow or thymus. However, if such a cell receives signals that indicatethe presence of an antigen, they may activate and undergo successiverounds of cell division. Some of the resulting progeny cells then revertto the resting state to become memory lymphocytes—B and T cells that areessentially primed for the next encounter with the stimulating allergen.The other progeny of activated virgin lymphocytes are effector cells,which survive for only a few days, but carry out specific defensiveactivities.

Lymphocyte activation refers to an ordered series of events throughwhich a resting lymphocyte passes as it is stimulated to divide andproduce progeny, some of which become effector cells. A full responseincludes both the induction of cell proliferation (mitogenesis) and theexpression of immunologic functions. Lymphocytes become activated whenspecific ligands bind to receptors on their surfaces. The ligands aredifferent for T cells and B cells, but the resulting intracellularphysiological mechanisms are similar.

While foreign antigens themselves can induce lymphocyte activation,especially large polymeric antigens that cross-linking surfaceimmunoglobulins on B-cells, or other glycoproteins on T-cells. However,most antigens are not polymeric and even when binding directly to theB-cell in large numbers fail to result in activation. B cells areactivated by these more common antigens when they are co-stimulated withnearly activated helper T-lymphocytes. Such stimulation may occur fromlymphokines secreted by the T-cell, but is transmitted most efficientlyby direct contact of the B cell with T-cell surface proteins thatinteract with certain B-cell surface receptors to generate a secondarysignal.

B-Cells

The defining feature of B-cells is the ability to synthesizeimmunoglobulins. Immunoglobulins (Ig) are an extremely diverse family ofproteins made up of related types of polypeptides called heavy chainsand light chains. Each Ig binds specifically with high affinity to itsown specific antigen. Mature B cells can express immunoglobulin in twodifferent forms, each of which serve unique functions. In resting Blymphocytes (virgin or memory) immunoglobulins are expressed only on thecell surface, where they act essentially as membrane-bound receptor forspecific antigens. In contrast, B cell effector cells (plasma cells)secrete immunoglobulin into the surrounding milieu. Such secretedimmunoglobulin retain the ability to recognize and bind (vis-à-vis themembrane-bound form on resting B-cells), and are typically referred toas antibodies.

When an activated B-lymphocyte divides, some of it progeny become memoryB cells, while the remainder differentiate into plasma cells. As plasmacells have a relatively short life span, unless new plasma cells areproduced, the population soon dies out and immunoglobulins are no longersecreted. As a result, activation of B cells typically results in atransient wave of proliferation, followed by a burst of antibodysecretion that increases and then subsides over several days or a fewweeks. B-cells are the primary cell type involved in humoral immunity,or the protective effect mediated through tissue fluids. Because theanti-IgE/M1′ antibodies of the invention actually deplete B-cells,including memory B-cells, they can be used to “reset” memory. Thus theeffect of this could be that the B-cell component that is driving theallergic response in individuals can be attenuation if not eliminated.

T-cells

T lymphocytes do not express immunoglobulins, but, instead detect thepresence of foreign substances by way of surface proteins called T-cellreceptors. These receptors recognize antigens by either direct contactor through influencing the activity of other immune cells. Together withmacrophages, T cells are the primary cell type involved in thecell-mediated immunity.

Unlike B-cells, T-cells can detect foreign substances only in specificcontexts. In particular, T-lymphocytes will recognize a foreign proteinonly if it first cleaved into small peptides, which are then displayedon the surface of a second host cell, called an antigen-presenting cell(APC). May types of host cells can present antigens under someconditions but certain types are more specifically adapted for thispurpose and are particularly important in controlling T-cell activity,and include macrophages and other B-cells. Antigen presentation dependsin part on specific proteins, called major histocompatibility complex(MHC) proteins, on the surface of the presenting cells. Thus, tostimulate cell-mediated immunity, foreign peptides must be presented toT-cells in combination with MHC peptides, and this combination must berecognized by a T-cell receptor.

There are two significant T-cell subsets: cytotoxic T lymphocytes (T_(c)cells or CTLs) and helper T cells (T_(H)) cells, which can roughly beidentified on the basis of cell surface expression of the marker CD8 andCD4. Tc cells are important in viral defense, and can kill virusesdirectly by recognizing certain cell surface expressed viral peptides.T_(H) cells promote proliferation, maturation and immunologic functionof other cell types, e.g., lymphokine secretion to control activities ofB cells, macrophages and cytotoxic T cells. Both virgin and memoryT-lymphocytes ordinarily remain in the resting state, and in this statethey do not exhibit significant helper or cytotoxic activity. Whenactivated, these cells undergo several rounds of mitotic division toproduce daughter cells. Some of these daughter cells return to theresting state as memory cells, but others become effector cells thatactively express helper of cytotoxic activity. These daughter cellsresemble their parents: CD4+ cells can only product CD4+ progeny, whileCD8+ cells yield only CD8+ progeny. Effector T-cells express cellsurface markers that are not expressed on resting T-cells, such as CD25,CD28, CD29, CD40L, transferrin receptors and class II MHC proteins. Whenthe activating stimuli is withdrawn, cytotoxic or helper activitygradually subsides over a period of several days as the effector cellseither die or revert to the resting state.

Similar to B-cell activation, T-lymphocyte responses to most antigensalso require two types of simultaneous stimuli. The first is theantigen, which if appropriately displayed by MHC proteins on anantigen-presenting cell, can be recognized and bound by T-cellreceptors. While this antigen-MHC complex does send a signal to the cellinterior, it is usually insufficient to result in T-cell activation.Full activation, such as occurs with helper T-cells, requirescostimulation with other specific ligands called costimulators that areexpressed on the surface of the antigen-presenting cell. Activation of acytotoxic T cell, on the other hand, generally requires IL-2, a cytokinesecreted by activated helper T cells.

The Immune Response

The three primary functional properties of the mammalian immune systemdistinguishing it from the other body's defenses include: (1)specificity—the ability to recognize and respond or not to respondindividually among a vast number of target molecules, (2)discrimination—the ability to determine self from non-self so as topeacefully coexist with all the innumerable proteins and other organicmaterial, yet still respond vigorously against foreign material that isintroduced to the body, and (3) memory—the ability to be molded byexperience such that subsequent encounters with a particular foreignpathogen will provoke a more rapid and vigorous response than whatoccurred at the initial encounter. Because the IgE antagonists of theinvention induce apoptosis in IgE-bearing B-cells, they are expected toattenuate or even erase immune memory to particular antigens. This isexpected to be of particular benefit when vigorous immune response tocommon allergens is pathological, such as is the case with atopicdisorders.

Virgin lymphocytes are continually released from the primary lymphoidorgans into the periphery, each carrying surface receptors that enableantigen binding. Antigen binding in B cells is mediated throughsurface-bound immunoglobulins, whereas in T-cells it is mediated byT-cell receptors. When virgin lymphocytes are not activated, they diewithin a few days after entering the periphery. Those that are activatedsurvive and proliferate, yielding daughter cells that may then undergofurther cycles of activation and proliferation. The speed and intensityof response to a given antigen is determined largely by clonalselection: the larger the population daughter cells or clones specificto a particular antigen, the greater the number of cell that canrecognize and participate in the immune response. Every immune responseis complex and intricately regulated sequence of events involvingseveral cell types. It is triggered when an immunogen enters the bodyand encounters a specialized class of cells called antigen-presentingcells (APCs). These APCs capture a minute amount of the immunogen anddisplay it in a form that can be recognized by antigen-specific helperT-lymphocytes. The helper T cells then become activated and, in turn,promote activation of other classes of lymphocytes, such as B cells orcytotoxic T cells. The activated lymphocytes then proliferate and carryout their specific effector functions. At each stage in this process,the lymphocytes and APCs communicate with one another through directcontact or by secreting regulatory cytokines.

Exogenous antigens that are captured by an APC undergo a series ofalterations called antigen processing. Such processing, especially ofproteinaceous immunogens involves denaturation and partial proteolyticdigestions, so that the immunogen is cleaved into short peptides. Alimited number of the resulting peptides then associated non-covalentlywith class II MHC proteins and are transported to the APC surface, aprocess known as antigen presentation. A CD4+ helper T lymphocyte thatcomes into direct contact with an APC may become activated, but it willdo so only if it expressed a T-cell receptor protein that can recognizeand bind the particular peptide-MHC complex presented by the APC.

Helper T (T_(H)) cells are the principal orchestrators of the immuneresponse because they are needed for activation of the two otherlymphatic effector cells: cytotoxic T (Tc) cells and antibody secretingplasma cells. T_(H) activation occurs early in an immune response andrequires at least two signals. One signal is provided by binding of theT-cell antigen receptor to the antigenic peptide-MHC complex on the APCsurface that is transmitted through the CD3 protein complex, while thesecond, costimulatory signal through the APC is thought to result frombinding of a separate signal-transmitting protein on the T-cell surfacewith a specific ligand on the APC. One known such interaction is theT-cell protein CD28 and the family of APC surface proteins known as B7.Other surface proteins pairs may also mediate costimulation.

Together, the two signals induce the helper T cell to begin secreting acytokine known as interleukin-2 (IL-2) and also to begin expressingspecific high affinity IL-2 receptors on its surface. IL-2 is a highlypotent mitogenic factor for T-lymphocytes and is essential for theproliferative response of activated T-cells. The effect of IL-2 on thecell from which it is secreted—a phenomenon known as an autocrineeffect. It has further been shown that even if a T-cell has receivedboth signals, it will not proliferate if its own surface IL-2 receptorsare blocked. IL-2 can also act on cells in the immediate vicinity, in aso-called paracrine effect. This effect is especially important toactivate Tc cells, which generally do not produce enough IL-2 tostimulate their own proliferation. In addition to IL-2, activated T_(H)cells secrete other cytokines and promote the growth, differentiation,and functions of B-cells, macrophages and other cell types.

The contact between and APC and an antigen-specific T_(H) cell also haseffect on the APC—one of the most important of which is the release ofIL-1. This cytokine is believed to act in an autocrine manner toincrease surface expression of class II MHC proteins and of variousadhesion molecules thereby strengthening binding of the T_(H) cell andenhancing antigen presentation. At the same time, IL-1 functions in aparacrine manner on the T_(H) cell to promote IL-2 secretion and IL-2receptor expression.

During activation of T_(H) cells in the manner previously described,some B-cells may also have been engaging the immunogen through theirantigen receptors, which are membrane-bound forms of the antibodies thatthey will later secrete. Unlike T-cells, B-cells recognize an immunogenin its free, unprocessed form. Specific antigen binding provides onetype of signal that can lead to B-cell activation. A second type isprovided by activated T_(H) cells, which express proteins that helpactivate the B cell by binding to non-immunoglobulin receptors on itssurface. These T_(H)-derived signals, which act on any B cell regardlessof its antigen specificity, are known as helper factors. These helperfactors include IL-2, IL-4 and IL-6. However, help is more efficientlyachieved through cell-cell contact, which allows proteins on the T-cellsurface to directly contact those on the B cell. The most effect form ofcontact-mediated help occurs when a protein called CD40 ligand (CD40L),which is expressed on T_(H) cells only after they become activated,binds to a protein called CD40 on B cells. In a process known asby-stander activation, contact with an activated B cell can even besufficient to activate resting B cells even though its surfaceimmunoglobulins have not engaged in antigen.

Tc lymphocytes function to eradicate cells that express foreign antigenson their surfaces, such as virus-infected host cells. Most Tc cellsexpress CD8 rather than CD4 and hence recognize antigens in associationwith class I rather than class II MHC proteins. When a somatic cell isinfected by a virus, some immunogenic viral proteins may undergoprocessing within the cell, and the resulting peptides may then appearas surface complexes with class I MHC molecules. These peptide-MHCcomplexes may then be recognized by the T-cell receptor of anantigen-specific clone, providing one of two signals necessary forTc-cell activation. This first signal alone induces high-affinity IL-2receptors on the Tc cell. The second signal is furnished by IL-2secreted from a nearby activated T_(H) lymphocyte. On receiving bothsignals, the activated Tc cell acquires cytotoxic activity, enabling itto kill the cell to which it is bound, as well as any other cellsbearing the same peptide-MHC class I complexes. In some cases, killingoccurs because the Tc releases specific toxins onto the target cell; inothers, the Tc induces the target cell to commit suicide by apoptosis.The activate Tc cell also proliferates, giving rise to additional Tccells with the same antigen specificity.

The IgE/Mast Cell/Mediatory Pathway.

IgE antibodies are fixed to the surface of mast cells and basophils atthe Fc portion of the molecule to a high affinity cell surface receptor,called FcεRI. The allergic reaction is initiated when the polyvalentallergen molecule binds to antibodies that are occupying thesereceptors. The result is a bridging of the FcεRI, which in turn signalsintracellularly causing the release and activation of mediators ofinflammation: histamine, leukotrienes, chemotactic factors,platelet-activating factor, and proteinases. These activated mediatorsact locally and cause increased vascular permeability, vasodilation,smooth muscle contraction and mucous gland secretion. Such events aretermed clinically the immediate or early phase, and occur within thefirst 15-30 minutes following allergen exposure. Over the succeeding 12hours there is progressive tissue infiltration of inflammatory cells,proceeding from neutrophils to eosinophils to mononuclear cells inresponse to other chemical mediators not quite fully understood. Thisperiod of time 6-12 hours after allergen exposure is designated the latephase and is characterized by clinical manifestations of cellularinflammation. Given that late phase reactions, especially in the lungoccur in the absence of early phase reactions, there is still notentirely understood if the late phase reaction is necessarily IgEmediated.

This mechanism is primarily responsible for the anaphylaxis, urticariaand the atopic diseases such as allergic rhinitis, allergic asthma,atopic dermatitis and allergic gastroenteropathy.

The Effector T-Lymphocyte/Lymphokine Pathway

Certain allergic diseases are mediated by allergen reaction with theeffector T-lymphocyte sensitized to the specific allergen from a priorexposure. When allergen is encountered, CD4+ T-cells become activated togenerate lymphokines, which results over the period of several days withthe accumulation of mononuclear cell infiltrate.

I. DEFINITIONS

An “allergen” or “immunogen” is any molecule that can trigger an immuneresponse. As used herein, the term covers either the antigenic moleculeitself, or its source, such as pollen grain, animal dander, insect venomor food product. This is contrasted with the term antigen, which refersto a molecule can be specifically recognized by an immunoglobulin orT-cell receptor. Any foreign substance capable of inducing an immuneresponse is a potential allergen. Many different chemicals of bothnatural and synthetic origin are known to be allergenic. Complex naturalorganic chemicals, especially proteins, are likely to causeantibody-mediated allergy, whereas simple organic compounds, inorganicchemicals, and metals more preferentially cause T-cell mediated allergy.In some cases, the same allergen may be responsible for more than onetype of allergy. Exposure to the allergen may be through inhalation,injection, injection, or skin contact.

The term “antibody” includes monoclonal antibodies (including fulllength antibodies which have an immunoglobulin Fc region), antibodycompositions with polyepitopic specificity, multispecific antibodies(e.g., bispecific antibodies, diabodies, and single-chain molecules, aswell as antibody fragments (e.g., Fab, F(ab′)₂, and Fv). The term“immunoglobulin” (Ig) is used interchangeably with “antibody” herein.

The basic 4-chain antibody unit is a heterotetrameric glycoproteincomposed of two identical light (L) chains and two identical heavy (H)chains. An IgM antibody consists of 5 of the basic heterotetramer unitsalong with an additional polypeptide called a J chain, and contains 10antigen binding sites, while IgA antibodies comprise from 2-5 of thebasic 4-chain units which can polymerize to form polyvalent assemblagesin combination with the J chain. In the case of IgGs, the 4-chain unitis generally about 150,000 daltons. Each L chain is linked to an H chainby one covalent disulfide bond, while the two H chains are linked toeach other by one or more disulfide bonds depending on the H chainisotype. Each H and L chain also has regularly spaced intrachaindisulfide bridges. Each H chain has at the N-terminus, a variable domain(V_(H)) followed by three constant domains (C_(H)) for each of the α andγ chains and four C_(H) domains for μ and ε isotypes. Each L chain hasat the N-terminus, a variable domain (V_(L)) followed by a constantdomain at its other end. The V_(L) is aligned with the V_(H) and theC_(L) is aligned with the first constant domain of the heavy chain(C_(H)1). Particular amino acid residues are believed to form aninterface between the light chain and heavy chain variable domains. Thepairing of a V_(H) and V_(L) together forms a single antigen-bindingsite. For the structure and properties of the different classes ofantibodies, see e.g., Basic and Clinical Immunology, 8th Edition, DanielP. Sties, Abba I. Terr and Tristram G. Parsolw (eds), Appleton & Lange,Norwalk, Conn., 1994, page 71 and Chapter 6.

The L chain from any vertebrate species can be assigned to one of twoclearly distinct types, called kappa and lambda, based on the amino acidsequences of their constant domains. Depending on the amino acidsequence of the constant domain of their heavy chains (CH),immunoglobulins can be assigned to different classes or isotypes. Thereare five classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, havingheavy chains designated α, δ, ε, γ and μ, respectively. The γ and αclasses are further divided into subclasses on the basis of relativelyminor differences in the CH sequence and function, e.g., humans expressthe following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.

An “isolated” antibody is one that has been identified, separated and/orrecovered from a component of its production environment (E.g.,naturally or recombinantly). Preferably, the isolated polypeptide isfree of association with all other components from its productionenvironment. Contaminant components of its production environment, suchas that resulting from recombinant transfected cells, are materials thatwould typically interfere with research, diagnostic or therapeutic usesfor the antibody, and may include enzymes, hormones, and otherproteinaceous or non-proteinaceous solutes. In preferred embodiments,the polypeptide will be purified: (1) to greater than 95% by weight ofantibody as determined by, for example, the Lowry method, and in someembodiments, to greater than 99% by weight; (1) to a degree sufficientto obtain at least 15 residues of N-terminal or internal amino acidsequence by use of a spinning cup sequenator, or (3) to homogeneity bySDS-PAGE under non-reducing or reducing conditions using Coomassie blueor, preferably, silver stain. Isolated antibody includes the antibody insitu within recombinant cells since at least one component of theantibody's natural environment will not be present. Ordinarily, however,an isolated polypeptide or antibody will be prepared by at least onepurification step.

The “variable region” or “variable domain” of an antibody refers to theamino-terminal domains of the heavy or light chain of the antibody. Thevariable domains of the heavy chain and light chain may be referred toas “VH” and “VL”, respectively. These domains are generally the mostvariable parts of the antibody (relative to other antibodies of the sameclass) and contain the antigen binding sites.

The term “variable” refers to the fact that certain segments of thevariable domains differ extensively in sequence among antibodies. The Vdomain mediates antigen binding and defines the specificity of aparticular antibody for its particular antigen. However, the variabilityis not evenly distributed across the entire span of the variabledomains. Instead, it is concentrated in three segments calledhypervariable regions (HVRs) both in the light-chain and the heavy chainvariable domains. The more highly conserved portions of variable domainsare called the framework regions (FR). The variable domains of nativeheavy and light chains each comprise four FR regions, largely adopting abeta-sheet configuration, connected by three HVRs, which form loopsconnecting, and in some cases forming part of, the beta-sheet structure.The HVRs in each chain are held together in close proximity by the FRregions and, with the HVRs from the other chain, contribute to theformation of the antigen binding site of antibodies (see Kabat et al.,Sequences of Immunological Interest, Fifth Edition, National Instituteof Health, Bethesda, Md. (1991)). The constant domains are not involveddirectly in the binding of antibody to an antigen, but exhibit variouseffector functions, such as participation of the antibody inantibody-dependent cellular toxicity.

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a population of substantially homogeneous antibodies,i.e., the individual antibodies comprising the population are identicalexcept for possible naturally occurring mutations and/orpost-translation modifications (e.g., isomerizations, amidations) thatmay be present in minor amounts. Monoclonal antibodies are highlyspecific, being directed against a single antigenic site. In contrast topolyclonal antibody preparations which typically include differentantibodies directed against different determinants (epitopes), eachmonoclonal antibody is directed against a single determinant on theantigen. In addition to their specificity, the monoclonal antibodies areadvantageous in that they are synthesized by the hybridoma culture,uncontaminated by other immunoglobulins. The modifier “monoclonal”indicates the character of the antibody as being obtained from asubstantially homogeneous population of antibodies, and is not to beconstrued as requiring production of the antibody by any particularmethod. For example, the monoclonal antibodies to be used in accordancewith the present invention may be made by a variety of techniques,including, for example, the hybridoma method (e.g., Kohler andMilstein., Nature, 256:495-97 (1975); Hongo et al., Hybridoma, 14 (3):253-260 (1995), Harlow et al., Antibodies: A Laboratory Manual, (ColdSpring Harbor Laboratory Press, 2^(nd) ed. 1988); Hammerling et al., in:Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y.,1981)), recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567),phage-display technologies (see, e.g., Clackson et al., Nature, 352:624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Sidhuet al., J. Mol. Biol. 338(2): 299-310 (2004); Lee et al., J. Mol. Biol.340(5): 1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132 (2004), and technologies for producing human or human-likeantibodies in animals that have parts or all of the human immunoglobulinloci or genes encoding human immunoglobulin sequences (see, e.g., WO1998/24893; WO 1996/34096; WO 1996/33735; WO 1991/10741; Jakobovits etal., Proc. Natl. Acad. Sci. USA 90: 2551 (1993); Jakobovits et al.,Nature 362: 255-258 (1993); Bruggemann et al., Year in Immunol. 7:33(1993); U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126;5,633,425; and 5,661,016; Marks et al., Bio/Technology 10: 779-783(1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature368: 812-813 (1994); Fishwild et al., Nature Biotechnol. 14: 845-851(1996); Neuberger, Nature Biotechnol. 14: 826 (1996); and Lonberg andHuszar, Intern. Rev. Immunol. 13: 65-93 (1995).

The term “naked antibody” refers to an antibody that is not conjugatedto a cytotoxic moiety or radiolabel.

The terms “full-length antibody,” “intact antibody” or “whole antibody”are used interchangeably to refer to an antibody in its substantiallyintact form, as opposed to an antibody fragment. Specifically wholeantibodies include those with heavy and light chains including an Fcregion. The constant domains may be native sequence constant domains(e.g., human native sequence constant domains) or amino acid sequencevariants thereof. In some cases, the intact antibody may have one ormore effector functions.

An “antibody fragment” comprises a portion of an intact antibody,preferably the antigen binding and/or the variable region of the intactantibody. Examples of antibody fragments include Fab, Fab′, F(ab′)₂ andFv fragments; diabodies; linear antibodies (see U.S. Pat. No. 5,641,870,Example 2; Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]);single-chain antibody molecules and multispecific antibodies formed fromantibody fragments.

Papain digestion of antibodies produced two identical antigen-bindingfragments, called “Fab” fragments, and a residual “Fc” fragment, adesignation reflecting the ability to crystallize readily. The Fabfragment consists of an entire L chain along with the variable regiondomain of the H chain (V_(H)), and the first constant domain of oneheavy chain (C_(H)1). Each Fab fragment is monovalent with respect toantigen binding, i.e., it has a single antigen-binding site. Pepsintreatment of an antibody yields a single large F(ab′)₂ fragment whichroughly corresponds to two disulfide linked Fab fragments havingdifferent antigen-binding activity and is still capable of cross-linkingantigen. Fab′ fragments differ from Fab fragments by having a fewadditional residues at the carboxy terminus of the C_(H)1 domainincluding one or more cysteines from the antibody hinge region. Fab′-SHis the designation herein for Fab′ in which the cysteine residue(s) ofthe constant domains bear a free thiol group. F(ab′)₂ antibody fragmentsoriginally were produced as pairs of Fab′ fragments which have hingecysteines between them. Other chemical couplings of antibody fragmentsare also known.

The Fc fragment comprises the carboxy-terminal portions of both H chainsheld together by disulfides. The effector functions of antibodies aredetermined by sequences in the Fc region, the region which is alsorecognized by Fc receptors (FcR) found on certain types of cells.

“Fv” is the minimum antibody fragment which contains a completeantigen-recognition and -binding site. This fragment consists of a dimerof one heavy- and one light-chain variable region domain in tight,non-covalent association. From the folding of these two domains emanatesix hypervariable loops (3 loops each from the H and L chain) thatcontribute the amino acid residues for antigen binding and conferantigen binding specificity to the antibody. However, even a singlevariable domain (or half of an Fv comprising only three HVRs specificfor an antigen) has the ability to recognize and bind antigen, althoughat a lower affinity than the entire binding site.

“Single-chain Fv” also abbreviated as “sFv” or “scFv” are antibodyfragments that comprise the VH and VL antibody domains connected into asingle polypeptide chain. Preferably, the sFv polypeptide furthercomprises a polypeptide linker between the V_(H) and V_(L) domains whichenables the sFv to form the desired structure for antigen binding. For areview of the sFv, see Pluckthun in The Pharmacology of MonoclonalAntibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, NewYork, pp. 269-315 (1994).

“Functional fragments” of the antibodies of the invention comprise aportion of an intact antibody, generally including the antigen bindingor variable region of the intact antibody or the F region of an antibodywhich retains or has modified FcR binding capability. Examples ofantibody fragments include linear antibody, single-chain antibodymolecules and multispecific antibodies formed from antibody fragments.

The term “diabodies” refers to small antibody fragments prepared byconstructing sFv fragments (see preceding paragraph) with short linkers(about 5-10) residues) between the V_(H) and V_(L) domains such thatinter-chain but not intra-chain pairing of the V domains is achieved,thereby resulting in a bivalent fragment, i.e., a fragment having twoantigen-binding sites. Bispecific diabodies are heterodimers of two“crossover” sFv fragments in which the V_(H) and V_(L) domains of thetwo antibodies are present on different polypeptide chains. Diabodiesare described in greater detail in, for example, EP 404,097; WO93/11161; Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448(1993).

The monoclonal antibodies herein specifically include “chimeric”antibodies (immunoglobulins) in which a portion of the heavy and/orlight chain is identical with or homologous to corresponding sequencesin antibodies derived from a particular species or belonging to aparticular antibody class or subclass, while the remainder of thechain(s) is(are) identical with or homologous to corresponding sequencesin antibodies derived from another species or belonging to anotherantibody class or subclass, as well as fragments of such antibodies, solong as they exhibit the desired biological activity (U.S. Pat. No.4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855(1984)). Chimeric antibodies of interest herein include PRIMATIZED®antibodies wherein the antigen-binding region of the antibody is derivedfrom an antibody produced by, e.g., immunizing macaque monkeys with anantigen of interest. As used herein, “humanized antibody” is used asubset of “chimeric antibodies.”

“Humanized” forms of non-human (e.g., murine) antibodies are chimericantibodies that contain minimal sequence derived from non-humanimmunoglobulin. In one embodiment, a humanized antibody is a humanimmunoglobulin (recipient antibody) in which residues from an HVR of therecipient are replaced by residues from an HVR of a non-human species(donor antibody) such as mouse, rat, rabbit or non-human primate havingthe desired specificity, affinity, and/or capacity. In some instances,FR residues of the human immunoglobulin are replaced by correspondingnon-human residues. Furthermore, humanized antibodies may compriseresidues that are not found in the recipient antibody or in the donorantibody. These modifications may be made to further refine antibodyperformance, such as binding affinity. In general, a humanized antibodywill comprise substantially all of at least one, and typically two,variable domains, in which all or substantially all of the hypervariableloops correspond to those of a non-human immunoglobulin sequence, andall or substantially all of the FR regions are those of a humanimmunoglobulin sequence, although the FR regions may include one or moreindividual FR residue substitutions that improve antibody performance,such as binding affinity, isomerization, immunogenicity, etc. The numberof these amino acid substitutions in the FR are typically no more than 6in the H chain, and in the L chain, no more than 3. The humanizedantibody optionally will also comprise at least a portion of animmunoglobulin constant region (Fc), typically that of a humanimmunoglobulin. For further details, see, e.g., Jones et al., Nature321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); andPresta, Curr. Op. Struct. Biol. 2:593-596 (1992). See also, for example,Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998);Harris, Biochem. Soc. Transactions 23:1035-1038 (1995); Hurle and Gross,Curr. Op. Biotech. 5:428-433 (1994); and U.S. Pat. Nos. 6,982,321 and7,087,409.

A “human antibody” is one that possesses an amino-acid sequencecorresponding to that of an antibody produced by a human and/or has beenmade using any of the techniques for making human antibodies asdisclosed herein. This definition of a human antibody specificallyexcludes a humanized antibody comprising non-human antigen-bindingresidues. Human antibodies can be produced using various techniquesknown in the art, including phage-display libraries. Hoogenboom andWinter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol.,222:581 (1991). Also available for the preparation of human monoclonalantibodies are methods described in Cole et al., Monoclonal Antibodiesand Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J.Immunol., 147(1):86-95 (1991). See also van Dijk and van de Winkel,Curr. Opin. Pharmacol., 5: 368-74 (2001). Human antibodies can beprepared by administering the antigen to a transgenic animal that hasbeen modified to produce such antibodies in response to antigenicchallenge, but whose endogenous loci have been disabled, e.g., immunizedxenomice (see, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 regardingXENOMOUSE™ technology). See also, for example, Li et al., Proc. Natl.Acad. Sci. USA, 103:3557-3562 (2006) regarding human antibodiesgenerated via a human B-cell hybridoma technology.

The term “hypervariable region,” “HVR,” or “HV,” when used herein refersto the regions of an antibody-variable domain that are hypervariable insequence and/or form structurally defined loops. Generally, antibodiescomprise six HVRs; three in the VH(H1, H2, H3), and three in the VL (L1,L2, L3). In native antibodies, H3 and L3 display the most diversity ofthe six HVRs, and H3 in particular is believed to play a unique role inconferring fine specificity to antibodies. See, e.g., Xu et al. Immunity13:37-45 (2000); Johnson and Wu in Methods in Molecular Biology 248:1-25(Lo, ed., Human Press, Totowa, N.J., 2003)). Indeed, naturally occurringcamelid antibodies consisting of a heavy chain only are functional andstable in the absence of light chain. See, e.g., Hamers-Casterman etal., Nature 363:446-448 (1993) and Sheriff et al., Nature Struct. Biol.3:733-736 (1996).

A number of HVR delineations are in use and are encompassed herein. TheHVRs that are Kabat complementarity-determining regions (CDRs) are basedon sequence variability and are the most commonly used (Kabat et al.,supra). Chothia refers instead to the location of the structural loops(Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). The AbM HVRsrepresent a compromise between the Kabat CDRs and Chothia structuralloops, and are used by Oxford Molecular's AbM antibody-modelingsoftware. The “contact” HVRs are based on an analysis of the availablecomplex crystal structures. The residues from each of these HVRs arenoted below.

Loop Kabat AbM Chothia Contact L1 L24-L34 L24-L34 L26-L34 L30-L36 L2L50-L56 L50-L56 L50-L56 L46-L55 L3 L89-L97 L89-L97 L91-L96 L89-L96 H1H31-H35B H26-H35B H26-H32 H30-H35B (Kabat Numbering) H1 H31-H35 H26-H35H26-H32 H30-H35 (Chothia Numbering) H2 H50-H65 H50-H58 H53-H56 H47-H58H3 H95-H102 H95-H102 H95-H102 H93-H101

HVRs may comprise “extended HVRs” as follows: 24-36 or 24-34 (L1), 46-56or 50-56 (L2), and 89-97 or 89-96 (L3) in the VL, and 26-35 (H1), 50-65or 47-65 (a preferred embodiment) (H2), and 93-102 (H3) in the VH. Thevariable-domain residues are numbered according to Kabat et al., supra,for each of these extended-HVR definitions.

“Framework” or “FR” residues are those variable-domain residues otherthan the HVR residues as herein defined.

The expression “variable-domain residue-numbering as in Kabat” or“amino-acid-position numbering as in Kabat,” and variations thereof,refers to the numbering system used for heavy-chain variable domains orlight-chain variable domains of the compilation of antibodies in Kabatet al., supra. Using this numbering system, the actual linear amino acidsequence may contain fewer or additional amino acids corresponding to ashortening of, or insertion into, a FR or HVR of the variable domain.For example, a heavy-chain variable domain may include a single aminoacid insert (residue 52a according to Kabat) after residue 52 of H2 andinserted residues (e.g. residues 82a, 82b, and 82c, etc. according toKabat) after heavy-chain FR residue 82. The Kabat numbering of residuesmay be determined for a given antibody by alignment at regions ofhomology of the sequence of the antibody with a “standard” Kabatnumbered sequence.

An “acceptor human framework” for the purposes herein is a frameworkcomprising the amino acid sequence of a VL or VH framework derived froma human immunoglobulin framework or a human consensus framework. Anacceptor human framework “derived from” a human immunoglobulin frameworkor a human consensus framework may comprise the same amino acid sequencethereof, or it may contain pre-existing amino acid sequence changes. Insome embodiments, the number of pre-existing amino acid changes are 10or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 orless, 3 or less, or 2 or less.

A “human consensus framework” is a framework that represents the mostcommonly occurring amino acid residues in a selection of humanimmunoglobulin VL or VH framework sequences. Generally, the selection ofhuman immunoglobulin VL or VH sequences is from a subgroup of variabledomain sequences. Generally, the subgroup of sequences is a subgroup asin Kabat et al., Sequences of Proteins of Immunological Interest, 5^(th)Ed. Public Health Service, National Institutes of Health, Bethesda, Md.(1991). In one embodiment, for the VL, the subgroup is subgroup kappa Ias in Kabat et al., supra. In one embodiment, for the VH, the subgroupis subgroup III as in Kabat et al., supra.

A “VH subgroup III consensus framework” comprises the consensus sequenceobtained from the amino acid sequences in variable heavy subgroup III ofKabat et al., supra. In one embodiment, the VH subgroup III consensusframework amino acid sequence comprises at least a portion or all ofeach of the following sequences: EVQLVESGGGLVQPGGSLRLSCAAS (H1) (SEQ IDNO:55), WVRQAPGKGLEWVA (SEQ ID NO:56)(H2),RFTISRDDSKNTLYLQMNSLRAEDTAVYYCAR (SEQ ID NO:57)(H3), WGQGTLVTVSS (SEQ IDNO:58)(H4).

A “VL subgroup I consensus framework” comprises the consensus sequenceobtained from the amino acid sequences in variable light kappa subgroupI of Kabat et al., supra. In one embodiment, the VH subgroup I consensusframework amino acid sequence comprises at least a portion or all ofeach of the following sequences: DIQMTQSPSSLSASVGDRVTITC (SEQ IDNO:59)(L1), WYQQKPGKAPKLLIY (SEQ ID NO:60)(L2),GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO:61)(L3), FGQGTKVEIKR (SEQ IDNO:62)(L4).

An “amino-acid modification” at a specified position, e.g. of the Fcregion, refers to the substitution or deletion of the specified residue,or the insertion of at least one amino acid residue adjacent thespecified residue. Insertion “adjacent” to a specified residue meansinsertion within one to two residues thereof. The insertion may beN-terminal or C-terminal to the specified residue. The preferred aminoacid modification herein is a substitution.

An “affinity-matured” antibody is one with one or more alterations inone or more HVRs thereof that result in an improvement in the affinityof the antibody for antigen, compared to a parent antibody that does notpossess those alteration(s). In one embodiment, an affinity-maturedantibody has nanomolar or even picomolar affinities for the targetantigen. Affinity-matured antibodies are produced by procedures known inthe art. For example, Marks et al., Bio/Technology 10:779-783 (1992)describes affinity maturation by VH- and VL-domain shuffling. Randommutagenesis of HVR and/or framework residues is described by, forexample: Barbas et al. Proc Nat. Acad. Sci. USA 91:3809-3813 (1994);Schier et al. Gene 169:147-155 (1995); Yelton et al. J. Immunol.155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995);and Hawkins et al., J. Mol. Biol. 226:889-896 (1992).

An antibody that “specifically binds to” or is “specific for” aparticular polypeptide or an epitope on a particular polypeptide is onethat binds to that particular polypeptide or epitope on a particularpolypeptide without substantially binding to any other polypeptide orpolypeptide epitope. For example, the M1′ specific antibodies of thepresent invention are specific to the M1′ extracellular segment of IgEfound on IgE bound on B-cells, but which is not present on secreted IgE.

A “blocking” antibody or an “antagonist” antibody is one that inhibitsor reduces a biological activity of the antigen it binds. In someembodiments, blocking antibodies or antagonist antibodies substantiallyor completely inhibit the biological activity of the antigen. Theapoptotic anti-IgE antibodies of the invention block the activity of IgEin mediating immune response in a manner so as reduce both free serumand total serum IgE.

Antibodies that “induce apoptosis” or are “apoptotic” are those thatinduce programmed cell death as determined by standard apoptosis assays,such as binding of annexin V, fragmentation of DNA, cell shrinkage,dilation of endoplamic reticulum, cell fragmentation, and/or formationof membrane vesicles (called apoptotic bodies). For example, theapoptotic activity of the anti-IgE antibodies of the present inventioncan be showed by staining cells with surface bound IgE with annexin V.

The term “total serum IgE” refers to a total amount of IgE present in asample, including both free or unbound, as well as IgE that is complexedwith a binding partner (E.g., anti-IgE antibody, IgE-bearing B-cell).“Free serum IgE” refers to IgE that is not bound to a binding partner.

The term “allergen-specific IgE” refers to IgE that is specific to aparticular antigen, resulting from an initial exposure to allergen in aprocess known as allergy sensitization, and which binds the surface ofmast cells and basophils and which can result in the activation of mastcells and basophils upon subsequent exposure to the same allergen.Several mitogenic factors in viruses (e.g., Cytomegalovirus—CMV),bacteria (e.g., Staphylococcus), helminths (e.g., Ascaris, Schistosoma)and adjuvant factors in air pollution (e.g., cigarette smoke, and dieselexhaust) stimulate the production of IgE molecules without initiatingany allergen specific IgE-sensitization. Thus, because IgE levels mayelevate in a manner that does not necessarily predispose the host tobecome more susceptible to an IgE-mediated disorder, allergen-specificIgE levels are sometimes used in clinical evaluations.

The term “specifically deplete IgE-producing B-cells” means the abilityto specifically reduce the population of or effectiveness of B-cellsthat specifically secrete IgE (i.e., plasma cells), but that does notsignificantly affect the population or effectiveness of B-cells thatsecrete other immunoglobulins, such as IgG1, IgG2, IgG3, IgG4, IgA andIgM.

The term “solid phase” describes a non-aqueous matrix to which theantibody of the present invention can adhere. Examples of solid phasesencompassed herein include those formed partially or entirely of glass(e.g., controlled pore glass), polysaccharides (e.g., agarose),polyacrylamides, polystyrene, polyvinyl alcohol and silicones. Incertain embodiments, depending on the context, the solid phase cancomprise the well of an assay plate; in others it is a purificationcolumn (e.g., an affinity chromatography column). This term alsoincludes a discontinuous solid phase of discrete particles, such asthose described in U.S. Pat. No. 4,275,149.

Antibody “effector functions” refer to those biological activitiesattributable to the Fc region (a native sequence Fc region or amino acidsequence variant Fc region) of an antibody, and vary with the antibodyisotype. Examples of antibody effector functions include: C1q bindingand complement dependent cytotoxicity; Fc receptor binding;antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and Bcell activation.

“Antibody-dependent cell-mediated cytotoxicity” or ADCC refers to a formof cytotoxicity in which secreted Ig bound onto Fc receptors (FcRs)present on certain cytotoxic cells (e.g., natural killer (NK) cells,neutrophils and macrophages) enable these cytotoxic effector cells tobind specifically to an antigen-bearing target cell and subsequentlykill the target cell with cytotoxins. The antibodies “arm” the cytotoxiccells and are required for killing of the target cell by this mechanism.The primary cells for mediating ADCC, NK cells, express FcγRIII only,whereas monocytes express FcγRI, FcγRII and FcγRIII. Fc expression onhematopoietic cells is summarized in Table 3 on page 464 of Ravetch andKinet, Annu. Rev. Immunol. 9: 457-92 (1991). To assess ADCC activity ofa molecule of interest, an in vitro ADCC assay, such as that describedin U.S. Pat. No. 5,500,362 or 5,821,337 may be performed. Usefuleffector cells for such assays include peripheral blood mononuclearcells (PBMC) and natural killer (NK) cells. Alternatively, oradditionally, ADCC activity of the molecule of interest may be assessedin vivo, e.g., in an animal model such as that disclosed in Clynes etal., PNAS USA 95:652-656 (1998).

Unless indicated otherwise herein, the numbering of the residues in animmunoglobulin heavy chain is that of the EU index as in Kabat et al.,supra. The “EU index as in Kabat” refers to the residue numbering of thehuman IgG1 EU antibody.

The term “Fc region” herein is used to define a C-terminal region of animmunoglobulin heavy chain, including native-sequence Fc regions andvariant Fc regions. Although the boundaries of the Fc region of animmunoglobulin heavy chain might vary, the human IgG heavy-chain Fcregion is usually defined to stretch from an amino acid residue atposition Cys226, or from Pro230, to the carboxyl-terminus thereof. TheC-terminal lysine (residue 447 according to the EU numbering system) ofthe Fc region may be removed, for example, during production orpurification of the antibody, or by recombinantly engineering thenucleic acid encoding a heavy chain of the antibody. Accordingly, acomposition of intact antibodies may comprise antibody populations withall K447 residues removed, antibody populations with no K447 residuesremoved, and antibody populations having a mixture of antibodies withand without the K447 residue. Suitable native-sequence Fc regions foruse in the antibodies of the invention include human IgG1, IgG2, IgG3and IgG4.

“Fc receptor” or “FcR” describes a receptor that binds to the Fc regionof an antibody. The preferred FcR is a native sequence human FcR.Moreover, a preferred FcR is one which binds an IgG antibody (a gammareceptor) and includes receptors of the FcγRI, FcγRII, and FcγRIIIsubclasses, including allelic variants and alternatively spliced formsof these receptors, FcγRII receptors include FcγRIIA (an “activatingreceptor”) and FcγRIIB (an “inhibiting receptor”), which have similaramino acid sequences that differ primarily in the cytoplasmic domainsthereof. Activating receptor FcγRIIA contains an immunoreceptortyrosine-based activation motif (ITAM) in its cytoplasmic domain.Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-basedinhibition motif (ITIM) in its cytoplasmic domain. (see M. Daëron, Annu.Rev. Immunol 15:203-234 (1997). FcRs are reviewed in Ravetch and Kinet,Annu. Rev. Immunol 9: 457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126: 330-41 (1995).Other FcRs, including those to be identified in the future, areencompassed by the term “FcR” herein.

The term “Fc receptor” or “FcR” also includes the neonatal receptor,FcRn, which is responsible for the transfer of maternal IgGs to thefetus. Guyer et al., J. Immunol. 117: 587 (1976) and Kim et al., J.Immunol. 24: 249 (1994). Methods of measuring binding to FcRn are known(see, e.g., Ghetie and Ward, Immunol Today 18: (12): 592-8 (1997);Ghetie et al., Nature Biotechnology 15 (7): 637-40 (1997); Hinton etal., J. Biol. Chem. 279 (8): 6213-6 (2004); WO 2004/92219 (Hinton etal).

Binding to FcRn in vivo and serum half-life of human FcRn high-affinitybinding polypeptides can be assayed, e.g., in transgenic mice ortransfected human cell lines expressing human FcRn, or in primates towhich the polypeptides having a variant Fc region are administered. WO2004/42072 (Presta) describes antibody variants which improved ordiminished binding to FcRs. See also, e.g., Shields et al., J. Biol.Chem. 9(2): 6591-6604 (2001).

“Human effector cells” are leukocytes which express one or more FcRs andperform effector functions. Preferably, the cells express at leastFcγRIII and perform ADCC effector function. Examples of human leukocyteswhich mediate ADCC include peripheral blood mononuclear cells (PBMC),natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils,with PBMCs and MNK cells being preferred. The effector cells may beisolated from a native source, e.g., blood.

“Complement dependent cytotoxicity” or “CDC” refers to the lysis of atarget cell in the presence of complement. Activation of the classicalcomplement pathway is initiated by the binding of the first component ofthe complement system (C1q) to antibodies (of the appropriate subclass)which are bound to their cognate antigen. To assess complementactivation, a CDC assay, e.g., as described in Gazzano-Santoro et al.,J. Immunol. Methods 202: 163 (1996), may be performed.

Polypeptide variants with altered Fc region amino acid sequences andincreased or decreased C1q binding capability are described in U.S. Pat.No. 6,194,551B1 and WO99/51642. The contents of those patentpublications are specifically incorporated herein by reference. See,also, Idusogie et al. J. Immunol. 164: 4178-4184 (2000).

The N-glycosylation site in IgG is at Asn297 in the CH2 domain. Thepresent invention also provides compositions of a CD20-binding,humanized antibody having a Fc region, wherein about 80-100% (andpreferably about 90-99%) of the antibody in the composition comprises amature core carbohydrate structure which lacks fucose, attached to theFc region of the glycoprotein. Such compositions were demonstratedherein to exhibit a surprising improvement in binding to FcγRIIIA(F158), which is not as effective as FcγRIIIA (V158) in interacting withhuman IgG. Thus, the compositions herein are anticipated to be superiorto previously described anti-CD20 antibody compositions, especially fortherapy of human patients who express FcγRIIIA (F158). FcγRIIIA (F158)is more common than FcγRIIIA (V158) in normal, healthy African Americansand Caucasians. See Lehrnbecher et al. Blood 94:4220 (1999). The presentapplication further demonstrates the synergistic increase in FcγRIIIbinding and/or ADCC function that results from combining theglycosylation variations herein with amino acid sequence modification(s)in the Fc region of the glycoprotein.

“Binding affinity” generally refers to the strength of the sum total ofnon-covalent interactions between a single binding site of a molecule(e.g., an antibody) and its binding partner (e.g., an antigen). Unlessindicated otherwise, as used herein, “binding affinity” refers tointrinsic binding affinity that reflects a 1:1 interaction betweenmembers of a binding pair (e.g., antibody and antigen). The affinity ofa molecule X for its partner Y can generally be represented by thedissociation constant (Kd). Affinity can be measured by common methodsknown in the art, including those described herein. Low-affinityantibodies generally bind antigen slowly and tend to dissociate readily,whereas high-affinity antibodies generally bind antigen faster and tendto remain bound longer. A variety of methods of measuring bindingaffinity are known in the art, any of which can be used for purposes ofthe present invention. Specific illustrative and exemplary embodimentsfor measuring binding affinity are described in the following.

In one embodiment, the “Kd” or “Kd value” according to this invention ismeasured by a radiolabeled antigen-binding assay (RIA) performed withthe Fab version of an antibody of interest and its antigen as describedby the following assay. Solution-binding affinity of Fabs for antigen ismeasured by equilibrating Fab with a minimal concentration of(¹²⁵I)-labeled antigen in the presence of a titration series ofunlabeled antigen, then capturing bound antigen with an anti-Fabantibody-coated plate (see, e.g., Chen et al., J. Mol. Biol. 293:865-881(1999)). To establish conditions for the assay, microtiter plates (DYNEXTechnologies, Inc.) are coated overnight with 5 μg/ml of a capturinganti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), andsubsequently blocked with 2% (w/v) bovine serum albumin in PBS for twoto five hours at room temperature (approximately 23° C.). In anon-adsorbent plate (Nunc #269620), 100 pM or 26 pM [¹²⁵I]-antigen aremixed with serial dilutions of a Fab of interest (e.g., consistent withassessment of the anti-VEGF antibody, Fab-12, in Presta et al., CancerRes. 57:4593-4599 (1997)). The Fab of interest is then incubatedovernight; however, the incubation may continue for a longer period(e.g., about 65 hours) to ensure that equilibrium is reached.Thereafter, the mixtures are transferred to the capture plate forincubation at room temperature (e.g., for one hour). The solution isthen removed and the plate washed eight times with 0.1% TWEEN-20™surfactant in PBS. When the plates have dried, 150 μl/well ofscintillant (MICROSCINT-20™; Packard) is added, and the plates arecounted on a TOPCOUNT™ gamma counter (Packard) for ten minutes.Concentrations of each Fab that give less than or equal to 20% ofmaximal binding are chosen for use in competitive binding assays.

According to another embodiment, the Kd is measured by usingsurface-plasmon resonance assays using a BIACORE®-2000 or aBIACORE®-3000 instrument (BIAcore, Inc., Piscataway, N.J.) at 25° C.with immobilized antigen CM5 chips at ˜10 response units (RU). Briefly,carboxymethylated dextran biosensor chips (CM5, BIAcore Inc.) areactivated with N-ethyl-N′-(3-dimethylaminopropyl)-carbodiimidehydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to thesupplier's instructions. Antigen is diluted with 10 mM sodium acetate,pH 4.8, to 5 μg/ml (˜0.2 μM) before injection at a flow rate of 5μl/minute to achieve approximately 10 response units (RU) of coupledprotein. Following the injection of antigen, 1 M ethanolamine isinjected to block unreacted groups. For kinetics measurements, two-foldserial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with0.05% TWEEN 20™ surfactant (PBST) at 25° C. at a flow rate ofapproximately 25 μl/min. Association rates (k_(on)) and dissociationrates (k_(off)) are calculated using a simple one-to-one Langmuirbinding model (BIAcore® Evaluation Software version 3.2) bysimultaneously fitting the association and dissociation sensorgrams. Theequilibrium dissociation constant (Kd) is calculated as the ratiok_(off)/k_(on). See, e.g., Chen et al., J. Mol. Biol. 293:865-881(1999). If the on-rate exceeds 10⁶ M⁻¹ s⁻¹ by the surface-plasmonresonance assay above, then the on-rate can be determined by using afluorescent quenching technique that measures the increase or decreasein fluorescence-emission intensity (excitation=295 nm; emission=340 nm,16 nm band-pass) at 25° C. of a 20 nM anti-antigen antibody (Fab form)in PBS, pH 7.2, in the presence of increasing concentrations of antigenas measured in a spectrometer, such as a stop-flow-equippedspectrophotometer (Aviv Instruments) or a 8000-series SLM-AMINCO™spectrophotometer (ThermoSpectronic) with a stirred cuvette.

An “on-rate,” “rate of association,” “association rate,” or “k_(on)”according to this invention can also be determined as described aboveusing a BIACORE®-2000 or a BIACORE®-3000 system (BIAcore, Inc.,Piscataway, N.J.).

The phrase “substantially reduced,” or “substantially different,” asused herein, denotes a sufficiently high degree of difference betweentwo numeric values (generally one associated with a molecule and theother associated with a reference/comparator molecule) such that one ofskill in the art would consider the difference between the two values tobe of statistical significance within the context of the biologicalcharacteristic measured by said values (e.g., Kd values). The differencebetween said two values is, for example, greater than about 10%, greaterthan about 20%, greater than about 30%, greater than about 40%, and/orgreater than about 50% as a function of the value for thereference/comparator molecule.

The term “substantially similar” or “substantially the same,” as usedherein, denotes a sufficiently high degree of similarity between twonumeric values (for example, one associated with an antibody of theinvention and the other associated with a reference/comparatorantibody), such that one of skill in the art would consider thedifference between the two values to be of little or no biologicaland/or statistical significance within the context of the biologicalcharacteristic measured by said values (e.g., Kd values). The differencebetween said two values is, for example, less than about 50%, less thanabout 40%, less than about 30%, less than about 20%, and/or less thanabout 10% as a function of the reference/comparator value.

“Percent (%) amino acid sequence identity” and “homology” with respectto a peptide, polypeptide or antibody sequence are defined as thepercentage of amino acid residues in a candidate sequence that areidentical with the amino acid residues in the specific peptide orpolypeptide sequence, after aligning the sequences and introducing gaps,if necessary, to achieve the maximum percent sequence identity, and notconsidering any conservative substitutions as part of the sequenceidentity. Alignment for purposes of determining percent amino acidsequence identity can be achieved in various ways that are within theskill in the art, for instance, using publicly available computersoftware such as BLAST, BLAST-2, ALIGN or MEGALIGN™ (DNASTAR) software.Those skilled in the art can determine appropriate parameters formeasuring alignment, including any algorithms needed to achieve maximalalignment over the full length of the sequences being compared. Forpurposes herein, however, % amino acid sequence identity values aregenerated using the sequence comparison computer program ALIGN-2,authored by Genentech, Inc. The source code of ALIGN-2 has been filedwith user documentation in the U.S. Copyright Office, Washington D.C.,20559, where it is registered under U.S. Copyright Registration No.TXU510087. The ALIGN-2 program is publicly available through Genentech,Inc., South San Francisco, Calif. The ALIGN-2 program should be compiledfor use on a UNIX operating system, preferably digital UNIX V4.0D. Allsequence comparison parameters are set by the ALIGN-2 program and do notvary.

In situations where ALIGN-2 is employed for amino acid sequencecomparisons, the % amino acid sequence identity of a given amino acidsequence A to, with, or against a given amino acid sequence B (which canalternatively be phrased as a given amino acid sequence A that has orcomprises a certain % amino acid sequence identity to, with, or againsta given amino acid sequence B) is calculated as follows:

100 times the fraction X/Y

where X is the number of amino acid residues scored as identical matchesby the sequence alignment program ALIGN-2 in that program's alignment ofA and B, and where Y is the total number of amino acid residues in B. Itwill be appreciated that where the length of amino acid sequence A isnot equal to the length of amino acid sequence B, the % amino acidsequence identity of A to B will not equal the % amino acid sequenceidentity of B to A.

Unless specifically stated otherwise, all % amino acid sequence identityvalues used herein are obtained as described in the immediatelypreceding paragraph using the ALIGN-2 computer program.

An “isolated” nucleic acid molecule encoding the antibodies herein is anucleic acid molecule that is identified and separated from at least onecontaminant nucleic acid molecule with which it is ordinarily associatedin the environment in which it was produced. Preferably, the isolatednucleic acid is free of association with all components associated withthe production environment. The isolated nucleic acid molecules encodingthe polypeptides and antibodies herein is in a form other than in theform or setting in which it is found in nature. Isolated nucleic acidmolecules therefore are distinguished from nucleic acid encoding thepolypeptides and antibodies herein existing naturally in cells.

The term “control sequences” refers to DNA sequences necessary for theexpression of an operably linked coding sequence in a particular hostorganism. The control sequences that are suitable for prokaryotes, forexample, include a promoter, optionally an operator sequence, and aribosome binding site. Eukaryotic cells are known to utilize promoters,polyadenylation signals, and enhancers.

Nucleic acid is “operably linked” when it is placed into a functionalrelationship with another nucleic acid sequence. For example, DNA for apresequence or secretory leader is operably linked to DNA for apolypeptide if it is expressed as a preprotein that participates in thesecretion of the polypeptide; a promoter or enhancer is operably linkedto a coding sequence if it affects the transcription of the sequence; ora ribosome binding site is operably linked to a coding sequence if it ispositioned so as to facilitate translation. Generally, “operably linked”means that the DNA sequences being linked are contiguous, and, in thecase of a secretory leader, contiguous and in reading phase. However,enhancers do not have to be contiguous. Linking is accomplished byligation at convenient restriction sites. If such sites do not exist,the synthetic oligonucleotide adaptors or linkers are used in accordancewith conventional practice.

The term “epitope tagged” when used herein refers to a chimericpolypeptide comprising a polypeptide or antibody described herein fusedto a “tag polypeptide”. The tag polypeptide has enough residues toprovide an epitope against which an antibody can be made, yet is shortenough such that it does not interfere with activity of the polypeptideto which it is fused. The tag polypeptide preferably also is fairlyunique so that the antibody does not substantially cross-react withother epitopes. Suitable tag polypeptides generally have at least sixamino acid residues and usually between about 8 and 50 amino acidresidues (preferably, between about 10 and 20 amino acid residues).

As used herein, the term “immunoadhesin” designates antibody-likemolecules which combine the binding specificity of a heterologousprotein (an “adhesion”) with the effector functions of immunoglobulinconstant domains. Structurally, the immunoadhesins comprise a fusion ofan amino acid sequence with the desired binding specificity which isother than the antigen recognition and binding site of an antibody(i.e., is “heterologous”), and an immunoglobulin constant domainsequence. The adhesin part of an immunoadhesin molecule typically is acontiguous amino acid sequence comprising at least the binding site of areceptor or a ligand. The immunoglobulin constant domain sequence in theimmunoadhesin may be obtained from any immunoglobulin, such as IgG-1,IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE,IgD or IgM. The Ig fusions preferably include the substitution of adomain of a polypeptide or antibody described herein in the place of atleast one variable region within an Ig molecule. In a particularlypreferred embodiment, the immunoglobulin fusion includes the hinge, CH2and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. Forthe production of immunoglobulin fusions see also U.S. Pat. No.5,428,130 issued Jun. 27, 1995. For example, useful immunoadhesins assecond medicaments useful for combination therapy herein includepolypeptides that comprise the BLyS-binding portions of a BLyS receptorwithout the transmembrane of BR3, TACI or BCMA is fused to a constantdomain of an immunoglobulin sequence.

A “fusion protein” and a “fusion polypeptide” refer to a polypeptidehaving two portions covalently linked together, where each of theportions is a polypeptide having a different properly. The property maybe a biological property, such as activity in vitro or in vivo. Theproperty may also be simple chemical or physical property, such asbinding to a target molecule, catalysis of a reaction, etc. The twoportions may be linked directly by a single peptide bond or through apeptide linker will be in reading frame with each other.

A “stable” formulation is one in which the protein therein essentiallyretains its physical and chemical stability and integrity upon storage.Various analytical techniques for measuring protein stability areavailable in the art and are reviewed in Peptide and Protein DrugDelivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, N.Y.,Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993).Stability can be measured at a selected temperature for a selected timeperiod. For rapid screening, the formulation may be kept at 40° C. for 2weeks to 1 month, at which time stability is measured. Where theformulation is to be stored at 2-8° C., generally the formulation shouldbe stable at 30° C. or 40° C. for at least 1 month and/or stable at 2-8°C. for at least 2 years. Where the formulation is to be stored at 30°C., generally the formulation should be stable for at least 2 years at30° C. and/or stable at 40° C. for at least 6 months. For example, theextent of aggregation during storage can be used as an indicator ofprotein stability. Thus, a “stable” formulation may be one wherein lessthan about 10% and preferably less than about 5% of the protein arepresent as an aggregate in the formulation. In other embodiments, anyincrease in aggregate formation during storage of the formulation can bedetermined.

A “reconstituted” formulation is one which has been prepared bydissolving a lyophilized protein or antibody formulation in a diluentsuch that the protein is dispersed throughout. The reconstitutedformulation is suitable for administration (e.g. parenteraladministration) to a patient to be treated with the protein of interestand, in certain embodiments of the invention, may be one which issuitable for subcutaneous administration.

An “isotonic” formulation is one which has essentially the same osmoticpressure as human blood. Isotonic formulations will generally have anosmotic pressure from about 250 to 350 mOsm. The term “hypotonic”describes a formulation with an osmotic pressure below that of humanblood. Correspondingly, the term “hypertonic” is used to describe aformulation with an osmotic pressure above that of human blood.Isotonicity can be measured using a vapor pressure or ice-freezing typeosmometer, for example. The formulations of the present invention arehypertonic as a result of the addition of salt and/or buffer.

“Carriers” as used herein include pharmaceutically acceptable carriers,excipients, or stabilizers that are nontoxic to the cell or mammal beingexposed thereto at the dosages and concentrations employed. Often thephysiologically acceptable carrier is an aqueous pH buffered solution.Examples of physiologically acceptable carriers include buffers such asphosphate, citrate, and other organic acids; antioxidants includingascorbic acid; low molecular weight (less than about 10 residues)polypeptide; proteins, such as serum albumin, gelatin, orimmunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone;amino acids such as glycine, glutamine, asparagine, arginine or lysine;monosaccharides, disaccharides, and other carbohydrates includingglucose, mannose, or dextrins; chelating agents such as EDTA; sugaralcohols such as mannitol or sorbitol; salt-forming counterions such assodium; and/or nonionic surfactants such as TWEEN™, polyethylene glycol(PEG), and PLURONICS™.

A “package insert” refers to instructions customarily included incommercial packages of medicaments that contain information about theindications customarily included in commercial packages of medicamentsthat contain information about the indications, usage, dosage,administration, contraindications, other medicaments to be combined withthe packaged product, and/or warnings concerning the use of suchmedicaments, etc.

A “pharmaceutically acceptable acid” includes inorganic and organicacids which are non toxic at the concentration and manner in which theyare formulated. For example, suitable inorganic acids includehydrochloric, perchloric, hydrobromic, hydroiodic, nitric, sulfuric,sulfonic, sulfinic, sulfanilic, phosphoric, carbonic, etc. Suitableorganic acids include straight and branched-chain alkyl, aromatic,cyclic, cycloaliphatic, arylaliphatic, heterocyclic, saturated,unsaturated, mono, di- and tri-carboxylic, including for example,formic, acetic, 2-hydroxyacetic, trifluoroacetic, phenylacetic,trimethylacetic, t-butyl acetic, anthranilic, propanoic,2-hydroxypropanoic, 2-oxopropanoic, propandioic, cyclopentanepropionic,cyclopentane propionic, 3-phenylpropionic, butanoic, butandioic,benzoic, 3-(4-hydroxybenzoyl)benzoic, 2-acetoxy-benzoic, ascorbic,cinnamic, lauryl sulfuric, stearic, muconic, mandelic, succinic,embonic, fumaric, malic, maleic, hydroxymaleic, malonic, lactic, citric,tartaric, glycolic, glyconic, gluconic, pyruvic, glyoxalic, oxalic,mesylic, succinic, salicylic, phthalic, palmoic, palmeic, thiocyanic,methanesulphonic, ethanesulphonic, 1,2-ethanedisulfonic,2-hydroxyethanesulfonic, benzenesulphonic, 4-chorobenzenesulfonic,napthalene-2-sulphonic, p-toluenesulphonic, camphorsulphonic,4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic, glucoheptonic,4,4′-methylenebis-3-(hydroxy-2-ene-1-carboxylic acid), hydroxynapthoic.

“Pharmaceutically-acceptable bases” include inorganic and organic baseswhich are non-toxic at the concentration and manner in which they areformulated. For example, suitable bases include those formed frominorganic base forming metals such as lithium, sodium, potassium,magnesium, calcium, ammonium, iron, zinc, copper, manganese, aluminum,N-methylglucamine, morpholine, piperidine and organic nontoxic basesincluding, primary, secondary and tertiary amines, substituted amines,cyclic amines and basic ion exchange resins, [e.g., N(R′)₄ ⁺(where R′ isindependently H or C₁₋₄ alkyl, e.g., ammonium, Tris)], for example,isopropylamine, trimethylamine, diethylamine, triethylamine,tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine,dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine,hydrabamine, choline, betaine, ethylenediamine, glucosamine,methylglucamine, theobromine, purines, piperazine, piperidine,N-ethylpiperidine, polyamine resins and the like. Particularly preferredorganic non-toxic bases are isopropylamine, diethylamine, ethanolamine,trimethamine, dicyclohexylamine, choline, and caffeine.

Additional pharmaceutically acceptable acids and bases useable with thepresent invention include those which are derived from the amino acids,for example, histidine, glycine, phenylalanine, aspartic acid, glutamicacid, lysine and asparagine.

“Pharmaceutically acceptable” buffers and salts include those derivedfrom both acid and base addition salts of the above indicated acids andbases. Specific buffers and/or salts include histidine, succinate andacetate.

A “pharmaceutically acceptable sugar” is a molecule which, when combinedwith a protein of interest, significantly prevents or reduces chemicaland/or physical instability of the protein upon storage. When theformulation is intended to be lyophilized and then reconstituted,“pharmaceutically acceptable sugars” may also be known as a“lyoprotectant”. Exemplary sugars and their corresponding sugar alcoholsinclude: an amino acid such as monosodium glutamate or histidine; amethylamine such as betaine; a lyotropic salt such as magnesium sulfate;a polyol such as trihydric or higher molecular weight sugar alcohols,e.g. glycerin, dextran, erythritol, glycerol, arabitol, xylitol,sorbitol, and mannitol; propylene glycol; polyethylene glycol;PLURONICS®; and combinations thereof. Additional exemplarylyoprotectants include glycerin and gelatin, and the sugars mellibiose,melezitose, raffinose, mannotriose and stachyose. Examples of reducingsugars include glucose, maltose, lactose, maltulose, iso-maltulose andlactulose. Examples of non-reducing sugars include non-reducingglycosides of polyhydroxy compounds selected from sugar alcohols andother straight chain polyalcohols. Preferred sugar alcohols aremonoglycosides, especially those compounds obtained by reduction ofdisaccharides such as lactose, maltose, lactulose and maltulose. Theglycosidic side group can be either glucosidic or galactosidic.Additional examples of sugar alcohols are glucitol, maltitol, lactitoland iso-maltulose. The preferred pharmaceutically-acceptable sugars arethe non-reducing sugars trehalose or sucrose. Pharmaceuticallyacceptable sugars are added to the formulation in a “protecting amount”(e.g. pre-lyophilization) which means that the protein essentiallyretains its physical and chemical stability and integrity during storage(e.g., after reconstitution and storage).

The “dituent” of interest herein is one which is pharmaceuticallyacceptable (safe and non-toxic for administration to a human) and isuseful for the preparation of a liquid formulation, such as aformulation reconstituted after lyophilization. Exemplary diluentsinclude sterile water, bacteriostatic water for injection (BWFI), a pHbuffered solution (e.g. phosphate-buffered saline), sterile salinesolution, Ringer's solution or dextrose solution. In an alternativeembodiment, diluents can include aqueous solutions of salts and/orbuffers.

A “preservative” is a compound which can be added to the formulationsherein to reduce bacterial activity. The addition of a preservative may,for example, facilitate the production of a multi-use (multiple-dose)formulation. Examples of potential preservatives includeoctadecyldimethylbenzyl ammonium chloride, hexamethonium chloride,benzalkonium chloride (a mixture of alkylbenzyldimethylammoniumchlorides in which the alkyl groups are long-chain compounds), andbenzethonium chloride. Other types of preservatives include aromaticalcohols such as phenol, butyl and benzyl alcohol, alkyl parabens suchas methyl or propyl paraben, catechol, resorcinol, cyclohexanol,3-pentanol, and m-cresol. The most preferred preservative herein isbenzyl alcohol.

“Treatment” refers to clinical intervention designed to alter thenatural course of the individual or cell being treated, and can beperformed either for prophylaxis or during the course of clinicalpathology. Desirable effects of treatment include preventing occurrenceor recurrence of disease, preventing metastasis, decreasing the rate ofdisease progression, ameliorating or palliating the disease state, andremission or improved prognosis. In some embodiments, antibodies of theinvention are used to delay development of a disease or disorder. Asubject is successfully “treated”, for example, using the apoptoticanti-IgE antibodies of the invention if one or more symptoms associatedwith an IgE-mediated disorder is mitigated.

An “effective amount” refers to at least an amount effective, at dosagesand for periods of time necessary, to achieve the desired or indicatedeffect, including a therapeutic or prophylactic result.

A “therapeutically effective amount” is at least the minimumconcentration required to effect a measurable improvement or preventionof a particular disorder. A therapeutically effective amount herein mayvary according to factors such as the disease state, age, sex, andweight of the patient, and the ability of the antibody to elicit adesired response in the individual. A therapeutically effective amountis also one in which any toxic or detrimental effects of the antibodyare outweighed by the therapeutically beneficial effects. A“prophylactically effective amount” refers to an amount effective, atthe dosages and for periods of time necessary, to achieve the desiredprophylactic result. Typically but not necessarily, since a prophylacticdose is used in subjects prior to or at the earlier stage of disease,the prophylactically effective amount can be less than thetherapeutically effective amount.

“Chronic” administration refers to administration of the medicament(s)in a continuous as opposed to acute mode, so as to main the initialtherapeutic effect (activity) for an extended period of time.“Intermittent” administration is treatment that is not consecutivelydone without interruption, but rather is cyclic in nature.

“Mammal” for purposes of treatment refers to any animal classified as amammal, including humans, domestic and farm animals, and zoo, sports, orpet animals, such as dogs, horses, rabbits, cattle, pigs, hamsters,gerbils, mice, ferrets, rats, cats, etc. Preferably, the mammal ishuman.

The term “pharmaceutical formulation” refers to a preparation that is insuch form as to permit the biological activity of the active ingredientto be effective, and that contains no additional components that areunacceptably toxic to a subject to which the formulation would beadministered. Such formulations are sterile.

A “sterile” formulation is aseptic or free from all livingmicroorganisms and their spores.

The term “about” as used herein refers to the usual error range for therespective value readily known to the skilled person in this technicalfield.

An “antihistamine” as used herein is an agent that antagonizes thephysiological effect of histamine. The binding of histamine to itsreceptors, H₁ and H₂ results in the characteristic allergic symptoms andeffects or itching, redness, swelling etc. Many antihistamines act byblocking the binding of histamine to its receptors, H1, H2; howeverothers are believed to operate by inhibiting the release of histamine.Examples of antihistamines are chlorpheniramine, diphenhydramine,promethazine, cromolyn sodium, astemizole, azatadine maleate,bropheniramine maleate, carbinoxamine maleate, cetirizine hydrochloride,clemastine fumarate, cyproheptadine hydrochloride, dexbrompheniraminemaleate, dexchlorpheniramine maleate, dimenhydrinate, diphenhydraminehydrochloride, doxylamine succinate, fexofendadine hydrochloride,terphenadine hydrochloride, hydroxyzine hydrochloride, loratidine,meclizine hydrochloride, tripelannamine citrate, tripelennaminehydrochloride, triprolidine hydrochloride.

A “bronchodilator” as used herein, describes agents that antagonize orreverse bronchoconstriction, a physiological event that occurs typicallyin early phase asthmatic reactions resulting in decreased lung capacityand shortness of breath. Example bronchodilators include epinephrine, abroad acting alpha and beta-adrenergic, and the beta-adrenergics,albuterol, pirbuterol, metaproterenol, salmeterol, and isoetharine.Bronchodilation can also be achieved through administration ofxanthines, including aminophylline and theophylline.

A “glucocorticoid” as used herein describes steroidal based agentshaving anti-inflammatory activity. Glucocorticoids are commonly used toattenuate late phase asthmatic reaction. Example glucocorticoids includeprednisone, beclomethasone dipropionate, triamcinolone acetonide,flunisolide, betamethasone, budesonide, dexamethasone, desamehasonetramcinolone, fludrocortisone acetate, flunisolide, fluticasonepropionate, hydrocortisone, prednisolone [including methylprednisolone(e.g., SOLU-MEDROL® methlprednisolone sodium succinate)], andtriamcinolone.

A “non-steroidal anti-inflammatory drug” or “NSAID”, as used hereindescribes agents having anti-inflammatory activity that are notsteroidal based. Example NSAID's include acematacin, acetaminophen,aspirin, azapropazone, benorylate, bromfenac sodium, cyclooxygenase(COX)-2 inhibitors such as GR 253035, MK966, celecoxib (CELEBREX®;4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzene-sulfonamide) and valdecoxib (BEXTRA®), diclofenac, diclofenacretard, diclofenac sodium, diflunisal, etodolac, fenbufen, fenoprofencalcium, flurbiprofen, ibuprofen, ibuprofen retard, indomethacin,ketoprofen, meclofenamate sodium, mefenamic acid, meloxicam (MOBIC®),nabumetone, naproxen, naproxen sodium, oxyphenbutazone, phenylbutzone,piroxicam, sulindac, tenoxicam, tiaprofenic acid, tolmetin, tolmetinsodium, including salts and derivatives thereof, etc.

The term “IgE-mediated disorders” includes atopic disorders, which arecharacterized by a general inherited propensity to respondimmunologically to many common naturally occurring inhaled and ingestedantigens and the continual production of IgE antibodies. Specific atopicdisorders include allergic asthma, allergic rhinitis (conjunctivitis),atopic dermatitis, food allergy, anaphylaxis, contact dermatitis,allergic gastroenteropathy, allergic bronchopulmonary aspergillosis andallergic purpura (Henoch-Schönlein). Atopic patients often have multipleallergies, meaning that they have IgE antibodies to, and symptoms from,many environmental allergens, including seasonal, perennial andoccupational allergens. Example seasonal allergens include pollens(e.g., grass, tree, rye, timothy, ragweed), while example perennialallergens include fungi (e.g., molds, mold spores), feathers, animal(e.g., pet or other animal dander) and insect (e.g., dust mite) debris.Example occupational allergens also include animal (e.g. mice) and plantantigens as well as drugs, detergents, metals and immunoenhancers suchas isocyanates. Non-antigen specific stimuli that can result in anIgE-mediated reaction include infection, irritants such as smoke,combustion fumes, diesel exhaust particles and sulphur dioxide,exercise, cold and emotional stress. Specific hypersensitivity reactionsin atopic and nonatopic individuals with a certain genetic backgroundmay result from exposure to proteins in foods (e.g., legumes, peanuts),venom (e.g., insect, snake), vaccines, hormones, antiserum, enzymes,latex, antibiotics, muscle relaxants, vitamins, cytotoxins, opiates, andpolysaccharides such as dextrin, iron dextran and polygeline.

Other disorders associated with elevated IgE levels, that appear to beIgE-mediated and are treatable with the formulations of this presentinvention include: ataxia-telangiectasia, Churg-Strauss Syndrome,eczema, enteritis, gastroenteropathy, graft-versus-host reaction,hyper-IgE (Job's) syndrome, hypersensitivity (e.g., anaphylactichypersensitivity, candidiasis, vasculitis), IgE myeloma, inflammatorybowel disease (e.g., Crohn's disease, ulcerative colitis, indeterminatecolitis and infectious colitis), mucositis (e.g., oral mucositis,gastrointestinal mucositis, nasal mucositis and proctitis), necrotizingenterocolitis and esophagitis, parasitic diseases (e.g.,trypanosomiasis), hypersensitivity vasculitis, urticaria andWiskott-Aldrich syndrome.

Additionally, disorders that may be treatable by lowering IgE levels,regardless of whether the disorders themselves are associated withelevated IgE, and thus should be considered within the scope of“IgE-mediated disorder” include: Addison's disease (chronicadrenocortical insufficiency), alopecia, hereditary angioedema,anigioedema (Bannister's disease, angioneurotic edema), ankylosingspondylitis, aplastic anemia, arteritis, amyloidosis, immune disorders,such as autoimmune hemolytic anemia, autoimmune oophoritis, autoimmuneorchitis, autoimmune polyendocrine failure, autoimmune hemolytic anemia,autoimmunocytopenia, autoimmune glomerulonephritis, Behcet's disease,bronchitis, Buerger's disease, bullous pemphigoid, Caplan's syndrome(rheumatoid pneumoconiosis), carditis, celiac sprue, Chediak-Higashisyndrome, chronic obstructive lung Disease (COPD), Cogan-Reese syndrome(iridocorneal endothelial syndrome), CREST syndrome, dermatitisherpetiformis (Duhring's disease), diabetes mellitus, eosinophilicfasciitis, eosinophilic nephritis, episcleritis, extrinsic allergicalveolitis, familial paroxysmal polyserositis, Felty's syndrome,fibrosing alveolitis, glomerulonephritis, Goodpasture's syndrome,granulocytopenia, granuloma, granulomatosis, granuloma myositis, Graves'disease, Guillain-Barre syndrome (polyneuritis), Hashimoto's thyroiditis(lymphadenoid goiter), hemochromatosis, histocytosis, hypereosinophilicsyndrome, irritable bowel syndrome, juvenile arthritis, keratitis,leprosy, lupus erythematosus, Lyell's disease, Lyme disease, mixedconnective tissue disease, mononeuritis, mononeuritis multiplex,Muckle-Wells syndrome, mucocutaneous lymphoid syndrome (Kawasaki'sdisease), multicentric reticulohistiocystosis, multiple sclerosis,myasthenia gravis, mycosis fungoides, panninculitis, pemphigoid,pemphigus, pericarditis, polyneuritis, polyarteritis nodoas, psoriasis,psoriatic arthritis, pulmonary arthritis, pulmonary adenomatosis,pulmonary fibrosis, relapsing polychondritis, rheumatic fever,rheumatoid arthritis, rhinosinusitis (sinusitis), sarcoidosis,scleritis, sclerosing cholangitis, serum sickness, Sezary syndrome,Sjögren's syndrome, Stevens-Johnson syndrome, systemic mastocytosis,transplant rejection, thrombocytopenic purpura, thymic alymphoplasia,uveitis, vitiligo, Wegener's granulomatosis.

An “autoimmune disorder” herein is a disease or disorder arising fromand directed against an individual's own tissues or organs or aco-segregation or manifestation thereof or resulting conditiontherefrom. In many of these autoimmune and inflammatory disorders, anumber of clinical and laboratory markers may exist, including, but notlimited to, hypergammaglobulinemia, high levels of autoantibodies,antigen-antibody complex deposits in tissues, benefit fromcorticosteroid or immunosuppressive treatments, and lymphoid cellaggregates in affected tissues. Without being limited to any one theoryregarding B-cell mediated autoimmune disorder, it is believed that Bcells demonstrate a pathogenic effect in human autoimmune diseasesthrough a multitude of mechanistic pathways, including autoantibodyproduction, immune complex formation, dendritic and T-cell activation,cytokine synthesis, direct chemokine release, and providing a nidus forectopic neo-lymphogenesis. Each of these pathways may participate todifferent degrees in the pathology of autoimmune diseases.

“Autoimmune disease” can be an organ-specific disease (i.e., the immuneresponse is specifically directed against an organ system such as theendocrine system, the hematopoietic system, the skin, thecardiopulmonary system, the gastrointestinal and liver systems, therenal system, the thyroid, the ears, the neuromuscular system, thecentral nervous system, etc.) or a systemic disease that can affectmultiple organ systems (for example, systemic lupus erythematosus (SLE),rheumatoid arthritis (RA), polymyositis, etc.). Preferred such diseasesinclude autoimmune rheumatologic disorders (such as, for example, RA,Sjögren's syndrome, scleroderma, lupus such as SLE and lupus nephritis,polymyositis-dermatomyositis, cryoglobulinemia, anti-phospholipidantibody syndrome, and psoriatic arthritis), autoimmune gastrointestinaland liver disorders (such as, for example, inflammatory bowel diseases(e.g., ulcerative colitis and Crohn's disease), autoimmune gastritis andpernicious anemia, autoimmune hepatitis, primary biliary cirrhosis,primary sclerosing cholangitis, and celiac disease), vasculitis (suchas, for example, ANCA-negative vasculitis and ANCA-associatedvasculitis, including Churg-Strauss vasculitis, Wegener'sgranulomatosis, and microscopic polyangiitis), autoimmune neurologicaldisorders (such as, for example, multiple sclerosis, opsoclonusmyoclonus syndrome, myasthenia gravis, neuromyelitis optica, Parkinson'sdisease, Alzheimer's disease, and autoimmune polyneuropathies), renaldisorders (such as, for example, glomerulonephritis, Goodpasture'ssyndrome, and Berger's disease), autoimmune dermatologic disorders (suchas, for example, psoriasis, urticaria, hives, pemphigus vulgaris,bullous pemphigoid, and cutaneous lupus erythematosus), hematologicdisorders (such as, for example, thrombocytopenic purpura, thromboticthrombocytopenic purpura, post-transfusion purpura, and autoimmunehemolytic anemia), atherosclerosis, uveitis, autoimmune hearing diseases(such as, for example, inner ear disease and hearing loss), Behcet'sdisease, Raynaud's syndrome, organ transplant, and autoimmune endocrinedisorders (such as, for example, diabetic-related autoimmune diseasessuch as insulin-dependent diabetes mellitus (IDDM), Addison's disease,and autoimmune thyroid disease (e.g., Graves' disease and thyroiditis)).More preferred such diseases include, for example, RA, ulcerativecolitis, ANCA-associated vasculitis, lupus, multiple sclerosis,Sjögren's syndrome, Graves' disease, IDDM, pernicious anemia,thyroiditis, and glomerulonephritis.

The term “cytotoxic agent” as used herein refers to a substance thatinhibits or prevents the function of cells and/or causes destruction ofcells. The term includes radioactive isotopes (eg. At²¹¹, I¹³¹, I¹²⁵,Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³² and radioactive isotopes of Lu),and toxins such as small-molecule toxins or enzymatically active toxinsof bacterial, fungal, plant or animal origin, or fragments thereof.

A “chemotherapeutic agent” is a chemical compound useful in thetreatment of cancer. Examples of chemotherapeutic agents includealkylating agents such as thiotepa and cyclophosphamide (CYTOXAN®);alkyl sulfonates such as busulfan, improsulfan, and piposulfan;aziridines such as benzodopa, carboquone, meturedopa, and uredopa;ethylenimines and methylamelamines including altretamine,triethylenemelamine, trietylenephosphoramide,triethiylenethiophosphoramide and trimethylolomelamine; acetogenins(especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol(dronabinol, MARINOL®); beta-lapachone; lapachol; colchicines; betulinicacid; a camptothecin (including the synthetic analogue topotecan(HYCAMTIN®), CPT-11 (irinotecan, CAMPTOSAR®), acetylcamptothecin,scopolectin, and 9-aminocamptothecin); bryostatin; pemetrexed;callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesinsynthetic analogues); podophyllotoxin; podophyllinic acid; teniposide;cryptophycins (particularly cryptophycin 1 and cryptophycin 8);dolastatin; duocarmycin (including the synthetic analogues, KW-2189 andCB1-TM1); eleutherobin; pancratistatin; TLK-286; CDP323, an oral alpha-4integrin inhibitor; a sarcodictyin; spongistatin; nitrogen mustards suchas chlorambucil, chlornaphazine, cholophosphamide, estramustine,ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride,melphalan, novembichin, phenesterine, prednimustine, trofosfamide,uracil mustard; nitrosureas such as carmustine, chlorozotocin,fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such asthe enediyne antibiotics (e.g., calicheamicin, especially calicheamicingamma1I and calicheamicin omega1I (see, e.g., Nicolaou et al., Angew.Chem. Intl. Ed. Engl., 33: 183-186 (1994)); dynemicin, includingdynemicin A; an esperamicin; as well as neocarzinostatin chromophore andrelated chromoprotein enediyne antibiotic chromophores), aclacinomysins,actinomycin, authramycin, azaserine, bleomycins, cactinomycin,carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin,daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin(including ADRIAMYCIN®, morpholino-doxorubicin,cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, doxorubicin HClliposome injection (DOXIL®) and deoxydoxorubicin), epirubicin,esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C,mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin,puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin,tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such asmethotrexate, gemcitabine (GEMZAR®), tegafur (UFTORAL®), capecitabine(XELODA®), an epothilone, and 5-fluorouracil (5-FU); folic acidanalogues such as denopterin, methotrexate, pteropterin, trimetrexate;purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine,thioguanine; pyrimidine analogs such as ancitabine, azacitidine,6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine,enocitabine, floxuridine, and imatinib (a 2-phenylaminopyrimidinederivative), as well as other c-Kit inhibitors; anti-adrenals such asaminoglutethimide, mitotane, trilostane; folic acid replenisher such asfrolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinicacid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate;defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate;etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine;maytansinoids such as maytansine and ansamitocins; mitoguazone;mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet;pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; PSK®polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane;rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone;2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin,verracurin A, roridin A and anguidine); urethan; vindesine (ELDISINE®,FILDESIN®); dacarbazine; mannomustine; mitobronitol; mitolactol;pipobroman; gacytosine; arabinoside (“Ara-C”); thiotepa; taxoids, e.g.,paclitaxel (TAXOL®), albumin-engineered nanoparticle formulation ofpaclitaxel (ABRAXANE™), and doxetaxel (TAXOTERE®); chloranbucil;6-thioguanine; mercaptopurine; methotrexate; platinum analogs such ascisplatin and carboplatin; vinblastine (VELBAN®); platinum; etoposide(VP-16); ifosfamide; mitoxantrone; vincristine (ONCOVIN®); oxaliplatin;leucovovin; vinorelbine (NAVELBINE®); novantrone; edatrexate;daunomycin; aminopterin; ibandronate; topoisomerase inhibitor RFS 2000;difluoromethylornithine (DMFO); retinoids such as retinoic acid;pharmaceutically acceptable salts, acids or derivatives of any of theabove; as well as combinations of two or more of the above such as CHOP,an abbreviation for a combined therapy of cyclophosphamide, doxorubicin,vincristine, and prednisolone, and FOLFOX, an abbreviation for atreatment regimen with oxaliplatin (ELOXATIN™) combined with 5-FU andleucovovin.

Also included in this definition are anti-hormonal agents that act toregulate, reduce, block, or inhibit the effects of hormones that canpromote the growth of cancer, and are often in the form of systemic, orwhole-body treatment. They may be hormones themselves. Examples includeanti-estrogens and selective estrogen receptor modulators (SERMs),including, for example, tamoxifen (including NOLVADEX® tamoxifen),raloxifene (EVISTA®), droloxifene, 4-hydroxytamoxifen, trioxifene,keoxifene, LY117018, onapristone, and toremifene (FARESTON®);anti-progesterones; estrogen receptor down-regulators (ERDs); estrogenreceptor antagonists such as fulvestrant (FASLODEX®); agents thatfunction to suppress or shut down the ovaries, for example, leutinizinghormone-releasing hormone (LHRH) agonists such as leuprolide acetate(LUPRON® and ELIGARD®), goserelin acetate, buserelin acetate andtripterelin; anti-androgens such as flutamide, nilutamide andbicalutamide; and aromatase inhibitors that inhibit the enzymearomatase, which regulates estrogen production in the adrenal glands,such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrolacetate (MEGASE®), exemestane (AROMASIN®), formestanie, fadrozole,vorozole (RIVISOR®), letrozole (FEMARA®), and anastrozole (ARIMIDEX®).In addition, such definition of chemotherapeutic agents includesbisphosphonates such as clodronate (for example, BONEFOS® or OSTAC®),etidronate (DIDROCAL®), NE-58095, zoledronic acid/zoledronate (ZOMETA®),alendronate (FOSAMAX®), pamidronate (AREDIA®), tiludronate (SKELID®), orrisedronate (ACTONEL®); as well as troxacitabine (a 1,3-dioxolanenucleoside cytosine analog); anti-sense oligonucleotides, particularlythose that inhibit expression of genes in signaling pathways implicatedin abherant cell proliferation, such as, for example, PKC-alpha, Raf,H-Ras, and epidermal growth factor receptor (EGF-R); vaccines such asTHERATOPE® vaccine and gene therapy vaccines, for example, ALLOVECTIN®vaccine, LEUVECTIN® vaccine, and VAXID® vaccine; topoisomerase 1inhibitor (e.g., LURTOTECAN®); an anti-estrogen such as fulvestrant; aKit inhibitor such as imatinib or EXEL-0862 (a tyrosine kinaseinhibitor); EGFR inhibitor such as erlotinib or cetuximab; an anti-VEGFinhibitor such as bevacizumab; arinotecan; rmRH (e.g., ABARELIX®);lapatinib and lapatinib ditosylate (an ErbB-2 and EGFR dual tyrosinekinase small-molecule inhibitor also known as GW572016); 17AAG(geldanamycin derivative that is a heat shock protein (Hsp) 90 poison),and pharmaceutically acceptable salts, acids or derivatives of any ofthe above.

A “growth-inhibitory agent” refers to a compound or composition thatinhibits growth of a cell, which growth depends on receptor activationeither in vitro or in vivo. Thus, the growth-inhibitory agent includesone that significantly reduces the percentage of receptor-dependentcells in S phase. Examples of growth-inhibitory agents include agentsthat block cell-cycle progression (at a place other than S phase), suchas agents that induce G1 arrest and M-phase arrest. Classical M-phaseblockers include the vincas and vinca alkaloids (vincristine andvinblastine), taxanes, and topoisomerase II inhibitors such asdoxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Thoseagents that arrest G1 also spill over into S-phase arrest, for example,DNA alkylating agents such as tamoxifen, prednisone, dacarbazine,mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.Further information can be found in The Molecular Basis of Cancer,Mendelsohn and Israel, eds., Chapter 1, entitled “Cell cycle regulation,oncogenes, and antineoplastic drugs” by Murakami et al (WB Saunders:Philadelphia, 1995), especially p. 13. The taxanes (paclitaxel anddocetaxel) are anticancer drugs both derived from the yew tree.Docetaxel (TAXOTERE®, Rhone-Poulenc Rorer), derived from the Europeanyew, is a semisynthetic analogue of paclitaxel (TAXOL®, Bristol-MyersSquibb).

The term “cytokine” is a generic term for proteins released by one cellpopulation that act on another cell as intercellular mediators. Examplesof such cytokines are lymphokines, monokines; interleukins (ILs) such asIL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11,IL-12, IL-13, IL-15, including PROLEUKIN® rIL-2; a tumor-necrosis factorsuch as TNF-α or TNF-β; and other polypeptide factors including LIF andkit ligand (KL). As used herein, the term cytokine includes proteinsfrom natural sources or from recombinant cell culture and biologicallyactive equivalents of the native-sequence cytokines, includingsynthetically produced small-molecule entities and pharmaceuticallyacceptable derivatives and salts thereof.

The term “hormone” refers to polypeptide hormones, which are generallysecreted by glandular organs with ducts. Included among the hormonesare, for example, growth hormone such as human growth hormone,N-methionyl human growth hormone, and bovine growth hormone; parathyroidhormone; thyroxine; insulin; proinsulin; relaxin; estradiol;hormone-replacement therapy; androgens such as calusterone,dromostanolone propionate, epitiostanol, mepitiostane, or testolactone;prorelaxin; glycoprotein hormones such as follicle stimulating hormone(FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH);prolactin, placental lactogen, mouse gonadotropin-associated peptide,gonadotropin-releasing hormone; inhibin; activin; mullerian-inhibitingsubstance; and thrombopoietin. As used herein, the term hormone includesproteins from natural sources or from recombinant cell culture andbiologically active equivalents of the native-sequence hormone,including synthetically produced small-molecule entities andpharmaceutically acceptable derivatives and salts thereof.

The term “growth factor” refers to proteins that promote growth, andinclude, for example, hepatic growth factor; fibroblast growth factor;vascular endothelial growth factor; nerve growth factors such as NGF-β;platelet-derived growth factor; transforming growth factors (TGFs) suchas TGF-α and TGF-β; insulin-like growth factor-I and -II; erythropoietin(EPO); osteoinductive factors; interferons such as interferon-α, -β, and-γ; and colony stimulating factors (CSFs) such as macrophage-CSF(M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF(G-CSF). As used herein, the term growth factor includes proteins fromnatural sources or from recombinant cell culture and biologically activeequivalents of the native-sequence growth factor, includingsynthetically produced small-molecule entities and pharmaceuticallyacceptable derivatives and salts thereof.

The term “integrin” refers to a receptor protein that allows cells bothto bind to and to respond to the extracellular matrix and is involved ina variety of cellular functions such as wound healing, celldifferentiation, homing of tumor cells and apoptosis. They are part of alarge family of cell adhesion receptors that are involved incell-extracellular matrix and cell-cell interactions. Functionalintegrins consist of two transmembrane glycoprotein subunits, calledalpha and beta, that are non-covalently bound. The alpha subunits allshare some homology to each other, as do the beta subunits. Thereceptors always contain one alpha chain and one beta chain. Examplesinclude Alpha6beta1, Alpha3beta1, Alpha7beta1, LFA-1 etc. As usedherein, the term “integrin” includes proteins from natural sources orfrom recombinant cell culture and biologically active equivalents of thenative-sequence integrin, including synthetically producedsmall-molecule entities and pharmaceutically acceptable derivatives andsalts thereof.

A “TNF antagonist” is defined herein as a molecule that decreases,blocks, inhibits, abrogates, or interferes with TNFα activity in vitro,in situ, and/or preferably in vivo. A suitable TNF antagonist can alsodecrease block, abrogate, interfere, prevent and/or inhibit TNF RNA, DNAor protein synthesis, TNFα release, TNFα receptor signaling, membraneTNFα cleavage, TNFα activity, TNFα production and/or synthesis. Such TNFantagonists include, but are not limited to, anti-TNFα antibodies,antigen-binding fragments thereof, specified mutants or domains thereofthat bind specifically to TNFα that, upon binding to TNFα, destroy ordeplete cells expressing the TNFα in a mammal and/or interferes with oneor more functions of those cells, a soluble TNF receptor (e.g., p55, p70or p85) or fragment, fusion polypeptides thereof, a small-molecule TNFantagonist, e.g., TNF binding protein I or II (TBP-I or TBP-II),nerelimonmab, CDP-571, infliximab, enteracept (ENBREL™), adalimulab(HUMIRA™), CDP-571, CDP-870, afelimomab, lenercept, and the like),antigen-binding fragments thereof, and receptor molecules that bindspecifically to TNFα; compounds that prevent and/or inhibit TNFαsynthesis, TNFα release or its action on target cells, such asthalidomide, tenidap, phosphodiesterase inhibitors (e.g., pentoxifyllineand rolipram), A2b adenosine receptor agonists and A2b adenosinereceptor enhancers; compounds that prevent and/or inhibit TNFα receptorsignalling, such as mitogen activated protein (MAP) kinase inhibitors;compounds that block and/or inhibit membrane TNFα cleavage, such asmetalloproteinase inhibitors; compounds that block and/or inhibit TNFαactivity, such as angiotensin converting enzyme (ACE) inhibitors (e.g.,captopril); and compounds that block and/or inhibit TNFα productionand/or synthesis, such as MAP kinase inhibitors. The preferredantagonist comprises an antibody.

“Tumor necrosis factor-alpha”, TNF-alpha”, or “TNFα” refers to a humanTNFα molecule comprising the amino acid sequence of Pennica et al.,Nature, 312:721 (1984) or Aggarwal et al., JBC, 260:2345 (1985). A “TNFαinhibitor” herein is an agent that inhibits, to some extent, abiological function of TNFα, generally through binding to TNFα andneutralizing its activity. Examples of TNFα inhibitors herein includeetanercept (ENBREL®), infliximab (REMICADE®), and adalimumab (HUMIRA™).

Examples of “integrin antagonists or antibodies” herein include an LFA-1antibody, such as efalizumab (RAPTIVA®) commercially available fromGenentech, or an alpha 4 integrin antibody such as natalizumab(ANTEGREN®) available from Biogen, or diazacyclic phenylalaninederivatives (WO 2003/89410), phenylalanine derivatives (WO 2003/70709,WO 2002/28830, WO 2002/16329 and WO 2003/53926), phenylpropionic acidderivatives (WO 2003/10135), enamine derivatives (WO 2001/79173),propanoic acid derivatives (WO 2000/37444), alkanoic acid derivatives(WO 2000/32575), substituted phenyl derivatives (U.S. Pat. Nos.6,677,339 and 6,348,463), aromatic amine derivatives (U.S. Pat. No.6,369,229), ADAM disintegrin domain polypeptides (US2002/0042368),antibodies to alphavbeta3 integrin (EP 633945), aza-bridged bicyclicamino acid derivatives (WO 2002/02556), etc.

The term “immunosuppressive agent” refers to a substance that acts tosuppress or mask the immune system of the subject being treated herein.This would include substances that suppress cytokine production,down-regulate or suppress self-antigen expression, or mask the MHCantigens. Examples of such agents include 2-amino-6-aryl-5-substitutedpyrimidines (see U.S. Pat. No. 4,665,077); non-steroidalanti-inflammatory drugs (NSAIDs); ganciclovir, tacrolimus,glucocorticoids such as cortisol or aldosterone, anti-inflammatoryagents such as a cyclooxygenase inhibitor, a 5-lipoxygenase inhibitor,or a leukotriene receptor antagonist; purine antagonists such asazathioprine or mycophenolate mofetil (MMF); trocade (Ro32-355); aperipheral sigma receptor antagonist such as ISR-31747; alkylatingagents such as cyclophosphamide; bromocryptine; danazol; dapsone;glutaraldehyde (which masks the MHC antigens, as described in U.S. Pat.No. 4,120,649); anti-idiotypic antibodies for MHC antigens and MHCfragments; cyclosporin A; steroids such as corticosteroids orglucocorticosteroids or glucocorticoid analogs, e.g., prednisone,methylprednisolone, including SOLU-MEDROL® methylprednisolone sodiumsuccinate, rimexolone, and dexamethasone; dihydrofolate reductaseinhibitors such as methotrexate (oral or subcutaneous); anti-malarialagents such as chloroquine and hydroxychloroquine; sulfasalazine;leflunomide; cytokine release inhibitors such as SB-210396 and SB-217969monoclonal antibodies and a MHC II antagonist such as ZD2315; a PG1receptor antagonist such as ZD4953; a VLA4 adhesion blocker such asZD7349; anti-cytokine or anti-cytokine receptor antibodies includinganti-interferon-alpha, -beta, or -gamma antibodies, anti-TNF-αantibodies (infliximab (REMICADE®) or adalimumab), anti-TNF-αimmunoadhesin (etanercept), anti-TNF-beta antibodies, interleukin-1(IL-1) blockers such as recombinant HuIL-1Ra and IL-1B inhibitor,anti-interleukin-2 (IL-2) antibodies and anti-IL-2 receptor antibodies;IL-2 fusion toxin; anti-L3T4 antibodies; leflunomide; heterologousanti-lymphocyte globulin; OPC-14597; NISV (immune response modifier); anessential fatty acid such as gammalinolenic acid or eicosapentaenoicacid; CD-4 blockers, pan-T antibodies, preferably anti-CD3 oranti-CD4/CD4a antibodies; co-stimulatory modifier (e.g., CTLA4-Fcfusion, also known as ABATACEPT™; anti-interleukin-6 (IL-6) receptorantibodies and antagonists; anti-LFA-1 antibodies, including anti-CD 11aand anti-CD18 antibodies; soluble peptide containing a LFA-3 bindingdomain (WO 1990/08187); streptokinase; IL-10; anti-IL-4 antagonists,anti-IL-13 antagonists and bispecific anti-IL-4/IL-13 antagonistantibodies, transforming growth factor-beta (TGF-beta); streptodornase;RNA or DNA from the host; FK506; RS-61443; enlimomab; CDP-855; PNPinhibitor; CH-3298; GW353430; 4162W94, chlorambucil; deoxyspergualin;rapamycin; T-cell receptor (U.S. Pat. No. 5,114,721); T-cell receptorfragments (Offner et al., Science, 251: 430-2 (1991); WO 1990/11294;Janeway, Nature, 341: 482-483 (1989); and WO 1991/01133); BAFFantagonists such as BAFF antibodies and BR3 antibodies; zTNF4antagonists (Mackay and Mackay, Trends Immunol., 23:113-5 (2002));biologic agents that interfere with T-cell helper signals, such asanti-CD40 receptor or anti-CD40 ligand (CD154), including blockingantibodies to CD40-CD40 ligand (e.g., Durie et al., Science, 261:1328-30 (1993); Mohan et al., J. Immunol., 154: 1470-80 (1995)) andCTLA4-Ig (Finck et al., Science, 265: 1225-7 (1994)); and T-cellreceptor antibodies (EP 340,109) such as T10B9. Some preferredimmunosuppressive agents herein include cyclophosphamide, chlorambucil,azathioprine, leflunomide, MMF, or methotrexate (MTX).

“Disease-modifying anti-rheumatic drugs” or “DMARDs” include, e.g.,chloroquine, hydroxycloroquine, myocrisin, auranofin, sulfasalazine,methotrexate, leflunomide, etanercept, infliximab (and oral andsubcutaneous MTX), azathioprine, D-penicilamine, gold salts (oral), goldsalts (intramuscular), minocycline, cyclosporine, e.g., cyclosporine Aand topical cyclosporine, staphylococcal protein A (Goodyear andSilverman, J. Exp. Med., 197:1125-39 (2003)), including salts andderivatives thereof, etc.

A “B cell” is a lymphocyte that matures within the bone marrow, andincludes a naïve B cell, memory B cell, or effector B cell (plasmacells). The B cell herein may be normal or non-malignant.

A “B-cell surface marker” or “B-cell surface antigen” herein is anantigen expressed on the surface of a B cell that can be targeted withan antagonist that binds thereto. Exemplary B-cell surface markersinclude the CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD40, CD53,CD72, CD73, CD74, CDw75, CDw76, CD77, CDw78, CD79a, CD79b, CD80, CD81,CD82, CD83, CDw84, CD85 and CD86 leukocyte surface markers (fordescriptions, see The Leukocyte Antigen Facts Book, 2^(nd) Edition.1997, ed. Barclay et al Academic Press, Harcourt Brace & Co., New York).Other B-cell surface markers include RP105, FcRH2, B-cell CR2, CCR6,P2×5, HLA-DOB, CXCR5, FCER2, BR3, Btig, NAG14, SLGC16270, FcRH1, IRTA2,ATWD578, FcRH3, IRTA1, FcRH6, BCMA, and 239287. The preferred B-cellsurface marker is preferentially expressed on B cells compared to othernon-B-cell tissues of a mammal and may be expressed on both precursorand mature B cells. The most preferred such markers are CD20 and CD22.

The “CD20” antigen, or “CD20,” is an about 35-kDa, non-glycosylatedphosphoprotein found on the surface of greater than 90% of B cells fromperipheral blood or lymphoid organs. CD20 is present on both normal Bcells as well as malignant B cells, but is not expressed on stem cells.Other names for CD20 in the literature include “B-lymphocyte-restrictedantigen” and “Bp35”. The CD20 antigen is described in Clark et al.,Proc. Natl. Acad. Sci. (USA) 82:1766 (1985), for example.

The “CD22” antigen, or “CD22,” also known as BL-CAM or Lyb8, is a type 1integral membrane glycoprotein with molecular weight of about 130(reduced) to 140 kD (unreduced). It is expressed in both the cytoplasmand cell membrane of B-lymphocytes. CD22 antigen appears early in B-celllymphocyte differentiation at approximately the same stage as the CD19antigen. Unlike other B-cell markers, CD22 membrane expression islimited to the late differentiation stages comprised between mature Bcells (CD22+) and plasma cells (CD22−). The CD22 antigen is described,for example, in Wilson et al., J. Exp. Med. 173:137 (1991) and Wilson etal., J. Immunol. 150:5013 (1993).

An “antibody that binds to a B-cell surface marker” is a molecule that,upon binding to a B-cell surface marker, destroys or depletes B cells ina mammal and/or interferes with one or more B-cell functions, e.g. byreducing or preventing a humoral response elicited by the B cell. Theantibody preferably is able to deplete B cells (i.e. reduce circulatingB-cell levels) in a mammal treated therewith. Such depletion may beachieved via various mechanisms such antibody-dependent cell-mediatedcytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC),inhibition of B-cell proliferation and/or induction of B-cell death(e.g. via apoptosis).

Examples of CD20 antibodies include: “C2B8,” which is now called“rituximab” (“RITUXAN®”) (U.S. Pat. No. 5,736,137); theyttrium-[90]-labelled 2B8 murine antibody designated “Y2B8” or“Ibritumomab Tiuxetan” (ZEVALIN®) commercially available from IDECPharmaceuticals, Inc. (U.S. Pat. No. 5,736,137; 2B8 deposited with ATCCunder accession no. HB11388 on Jun. 22, 1993); murine IgG2a “B1,” alsocalled “Tositumomab,” optionally labelled with ¹³¹I to generate the“131I-B1” or “iodine I131 tositumomab” antibody (BEXXAR™) commerciallyavailable from Corixa (see, also, U.S. Pat. No. 5,595,721); murinemonoclonal antibody “1F5” (Press et al. Blood 69(2):584-591 (1987) andvariants thereof including “framework patched” or humanized 1F5 (WO2003/002607, Leung, S.; ATCC deposit HB-96450); murine 2H7 and chimeric2H7 antibody (U.S. Pat. No. 5,677,180); a humanized 2H7 (WO 2004/056312(Lowman et al.) and as set forth below); HUMAX-CD20™ fully human,high-affinity antibody targeted at the CD20 molecule in the cellmembrane of B-cells (Genmab, Denmark; see, for example, Glennie and vande Winkel, Drug Discovery Today 8: 503-510 (2003) and Cragg et al.,Blood 101: 1045-1052 (2003)); the human monoclonal antibodies set forthin WO04/035607 (Teeling et al.); AME-133™ antibodies (Applied MolecularEvolution); A20 antibody or variants thereof such as chimeric orhumanized A20 antibody (cA20, hA20, respectively) (US 2003/0219433,Immunomedics); and monoclonal antibodies L27, G28-2, 93-1B3, B-C1 orNU-B2 available from the International Leukocyte Typing Workshop(Valentine et al., In: Leukocyte Typing III (McMichael, Ed., p. 440,Oxford University Press (1987)). The preferred CD20 antibodies hereinare chimeric, humanized, or human CD20 antibodies, more preferablyrituximab, a humanized 2H7, chimeric or humanized A20 antibody(Immunomedics), and HUMAX-CD20™ human CD20 antibody (Genmab).

The terms “rituximab” or “RITUXAN®” herein refer to the geneticallyengineered chimeric murine/human monoclonal antibody directed againstthe CD20 antigen and designated “C2B8” in U.S. Pat. No. 5,736,137,including fragments thereof that retain the ability to bind CD20.

Purely for the purposes herein and unless indicated otherwise, a“humanized 2H7” refers to a humanized CD20 antibody, or anantigen-binding fragment thereof, wherein the antibody is effective todeplete primate B cells in vivo. The antibody includes those set forthin US 2006/0062787 and the figures thereof, and including version 114,the sequences of which are provided in US 2006/0188495. See also US2006/0034835 and US 2006/0024300. In a summary of various preferredembodiments of the invention, the V region of variants based on 2H7version 16 as disclosed in US 2006/0062787 will have the amino acidsequences of v16 except at the positions of amino acid substitutionsthat are indicated in the table below. Unless otherwise indicated, the2H7 variants will have the same L chain as that of v16.

2H7 Heavy chain Light chain version (V_(H)) changes (V_(L)) changes Fcchanges 16 — 31 — — S298A, E333A, K334A 73 N100A M32L 75 N100A M32LS298A, E333A, K334A 96 D56A, N100A S92A 114 D56A, N100A M32L, S92AS298A, E333A, K334A 115 D56A, N100A M32L, S92A S298A, E333A, K334A,E356D, M358L 116 D56A, N100A M32L, S92A S298A, K334A, K322A 138 D56A,N100A M32L, S92A S298A, E333A, K334A, K326A 477 D56A, N100A M32L, S92AS298A, E333A, K334A, K326A, N434W 375 — — K334LOne preferred humanized 2H7 is an intact antibody or antibody fragmenthaving the sequence of version 16. Another preferred humanized 2H7 hasthe sequences of version 114.

“BAFF antagonists” are any molecules that block the activity of BAFF orBR3. They include immunoadhesins comprising a portion of BR3, TACI orBCMA that binds BAFF, or variants thereof that bind BAFF. In otheraspects, the BAFF antagonist is a BAFF antibody. A “BAFF antibody” is anantibody that binds BAFF, and preferably binds BAFF within a region ofhuman BAFF comprising residues 162-275 of human BAFF. In another aspect,the BAFF antagonist is a BR3 antibody. A “BR3 antibody” is an antibodythat binds BR3, and preferably binds BR3 within a region of human BR3comprising residues 23-38 of human BR3. The sequences of human BAFF andhuman BR3 are found, e.g., in US 2006/0062787. Other examples ofBAFF-binding polypeptides or BAFF antibodies can be found in, e.g., WO2002/092620, WO 2003/014294, Gordon et al., Biochemistry 42(20):5977-83(2003), Kelley et al, J. Biol. Chem. 279:16727-35 (2004), WO 1998/18921,WO 2001/12812, WO 2000/68378 and WO 2000/40716.

“Anti-IgE antibody” includes any antibody that binds specifically to IgEin a manner so as to not induce cross-linking when IgE is bound to thehigh affinity receptor on mast cells and basophils. Exemplary antibodiesinclude the antibodies of the invention as well as rhuMabE25 (E25,XOLAIR®), E26, E27, as well as CGP-5101 (Hu-901) and the HA antibody.The amino acid sequences of the heavy and light chain variable domainsof the humanized anti-IgE antibodies E25, E26 and E27 are disclosed, forexample in U.S. Pat. No. 6,172,213 and WO99/01556. The CGP-5101 (Hu-901)antibody is described in Corne et al., (1997) J. Clin. Invest. 99(5):879-887, WO 92/17207 and ATCC Dep. Nos. BRL-10706, BRL-11130, BRL-11131,BRL-11132 and BRL-11133. The HA antibody is described in U.S. Ser. No.60/444,229, WO2004/070011 and WO2004/070010.

II. MODES FOR CARRYING OUT THE INVENTION

A. Recombinant Preparation

The invention also provides an isolated nucleic acid encoding apoptoticanti-IgE antibodies, vectors and host cells comprising such nucleicacid, and recombinant techniques for the production of the antibody.

For recombinant production of the antibody, the nucleic acid encoding itis isolated and inserted into a replicable vector for further cloning(amplification of the DNA) or for expression. DNA encoding themonoclonal antibody is readily isolated and sequenced using conventionalprocedures (e.g., by using oligonucleotide proves that are capable ofbinding specifically to genes encoding the heavy and light chains of theantibody). Many vectors are available. The vector components generallyinclude, but are not limited to, one or more of the following, a signalsequence, an origin of replication, one or more marker genes, andenhancer element, a promoter, and a transcription termination sequence.

(1) Signal Sequence Component

The anti-IgE antibodies of this invention may be produced recombinantlynot only directly, but also as a fusion polypeptide with a heterologouspolypeptide, which is preferably a signal sequence or other polypeptidehaving a specific cleavage site at the N-terminus of the mature proteinor polypeptide. The heterologous signal sequence selected preferably isone that is recognized and processed (i.e., cleaved by a signalpeptidase) by the host cell. For prokaryotic host cells that do notrecognize and process the native mammalian signal sequence, the signalsequence is substituted by a prokaryotic signal sequence selected, forexample, from the group of the alkaline phosphatase, penicillinase, lpp,or heat-stable enterotoxin II leaders. For yeast secretion the nativesignal sequence may be substituted by, e.g., the yeast invertase leader,factor leader (including Saccharomyces and Kluyveromyces-factorleaders), or acid phosphatase leader, the C. albicans glucoamylaseleader, or the signal described in WO 90/13646. In mammalian cellexpression, mammalian signal sequences as well as viral secretoryleaders, for example, the herpes simplex gD signal, are available.

The DNA for such precursor region is ligated in reading frame to DNAencoding the IgE binding antibody.

(2) Origin of Replication

Both expression and cloning vectors contain a nucleic acid sequence thatenables the vector to replicate in one or more selected host cells.Generally, in cloning vectors this sequence is one that enables thevector to replicate independently of the host chromosomal DNA, andincludes origins of replication or autonomously replicating sequences.Such sequences are well known for a variety of bacteria, yeast, andviruses. The origin of replication from the plasmid pBR322 is suitablefor most Gram-negative bacteria, the 2μ plasmid origin is suitable foryeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV)are useful for cloning vectors in mammalian cells. Generally, the originof replication component is not needed for mammalian expression vectors(the SV40 origin may typically be used only because it contains theearly promoter).

(3) Selection Gene Component

Expression and cloning vectors may contain a selection gene, also termeda selectable marker. Typical selection genes encode proteins that (a)confer resistance to antibiotics or other toxins, e.g., ampicillin,neomycin, methotrexate, or tetracycline, (b) complement auxotrophicdeficiencies, or (c) supply critical nutrients not available fromcomplex media, e.g., the gene encoding D-alanine racemase for Bacilli.

One example of a selection scheme utilizes a drug to arrest growth of ahost cell. Those cells that are successfully transformed with aheterologous gene produce a protein conferring drug resistance and thussurvive the selection regimen. Examples of such dominant selection usethe drugs neomycin, mycophenolic acid and hygromycin.

Another example of suitable selectable markers for mammalian cells arethose that enable the identification of cells competent to take up theIgE binding antibody nucleic acid, such as DHFR, thymidine kinase,metallothionein-I and -II, preferably primate metallothionein genes,adenosine deaminase, ornithine decarboxylase, etc.

For example, cells transformed with the DHFR selection gene are firstidentified by culturing all of the transformants in a culture mediumthat contains methotrexate (Mtx), a competitive antagonist of DHFR. Anappropriate host cell when wild-type DHFR is employed is the Chinesehamster ovary (CHO) cell line deficient in DHFR activity (e.g., ATCCCRL-9096).

Alternatively, host cells (particularly wild-type hosts that containendogenous DHFR) transformed or co-transformed with DNA sequencesencoding IgE binding antibody, wild-type DHFR protein, and anotherselectable marker such as aminoglycoside 3′-phosphotransferase (APH) canbe selected by cell growth in medium containing a selection agent forthe selectable marker such as an aminoglycosidic antibiotic, e.g.,kanamycin, neomycin, or G418. See U.S. Pat. No. 4,965,199.

A suitable selection gene for use in yeast is the trp1 gene present inthe yeast plasmid YRp7 (Stinchcomb et al., Nature, 282:39 (1979)). Thetrp1 gene provides a selection marker for a mutant strain of yeastlacking the ability to grow in tryptophan, for example, ATCC No. 44076or PEP4-1. Jones, Genetics, 85:12 (1977). The presence of the trp1lesion in the yeast host cell genome then provides an effectiveenvironment for detecting transformation by growth in the absence oftryptophan. Similarly, Leu2-deficient yeast strains (ATCC 20,622 or38,626) are complemented by known plasmids bearing the Leu2 gene.

In addition, vectors derived from the 1.6 μm circular plasmid pKD1 canbe used for transformation of Kluyveromyces yeasts. Alternatively, anexpression system for large-scale production of recombinant calfchymosin was reported for K. lactis. Van den Berg, Bio/Technology, 8:135(1990). Stable multi-copy expression vectors for secretion of maturerecombinant human serum albumin by industrial strains of Kluyveromyceshave also been disclosed. Fleer et al., Bio/Technology, 9:968-975(1991).

(4) Promoter Component

Expression and cloning vectors usually contain a promoter that isrecognized by the host organism and is operably linked to the nucleicacid encoding the IgE binding antibody. Promoters suitable for use withprokaryotic hosts include the phoA promoter, -lactamase and lactosepromoter systems, alkaline phosphatase promoter, a tryptophan (trp)promoter system, and hybrid promoters such as the tac promoter. However,other known bacterial promoters are suitable. Promoters for use inbacterial systems also will contain a Shine-Dalgarno (S.D.) sequenceoperably linked to the DNA encoding the IgE binding antibody.

Promoter sequences are known for eukaryotes. Virtually all eukaryoticgenes have an AT-rich region located approximately 25 to 30 basesupstream from the site where transcription is initiated. Anothersequence found 70 to 80 bases upstream from the start of transcriptionof many genes is a CNCAAT region where N may be any nucleotide. At the3′ end of most eukaryotic genes is an AATAAA sequence that may be thesignal for addition of the poly A tail to the 3′ end of the codingsequence. All of these sequences are suitably inserted into eukaryoticexpression vectors.

Examples of suitable promoter sequences for use with yeast hosts includethe promoters for 3-phosphoglycerate kinase or other glycolytic enzymes,such as enolase, glyceraldehyde-3-phos-phate dehydrogenase, hexokinase,pyruvate decarboxylase, phospho-fructokinase, glucose-6-phosphateisomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphateisomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having theadditional advantage of transcription controlled by growth conditions,are the promoter regions for alcohol dehydrogenase 2, isocytochrome C,acid phosphatase, degradative enzymes associated with nitrogenmetabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase,and enzymes responsible for maltose and galactose utilization. Suitablevectors and promoters for use in yeast expression are further describedin EP 73,657. Yeast enhancers also are advantageously used with yeastpromoters.

IgE binding antibody transcription from vectors in mammalian host cellsis controlled, for example, by promoters obtained from the genomes ofviruses such as polyoma virus, fowlpox virus, adenovirus (such asAdenovirus 2), bovine papilloma virus, avian sarcoma virus,cytomegalovirus, a retrovirus, hepatitis-B virus and most preferablySimian Virus 40 (SV40), from heterologous mammalian promoters, e.g., theactin promoter or an immunoglobulin promoter, from heat-shock promoters,provided such promoters are compatible with the host cell systems.

The early and late promoters of the SV40 virus are conveniently obtainedas an SV40 restriction fragment that also contains the SV40 viral originof replication. The immediate early promoter of the humancytomegalovirus is conveniently obtained as a HindIII E restrictionfragment. A system for expressing DNA in mammalian hosts using thebovine papilloma virus as a vector is disclosed in U.S. Pat. No.4,419,446. A modification of this system is described in U.S. Pat. No.4,601,978. See also Reyes et al., Nature 297:598-601 (1982) onexpression of human-interferon cDNA in mouse cells under the control ofa thymidine kinase promoter from herpes simplex virus. Alternatively,the Rous Sarcoma Virus long terminal repeat can be used as the promoter.

(5) Enhancer Element Component

Transcription of a DNA encoding the IgE binding antibody of thisinvention by higher eukaryotes is often increased by inserting anenhancer sequence into the vector. Many enhancer sequences are now knownfrom mammalian genes (globin, elastase, albumin, -fetoprotein, andinsulin). Typically, however, one will use an enhancer from a eukaryoticcell virus. Examples include the SV40 enhancer on the late side of thereplication origin (bp 100-270), the cytomegalovirus early promoterenhancer, the polyoma enhancer on the late side of the replicationorigin, and adenovirus enhancers. See also Yaniv, Nature 297:17-18(1982) on enhancing elements for activation of eukaryotic promoters. Theenhancer may be spliced into the vector at a position 5′ or 3′ to theIgE binding antibody-encoding sequence, but is preferably located at asite 5′ from the promoter.

(6) Transcription Termination Component

Expression vectors used in eukaryotic host cells (yeast, fungi, insect,plant, animal, human, or nucleated cells from other multicellularorganisms) will also contain sequences necessary for the termination oftranscription and for stabilizing the mRNA. Such sequences are commonlyavailable from the 5′ and, occasionally 3′, untranslated regions ofeukaryotic or viral DNAs or cDNAs. These regions contain nucleotidesegments transcribed as polyadenylated fragments in the untranslatedportion of the mRNA encoding IgE binding antibody. One usefultranscription termination component is the bovine growth hormonepolyadenylation region. See WO94/11026 and the expression vectordisclosed therein.

(7) Selection and Transformation of Host Cells

Suitable host cells for cloning or expressing the DNA in the vectorsherein are the prokaryote, yeast, or higher eukaryote cells describedabove. Suitable prokaryotes for this purpose include eubacteria, such asGram-negative or Gram-positive organisms, for example,Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter,Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium,Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacillisuch as B. subtilis and B. licheniformis (e.g., B. licheniformis 41Pdisclosed in DD 266,710 published 12 Apr. 1989), Pseudomonas such as P.aeruginosa, and Streptomyces. One preferred E. coli cloning host is E.coli 294 (ATCC 31,446), although other strains such as E. coli B, E.coli X1776 (ATCC 31,537), and E. coli W3110 (ATCC 27,325) are suitable.These examples are illustrative rather than limiting.

Full length antibody, antibody fragments, and antibody fusion proteinscan be produced in bacteria, in particular when glycosylation and Fceffector function are not needed, such as when the therapeutic antibodyis conjugated to a cytotoxic agent (e.g., a toxin) and theimmunoconjugate by itself shows effectiveness in tumor cell destruction.Full length antibodies have greater half life in circulation. Productionin E. coli is faster and more cost efficient. For expression of antibodyfragments and polypeptides in bacteria, see, e.g., U.S. Pat. No.5,648,237 (Carter et. al.), U.S. Pat. No. 5,789,199 (Joly et al), andU.S. Pat. No. 5,840,523 (Simmons et al) which describes translationinitiation region (TIR) and signal sequences for optimizing expressionand secretion. After expression, the antibody is isolated from the E.coli cell paste in a soluble fraction and can be purified through, e.g.,a protein A or G column depending on the isotype. Final purification canbe carried out similar to the process for purifying antibody expressede.g., in CHO cells.

In addition to prokaryotes, eukaryotic microbes such as filamentousfungi or yeast are suitable cloning or expression hosts for IgE bindingantibody-encoding vectors. Saccharomyces cerevisiae, or common baker'syeast, is the most commonly used among lower eukaryotic hostmicroorganisms. However, a number of other genera, species, and strainsare commonly available and useful herein, such as Schizosaccharomycespombe; Kluyveromyces hosts such as, e.g., K. lactis, K. fragilis (ATCC12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K.waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K. thermotolerans,and K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070);Candida; Trichoderma reesia (EP 244,234); Neurospora crassa;Schwanniomyces such as Schwanniomyces occidentalis; and filamentousfungi such as, e.g., Neurospora, Penicillium, Tolypocladium, andAspergillus hosts such as A. nidulans and A. niger.

Suitable host cells for the expression of glycosylated IgE bindingantibody are derived from multicellular organisms. Examples ofinvertebrate cells include plant and insect cells. Numerous baculoviralstrains and variants and corresponding permissive insect host cells fromhosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti(mosquito), Aedes albopictus (mosquito), Drosophila melanogaster(fruitfly), and Bombyx mori have been identified. A variety of viralstrains for transfection are publicly available, e.g., the L-1 variantof Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV,and such viruses may be used as the virus herein according to thepresent invention, particularly for transfection of Spodopterafrugiperda cells.

Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato,and tobacco can also be utilized as hosts.

However, interest has been greatest in vertebrate cells, and propagationof vertebrate cells in culture (tissue culture) has become a routineprocedure. Examples of useful mammalian host cell lines are monkeykidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); humanembryonic kidney line (293 or 293 cells subcloned for growth insuspension culture, Graham et al., J. Gen. Virol. 36:59 (1977)); babyhamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovarycells/−DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216(1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251(1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkeykidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells(HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo ratliver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT060562, ATCC CCL51); TR1 cells (Mather et al., Annals N.Y. Acad. Sci.383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line(Hep G2).

Host cells are transformed with the above-described expression orcloning vectors for IgE binding antibody production and cultured inconventional nutrient media modified as appropriate for inducingpromoters, selecting transformants, or amplifying the genes encoding thedesired sequences.

(8) Culturing the Host Cells

The host cells used to produce the IgE binding antibody of thisinvention may be cultured in a variety of media. Commercially availablemedia such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM),(Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium((DMEM), Sigma) are suitable for culturing the host cells. In addition,any of the media described in Ham et al., Meth. Enz. 58:44 (1979),Barnes et al., Anal. Biochem. 102:255 (1980), U.S. Pat. No. 4,767,704;4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195;or U.S. Pat. Re. No. 30,985 may be used as culture media for the hostcells. Any of these media may be supplemented as necessary with hormonesand/or other growth factors (such as insulin, transferrin, or epidermalgrowth factor), salts (such as sodium chloride, calcium, magnesium, andphosphate), buffers (such as HEPES), nucleotides (such as adenosine andthymidine), antibiotics (such as GENTAMYCIN™ drug), trace elements(defined as inorganic compounds usually present at final concentrationsin the micromolar range), and glucose or an equivalent energy source.Any other necessary supplements may also be included at appropriateconcentrations that would be known to those skilled in the art. Theculture conditions, such as temperature, pH, and the like, are thosepreviously used with the host cell selected for expression, and will beapparent to the ordinarily skilled artisan.

(9) Purification of Antibody

When using recombinant techniques, the antibody can be producedintracellularly, in the periplasmic space, or directly secreted into themedium. If the antibody is produced intracellularly, as a first step,the particulate debris, either host cells or lysed fragments, areremoved, for example, by centrifugation or ultrafiltration. Carter etal., Bio/Technology 10: 163-167 (1992) describe a procedure forisolating antibodies which are secreted to the periplasmic space of E.coli. Briefly, cell paste is thawed in the presence of sodium acetate(pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30min. Cell debris can be removed by centrifugation. Where the antibody issecreted into the medium, supernatants from such expression systems aregenerally first concentrated using a commercially available proteinconcentration filter, for example, an Amicon or Millipore Pelliconultrafiltration unit. A protease inhibitor such as PMSF may be includedin any of the foregoing steps to inhibit proteolysis and antibiotics maybe included to prevent the growth of adventitious contaminants.

The antibody composition prepared from the cells can be purified using,for example, hydroxylapatite chromatography, gel electrophoresis,dialysis, and affinity chromatography, with affinity chromatographybeing the preferred purification technique. The suitability of protein Aas an affinity ligand depends on the species and isotype of anyimmunoglobulin Fc domain that is present in the antibody. Protein A canbe used to purify antibodies that are based on human 1, 2, or 4 heavychains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)). Protein G isrecommended for all mouse isotypes and for human 3 (Guss et al., EMBO J.5:15671575 (1986)). The matrix to which the affinity ligand is attachedis most often agarose, but other matrices are available. Mechanicallystable matrices such as controlled pore glass orpoly(styrene-divinyl)benzene allow for faster flow rates and shorterprocessing times than can be achieved with agarose. Where the antibodycomprises a CH³ domain, the Bakerbond ABX™resin (J. T. Baker,Phillipsburg, N.J.) is useful for purification. Other techniques forprotein purification such as fractionation on an ion-exchange column,ethanol precipitation, Reverse Phase HPLC, chromatography on silica,chromatography on heparin SEPHAROSE™ chromatography on an anion orcation exchange resin (such as a polyaspartic acid column),chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are alsoavailable depending on the antibody to be recovered.

Following any preliminary purification step(s), the mixture comprisingthe antibody of interest and contaminants may be subjected to low pHhydrophobic interaction chromatography using an elution buffer at a pHbetween about 2.5-4.5, preferably performed at low salt concentrations(e.g., from about 0-0.25M salt).

B. Antibody Preparation

1) Polyclonal Antibodies

Polyclonal antibodies are generally raised in animals by multiplesubcutaneous (sc) or intraperitoneal (ip) injections of the relevantantigen and an adjuvant. It may be useful to conjugate the relevantantigen to a protein that is immunogenic in the species to be immunized,e.g., keyhole limpet hemocyanin (KLH), serum albumin, bovinethyroglobulin, or soybean trypsin inhibitor, using a bifunctional orderivatizing agent, e.g., maleimidobenzoyl sulfosuccinimide ester(conjugation through cysteine residues), N-hydroxysuccinimide (throughlysien residues), glutaraldehyde, succinic anhydride, SOCl₂, orR¹N═C═NR, where R and R¹ are independently lower alkyl groups. Examplesof adjuvants which may be employed include Freund's complete adjuvantand MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalosedicorynomycolate). The immunization protocol may be selected by oneskilled in the art without undue experimentation.

The animals are immunized against the antigen, immunogenic conjugates,or derivatives by combining, e.g., 100 μg or 5 μg or the protein orconjugate (for rabbits or mice, respectively) with 3 volumes of Freund'scomplete adjuvant and injecting the solution intradermally at multiplesites. One month later, the animals are boosted with ⅕ to 1/10 theoriginal amount of peptide or conjugate in Freund's complete adjuvant bysubcutaneous injection at multiple sites. Seven to fourteen days later,the animals are bled and the serum is assayed for antibody titer.Animals are boosted until the titer plateaus. Conjugates also can bemade in recombinant cell culture as protein fusions. Also, aggregatingagents such as alum are suitable to enhance the immune response.

2) Monoclonal Antibodies

Monoclonal antibodies are obtained from a population of substantiallyhomogeneous antibodies, i.e., the individual antibodies comprising thepopulation are identical except for possible naturally occurringmutations and/or post-translational modifications (e.g., isomerizations,amidations) that may be present in minor amounts. Thus, the modifier“monoclonal” indicates the character of the antibody as not being amixture of discrete antibodies.

For example, the monoclonal antibodies may be made using the hybridomamethod first described by Kohler et al., Nature, 256:495 (1975), or maybe made by recombinant DNA methods (U.S. Pat. No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, suchas a hamster, is immunized as hereinabove described to elicitlymphocytes that produce or are capable of producing antibodies thatwill specifically bind to the protein used for immunization.Alternatively, lymphocytes may be immunized in vitro. Lymphocytes thenare fused with myeloma cells using a suitable fusing agent, such aspolyethylene glycol, to form a hybridoma cell (Goding, MonoclonalAntibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986).

The immunizing agent will typically include the antigenic protein or afusion variant thereof. Generally either peripheral blood lymphocytes(“PBLs”) are used if cells of human origin are desired, or spleen cellsor lymph node cells are used if non-human mammalian sources are desired.The lymphoctyes are then fused with an immortalized cell line using asuitable fusing agent, such as polyethylene glycol, to form a hybridomacell. Goding, Monoclonal Antibodies: Principles and Practice, AcademicPress (1986), pp. 59-103.

Immortalized cell lines are usually transformed mammalian cells,particularly myeloma cells of rodent, bovine and human origin. Usually,rat or mouse myeloma cell lines are employed. The hybridoma cells thusprepared are seeded and grown in a suitable culture medium thatpreferably contains one or more substances that inhibit the growth orsurvival of the unfused, parental myeloma cells. For example, if theparental myeloma cells lack the enzyme hypoxanthine guaninephosphoribosyl transferase (HGPRT or HPRT), the culture medium for thehybridomas typically will include hypoxanthine, aminopterin, andthymidine (HAT medium), which are substances that prevent the growth ofHGPRT-deficient cells.

Preferred immortalized myeloma cells are those that fuse efficiently,support stable high-level production of antibody by the selectedantibody-producing cells, and are sensitive to a medium such as HATmedium. Among these, preferred are murine myeloma lines, such as thosederived from MOPC-21 and MPC-11 mouse tumors available from the SalkInstitute Cell Distribution Center, San Diego, Calif. USA, and SP-2cells (and derivatives thereof, e.g., X63-Ag8-653) available from theAmerican Type Culture Collection, Manassas, Va. USA. Human myeloma andmouse-human heteromyeloma cell lines also have been described for theproduction of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001(1984); Brodeur et al, Monoclonal Antibody Production Techniques andApplications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed forproduction of monoclonal antibodies directed against the antigen.Preferably, the binding specificity of monoclonal antibodies produced byhybridoma cells is determined by immunoprecipitation or by an in vitrobinding assay, such as radioimmunoassay (RIA) or enzyme-linkedimmunosorbent assay (ELISA).

The culture medium in which the hybridoma cells are cultured can beassayed for the presence of monoclonal antibodies directed against thedesired antigen. Preferably, the binding affinity and specificity of themonoclonal antibody can be determined by immunoprecipitation or by an invitro binding assay, such as radioimmunoassay (RIA) or enzyme-linkedassay (ELISA). Such techniques and assays are known in the in art. Forexample, binding affinity may be determined by the Scatchard analysis ofMunson et al., Anal. Biochem., 107:220 (1980).

After hybridoma cells are identified that produce antibodies of thedesired specificity, affinity, and/or activity, the clones may besubcloned by limiting dilution procedures and grown by standard methods(Goding, supra). Suitable culture media for this purpose include, forexample, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells maybe grown in vivo as tumors in a mammal.

The monoclonal antibodies secreted by the subclones are suitablyseparated from the culture medium, ascites fluid, or serum byconventional immunoglobulin purification procedures such as, forexample, protein A-Sepharose, hydroxylapatite chromatography, gelelectrophoresis, dialysis, or affinity chromatography.

Monoclonal antibodies may also be made by recombinant DNA methods, suchas those described in U.S. Pat. No. 4,816,567, and as described above.DNA encoding the monoclonal antibodies is readily isolated and sequencedusing conventional procedures (e.g., by using oligonucleotide probesthat are capable of binding specifically to genes encoding the heavy andlight chains of murine antibodies). The hybridoma cells serve as apreferred source of such DNA. Once isolated, the DNA may be placed intoexpression vectors, which are then transfected into host cells such asE. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, ormyeloma cells that do not otherwise produce immunoglobulin protein, inorder to synthesize monoclonal antibodies in such recombinant hostcells. Review articles on recombinant expression in bacteria of DNAencoding the antibody include Skerra et al., Curr. Opinion in Immunol,5:256-262 (1993) and Plückthun, Immunol Revs. 130:151-188 (1992).

In a further embodiment, antibodies can be isolated from antibody phagelibraries generated using the techniques described in McCafferty et al.,Nature, 348:552-554 (1990). Clackson et al., Nature, 352:624-628 (1991)and Marks et al., J. Mol. Biol., 222:581-597 (1991) describe theisolation of murine and human antibodies, respectively, using phagelibraries. Subsequent publications describe the production of highaffinity (nM range) human antibodies by chain shuffling (Marks et al.,Bio/Technology, 10:779-783 (1992)), as well as combinatorial infectionand in vivo recombination as a strategy for constructing very largephage libraries (Waterhouse et al., Nucl. Acids Res., 21:2265-2266(1993)). Thus, these techniques are viable alternatives to traditionalmonoclonal antibody hybridoma techniques for isolation of monoclonalantibodies.

The DNA also may be modified, for example, by substituting the codingsequence for human heavy- and light-chain constant domains in place ofthe homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison, etal., Proc. Natl. Acad. Sci. USA, 81:6851 (1984)), or by covalentlyjoining to the immunoglobulin coding sequence all or part of the codingsequence for a non-immunoglobulin polypeptide. Typically suchnon-immunoglobulin polypeptides are substituted for the constant domainsof an antibody, or they are substituted for the variable domains of oneantigen-combining site of an antibody to create a chimeric bivalentantibody comprising one antigen-combining site having specificity for anantigen and another antigen-combining site having specificity for adifferent antigen.

The monoclonal antibodies described herein may by monovalent, thepreparation of which is well known in the art. For example, one methodinvolves recombinant expression of immunoglobulin light chain and amodified heavy chain. The heavy chain is truncated generally at anypoint in the Fc region so as to prevent heavy chain crosslinking.Alternatively, the relevant cysteine residues may be substituted withanother amino acid residue or are deleted so as to prevent crosslinking.In vitro methods are also suitable for preparing monovalent antibodies.Digestion of antibodies to produce fragments thereof, particularly Fabfragments, can be accomplished using routine techniques known in theart.

Chimeric or hybrid antibodies also may be prepared in vitro using knownmethods in synthetic protein chemistry, including those involvingcrosslinking agents. For example, immunotoxins may be constructed usinga disulfide-exchange reaction or by forming a thioether bond. Examplesof suitable reagents for this purpose include iminothiolate andmethyl-4-mercaptobutyrimidate.

3) Humanized Antibodies.

The antibodies of the invention may further comprise humanized or humanantibodies. Humanized forms of non-human (e.g., murine) antibodies arechimeric immunoglobulins, immunoglobulin chains or fragments thereof(such as Fv, Fab, Fab′, F(ab′)₂ or other antigen-binding subsequences ofantibodies) which contain minimal sequence derived from non-humanimmunoglobulin. Humanized antibodies include human immunoglobulins(recipient antibody) in which residues from a complementaritydetermining region (CDR) of the recipient are replaced by residues froma CDR of a non-human species (donor antibody) such as mouse, rat orrabbit having the desired specificity, affinity and capacity. In someinstances, Fv framework residues of the human immunoglobulin arereplaced by corresponding non-human residues. Humanized antibodies mayalso comprise residues which are found neither in the recipient antibodynor in the imported CDR or framework sequences. In general, thehumanized antibody will comprise substantially all of at least one, andtypically two, variable domain, in which all or substantially all of theCDR regions correspond to those of a non-human immunoglobulin and all orsubstantially all of the FR regions are those of a human immunoglobulinconsensus sequence. The humanized antibody optimally also will compriseat least a portion of an immunoglobulin constant region (Fc), typicallythat of a human immunoglobulin. Jones et al., Nature 321: 522-525(1986); Riechmann et al., Nature 332: 323-329 (1988) and Presta, Curr.Opin. Struct. Biol. 2: 593-596 (1992).

Methods for humanizing non-human antibodies are well known in the art.Generally, a humanized antibody has one or more amino acid residuesintroduced into it from a source which is non-human. These non-humanamino acid residues are often referred to as “import” residues, whichare typically taken from an “import” variable domain. Humanization canbe essentially performed following the method of Winter and co-workers,Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988), orthrough substituting rodent CDRs or CDR sequences for the correspondingsequences of a human antibody. Accordingly, such “humanized” antibodiesare chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantiallyless than an intact human variable domain has been substituted by thecorresponding sequence from a non-human species. In practice, humanizedantibodies are typically human antibodies in which some CDR residues andpossibly some FR residues are substituted by residues from analogoussites in rodent antibodies.

The choice of human variable domains, both light and heavy, to be usedin making the humanized antibodies is very important to reduceantigenicity. According to the so-called “best-fit” method, the sequenceof the variable domain of a rodent antibody is screened against theentire library of known human variable-domain sequences. The humansequence which is closest to that of the rodent is then accepted as thehuman framework (FR) for the humanized antibody. Sims et al., J.Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901(1987). Another method uses a particular framework derived from theconsensus sequence of all human antibodies of a particular subgroup oflight or heavy chains. The same framework may be used for severaldifferent humanized antibodies. Carter et al., Proc. Natl. Acad. Sci.USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993).

It is further important that antibodies be humanized with retention ofhigh affinity for the antigen and other favorable biological properties.To achieve this goal, according to a preferred method, humanizedantibodies are prepared by a process of analysis of the parentalsequences and various conceptual humanized products usingthree-dimensional models of the parental and humanized sequences.Three-dimensional immunoglobulin models are commonly available and arefamiliar to those skilled in the art. Computer programs are availablewhich illustrate and display probable three-dimensional conformationalstructures of selected candidate immunoglobulin sequences. Inspection ofthese displays permits analysis of the likely role of the residues inthe functioning of the candidate immunoglobulin sequence, i.e., theanalysis of residues that influence the ability of the candidateimmunoglobulin to bind its antigen. In this way, FR residues can beselected and combined from the recipient and import sequences so thatthe desired antibody characteristic, such as increased affinity for thetarget antigen(s), is achieved. In general, the CDR residues aredirectly and most substantially involved in influencing antigen binding.

Various forms of the humanized antibody are contemplated. For example,the humanized antibody may be an antibody fragment, such as an Fab,which is optionally conjugated with one or more cytotoxic agent(s) inorder to generate an immunoconjugate. Alternatively, the humanizedantibody may be an intact antibody, such as an intact IgG1 antibody.

4) Human Antibodies

As an alternative to humanization, human antibodies can be generated.For example, it is now possible to produce transgenic animals (e.g.,mice) that are capable, upon immunization, of producing a fullrepertoire of human antibodies in the absence of endogenousimmunoglobulin production. For example, it has been described that thehomozygous deletion of the antibody heavy-chain joining region (JH) genein chimeric and germ-line mutant mice results in complete inhibition ofendogenous antibody production. Transfer of the human germ-lineimmunoglobulin gene array in such germ-line mutant mice will result inthe production of human antibodies upon antigen challenge. See, e.g.,Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993);Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann et al., Yearin Immuno., 7:33 (1993); U.S. Pat. No. 5,591,669 and WO 97/17852.

Alternatively, phage display technology can be used to produce humanantibodies and antibody fragments in vitro, from immunoglobulin variable(V) domain gene repertoires from unimmunized donors. McCafferty et al.,Nature 348:552-553 (1990); Hoogenboom and Winter, J. Mol. Biol. 227: 381(1991). According to this technique, antibody V domain genes are clonedin-frame into either a major or minor coat protein gene of a filamentousbacteriophage, such as M13 or fd, and displayed as functional antibodyfragments on the surface of the phage particle. Because the filamentousparticle contains a single-stranded DNA copy of the phage genome,selections based on the functional properties of the antibody alsoresult in selection of the gene encoding the antibody exhibiting thoseproperties. Thus, the phage mimics some of the properties of the B-cell.Phage display can be performed in a variety of formats, reviewed in,e.g., Johnson, Kevin S, and Chiswell, David J., Curr. Opin Struct. Biol.3:564-571 (1993). Several sources of V-gene segments can be used forphage display. Clackson et al., Nature 352:624-628 (1991) isolated adiverse array of anti-oxazolone antibodies from a small randomcombinatorial library of V genes derived from the spleens of immunizedmice. A repertoire of V genes from unimmunized human donors can beconstructed and antibodies to a diverse array of antigens (includingself-antigens) can be isolated essentially following the techniquesdescribed by Marks et al., J. Mol. Biol. 222:581-597 (1991), or Griffithet al., EMBO J. 12:725-734 (1993). See also, U.S. Pat. Nos. 5,565,332and 5,573,905.

The techniques of Cole et al., and Boerner et al., are also availablefor the preparation of human monoclonal antibodies (Cole et al.,Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) andBoerner et al., J. Immunol. 147(1): 86-95 (1991). Similarly, humanantibodies can be made by introducing human immunoglobulin loci intotransgenic animals, e.g., mice in which the endogenous immunoglobulingenes have been partially or completely inactivated. Upon challenge,human antibody production is observed, which closely resembles that seenin humans in all respects, including gene rearrangement, assembly andantibody repertoire. This approach is described, for example, in U.S.Pat. Nos. 5,545,807; 5,545,806, 5,569,825, 5,625,126, 5,633,425,5,661,016 and in the following scientific publications: Marks et al.,Bio/Technology 10: 779-783 (1992); Lonberg et al., Nature 368: 856-859(1994); Morrison, Nature 368: 812-13 (1994), Fishwild et al., NatureBiotechnology 14: 845-51 (1996), Neuberger, Nature Biotechnology 14: 826(1996) and Lonberg and Huszar, Intern. Rev. Immunol. 13: 65-93 (1995).

Finally, human antibodies may also be generated in vitro by activated Bcells (see U.S. Pat. Nos. 5,567,610 and 5,229,275).

5) Antibody Fragments

In certain circumstances there are advantages to using antibodyfragments, rather than whole antibodies. Smaller fragment sizes allowfor rapid clearance, and may lead to improved access to solid tumors.

Various techniques have been developed for the production of antibodyfragments. Traditionally, these fragments were derived via proteolyticdigestion of intact antibodies (see, e.g., Morimoto et al., J BiochemBiophys. Method. 24:107-117 (1992); and Brennan et al., Science 229:81(1985)). However, these fragments can now be produced directly byrecombinant host cells. Fab, Fv and scFv antibody fragments can all beexpressed in and secreted from E. coli, thus allowing the facileproduction of large amounts of these fragments. Antibody fragments canbe isolated from the antibody phage libraries discussed above.Alternatively, Fab′-SH fragments can be directly recovered from E. coliand chemically coupled to form F(ab′)₂ fragments (Carter et al.,Bio/Technology 10:163-167 (1992)). According to another approach,F(ab′)₂ fragments can be isolated directly from recombinant host cellculture. Fab and F(ab′)₂ with increase in vivo half-life is described inU.S. Pat. No. 5,869,046. In other embodiments, the antibody of choice isa single chain Fv fragment (scFv). See WO 93/16185; U.S. Pat. No.5,571,894 and U.S. Pat. No. 5,587,458. The antibody fragment may also bea “linear antibody”, e.g., as described in U.S. Pat. No. 5,641,870. Suchlinear antibody fragments may be monospecific or bispecific.

6) Antibody Dependent Enzyme-Mediated Prodrug Therapy (ADEPT)

The antibodies of the present invention may also be used in ADEPT byconjugating the antibody to a prodrug-activating enzyme which converts aprodrug (e.g. a peptidyl chemotherapeutic agent, see WO 81/01145) to anactive anti-cancer drug. See, for example, WO 88/07378 and U.S. Pat. No.4,975,278.

The enzyme component of the immunoconjugate useful for ADEPT includesany enzyme capable of acting on a prodrug in such a way so as to convertit into its more active, cytotoxic form.

Enzymes that are useful in the method of this invention include, but arenot limited to, glycosidase, glucose oxidase, human lysozyme, humanglucuronidase, alkaline phosphatase useful for convertingphosphate-containing prodrugs into free drugs; arylsulfatase useful forconverting sulfate-containing prodrugs into free drugs; cytosinedeaminase useful for converting non-toxic 5-fluorocytosine into theanti-cancer drug 5-fluorouracil; proteases, such as serratia protease,thermolysin, subtilisin, carboxypeptidases (e.g., carboxypeptidase G2and carboxypeptidase A) and cathepsins (such as cathepsins B and L),that are useful for converting peptide-containing prodrugs into freedrugs; D-alanylcarboxypeptidases, useful for converting prodrugs thatcontain D-amino acid substituents; carbohydrate-cleaving enzymes such asβ-galactosidase and neuraminidase useful for converting glycosylatedprodrugs into free drugs; β-lactamase useful for converting drugsderivatized with β-lactams into free drugs; and penicillin amidases,such as penicillin Vamidase or penicillin G amidase, useful forconverting drugs derivatized at their amine nitrogens with phenoxyacetylor phenylacetyl groups, respectively, into free drugs. Alternatively,antibodies with enzymatic activity, also known in the art as “abzymes”can be used to convert the prodrugs of the invention into free activedrugs (see, e.g., Massey, Nature 328: 457-458 (1987)). Antibody-abzymeconjugates can be prepared as described herein for delivery of theabzyme to a tumor cell population.

The above enzymes can be covalently bound to the polypeptide orantibodies described herein by techniques well known in the art such asthe use of the heterobifunctional cross-linking agents discussed above.Alternatively, fusion proteins comprising at least the antigen bindingregion of the antibody of the invention linked to at least afunctionally active portion of an enzyme of the invention can beconstructed using recombinant DNA techniques well known in the art (see,e.g. Neuberger et al., Nature 312: 604-608 (1984)).

7) Bispecific and Polyspecific Antibodies

Bispecific antibodies (BsAbs) are antibodies that have bindingspecificities for at least two different epitopes, including those onthe same or another protein. Alternatively, one arm can be armed to bindto the target antigen, and another arm can be combined with an arm thatbinds to a triggering molecule on a leukocyte such as a T-cell receptormolecule (e.g., CD3), or Fc receptors for IgG (FcγR) such as FcγR1(CD64), FcγRII (CD32) and FcγRIII (CD16), so as to focus and localizecellular defense mechanisms to the target antigen-expressing cell. Suchantibodies can be derived from full length antibodies or antibodyfragments (e.g. F(ab′)₂ bispecific antibodies).

Bispecific antibodies may also be used to localize cytotoxic agents tocells which express the target antigen. Such antibodies possess one armthat binds the desired antigen and another arm that binds the cytotoxicagent (e.g., saporin, anti-interferon-a, vinca alkoloid, ricin A chain,methotrexate or radioactive isotope hapten). Examples of knownbispecific antibodies include anti-ErbB2/anti-FcgRIII (WO 96/16673),anti-ErbB2/anti-FcgRI (U.S. Pat. No. 5,837,234), anti-ErbB2/anti-CD3(U.S. Pat. No. 5,821,337).

Methods for making bispecific antibodies are known in the art.Traditional production of full length bispecific antibodies is based onthe coexpression of two immunoglobulin heavy-chain/light chain pairs,where the two chains have different specificities. Millstein et al.,Nature, 305:537-539 (1983). Because of the random assortment ofimmunoglobulin heavy and light chains, these hybridomas (quadromas)produce a potential mixture of 10 different antibody molecules, of whichonly one has the correct bispecific structure. Purification of thecorrect molecule, which is usually done by affinity chromatographysteps, is rather cumbersome, and the product yields are low. Similarprocedures are disclosed in WO 93/08829 and in Traunecker et al, EMBOJ., 10:3655-3659 (1991).

According to a different approach, antibody variable domains with thedesired binding specificities (antibody-antigen combining sites) arefused to immunoglobulin constant domain sequences. The fusion preferablyis with an immunoglobulin heavy chain constant domain, comprising atleast part of the hinge, CH2, and CH3 regions. It is preferred to havethe first heavy-chain constant region (CH1) containing the sitenecessary for light chain binding, present in at least one of thefusions. DNAs encoding the immunoglobulin heavy chain fusions and, ifdesired, the immunoglobulin light chain, are inserted into separateexpression vectors, and are co-transfected into a suitable hostorganism. This provides for great flexibility in adjusting the mutualproportions of the three polypeptide fragments in embodiments whenunequal ratios of the three polypeptide chains used in the constructionprovide the optimum yields. It is, however, possible to insert thecoding sequences for two or all three polypeptide chains in oneexpression vector when the expression of at least two polypeptide chainsin equal ratios results in high yields or when the ratios are of noparticular significance.

In a preferred embodiment of this approach, the bispecific antibodiesare composed of a hybrid immunoglobulin heavy chain with a first bindingspecificity in one arm, and a hybrid immunoglobulin heavy chain-lightchain pair (providing a second binding specificity) in the other arm. Itwas found that this asymmetric structure facilitates the separation ofthe desired bispecific compound from unwanted immunoglobulin chaincombinations, as the presence of an immunoglobulin light chain in onlyone half of the bispecific molecules provides for an easy way ofseparation. This approach is disclosed in WO 94/04690. For furtherdetails of generating bispecific antibodies, see, for example, Suresh etal., Methods in Enzymology 121: 210 (1986).

According to another approach described in WO 96/27011 or U.S. Pat. No.5,731,168, the interface between a pair of antibody molecules can beengineered to maximize the percentage of heterodimers which arerecovered from recombinant cell culture. The preferred interfacecomprises at least a part of the CH3 region of an antibody constantdomain. In this method, one or more small amino acid side chains fromthe interface of the first antibody molecule are replaced with largerside chains (e.g., tyrosine or tryptophan). Compensatory “cavities” ofidentical or similar size to the large side chains(s) are created on theinterface of the second antibody molecule by replacing large amino acidside chains with smaller ones (e.g., alanine or threonine). Thisprovides a mechanism for increasing the yield of the heterodimer overother unwanted end-products such as homodimers.

Techniques for generating bispecific antibodies from antibody fragmentshave been described in the literature. For example, bispecificantibodies can be prepared using chemical linkage. Brennan et al.,Science 229: 81 (1985) describe a procedure wherein intact antibodiesare proteolytically cleaved to generate F(ab′)₂ fragments. Thesefragments are reduced in the presence of the dithiol complexing agentsodium arsenite to stabilize vicinal dithiols and prevent intermoleculardisulfide formation. The Fab′ fragments generated are then converted tothionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives isthen reconverted to the Fab′-TNB derivative to form the bispecificantibody. The bispecific antibodies produced can be used as agents forthe selective immobilization of enzymes.

Fab′ fragments may be directly recovered from E. coli and chemicallycoupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describes the production of fully humanized bispecificantibody F(ab′)₂ molecules. Each Fab′ fragment was separately secretedfrom E. coli and subjected to directed chemical coupling in vitro toform the bispecific antibody. The bispecific antibody thus formed wasable to bind to cells overexpressing the ErbB2 receptor and normal humanT cells, as well as trigger the lytic activity of human cytotoxiclymphocytes against human breast tumor targets.

Various techniques for making and isolating bivalent antibody fragmentsdirectly from recombinant cell culture have also been described. Forexample, bivalent heterodimers have been produced using leucine zippers.Kostelny et al., J. Immunol, 148(5):1547-1553 (1992). The leucine zipperpeptides from the Fos and Jun proteins were linked to the Fab′ portionsof two different antibodies by gene fusion. The antibody homodimers werereduced at the hinge region to form monomers and then re-oxidized toform the antibody heterodimers. The “diabody” technology described byHollinger et al., Proc. Natl. Acad. Sci. USA, 90: 6444-6448 (1993) hasprovided an alternative mechanism for making bispecific/bivalentantibody fragments. The fragments comprise a heavy-chain variable domain(V_(H)) connected to a light-chain variable domain (V_(L)) by a linkerwhich is too short to allow pairing between the two domains on the samechain. Accordingly, the V_(H) and V_(L) domains of one fragment areforced to pair with the complementary V_(L) and V_(H) domains of anotherfragment, thereby forming two antigen-binding sites. Another strategyfor making bispecific/bivalent antibody fragments by the use ofsingle-chain Fv (sFv) dimers has also been reported. See Gruber et al.,J. Immunol, 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example,trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147: 60(1991).

Exemplary bispecific antibodies may bind to two different epitopes on agiven molecule. Alternatively, an anti-protein arm may be combined withan arm which binds to a triggering molecule on a leukocyte such as aT-cell receptor molecule (e.g., CD2, CD3, CD28 or B7), or Fc receptorsfor IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16)so as to focus cellular defense mechanisms to the cell expressing theparticular protein. Bispecific antibodies may also be used to localizecytotoxic agents to cells which express a particular protein. Suchantibodies possess a protein-binding arm and an arm which binds acytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTAor TETA. Another bispecific antibody of interest binds the protein ofinterest and further binds tissue factor (TF).

8) Multivalent Antibodies

A multivalent antibody may be internalized (and/or catabolized) fasterthan a bivalent antibody by a cell expressing an antigen to which theantibodies bind. The antibodies of the present invention can bemultivalent antibodies (which are other than of the IgM class) withthree or more antigen binding sites (e.g. tetravalent antibodies), whichcan be readily produced by recombinant expression of nucleic acidencoding the polypeptide chains of the antibody. The multivalentantibody can comprise a dimerization domain and three or more antigenbinding sites. The preferred dimerization domain comprises (or consistsof) an Fc region or a hinge region. In this scenario, the antibody willcomprise an Fc region and three or more antigen binding sitesamino-terminal to the Fc region. The preferred multivalent antibodyherein comprises (or consists of) three to about eight, but preferablyfour, antigen binding sites. The multivalent antibody comprises at leastone polypeptide chain (and preferably two polypeptide chains), whereinthe polypeptide chain(s) comprise two or more variable domains. Forinstance, the polypeptide chain(s) may compriseVD1-(X1)_(n)-VD2-(X2)_(n)-Fc, wherein VD1 is a first variable domain,VD2 is a second variable domain, Fc is one polypeptide chain of an Fcregion, X1 and X2 represent an amino acid or polypeptide, and n is 0or 1. For instance, the polypeptide chain(s) may comprise:VH-CH1-flexible linker-VH-CH1-Fc region chain; or VH-CH1-VH-CH1-Fcregion chain. The multivalent antibody herein preferably furthercomprises at least two (and preferably four) light chain variable domainpolypeptides. The multivalent antibody herein may, for instance,comprise from about two to about eight light chain variable domainpolypeptides. The light chain variable domain polypeptides contemplatedhere comprise a light chain variable domain and, optionally, furthercomprise a CL domain.

9) Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the presentinvention. Heteroconjugate antibodies are composed of two covalentlyjoined antibodies. For example, one of the antibodies in theheteroconjugate can be coupled to avidin, the other to biotin. Suchantibodies have, for example, been proposed to target immune systemcells to unwanted cells, U.S. Pat. No. 4,676,980, and for treatment ofHIV infection. WO 91/00360, WO 92/200373 and EP 0308936. It iscontemplated that the antibodies may be prepared in vitro using knownmethods in synthetic protein chemistry, including those involvingcrosslinking agents. For example, immunotoxins may be constructed usinga disulfide exchange reaction or by forming a thioether bond. Examplesof suitable reagents for this purpose include iminothiolate andmethyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S.Pat. No. 4,676,980. Heteroconjugate antibodies may be made using anyconvenient cross-linking methods. Suitable cross-linking agents are wellknown in the art, and are disclosed in U.S. Pat. No. 4,676,980, alongwith a number of cross-linking techniques.

10) Effector Function Engineering

It may be desirable to modify the antibody of the invention with respectto effector function, e.g., so as to enhance antigen-dependentcell-mediated cyotoxicity (ADCC) and/or complement dependentcytotoxicity (CDC) of the antibody. This may be achieved by introducingone or more amino acid substitutions in an Fc region of the antibody.Alternatively or additionally, cysteine residue(s) may be introduced inthe Fc region, thereby allowing interchain disulfide bond formation inthis region. The homodimeric antibody thus generated may have improvedinternalization capability and/or increased complement-mediated cellkilling and antibody-dependent cellular cytotoxicity (ADCC). See Caronet al., J. Exp Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol.148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumoractivity may also be prepared using heterobifunctional cross-linkers asdescribed in Wolff et al., Cancer Research 53:2560-2565 (1993).Alternatively, an antibody can be engineered which has dual Fc regionsand may thereby have enhanced complement lysis and ADCC capabilities.See Stevenson et al., Anti-Cancer Drug Design 3:219-230 (1989).

To increase the serum half life of the antibody, one may incorporate asalvage receptor binding epitope into the antibody (especially anantibody fragment) as described in U.S. Pat. No. 5,739,277, for example.As used herein, the term “salvage receptor binding epitope” refers to anepitope of the Fc region of an IgG molecule (e.g., IgG₁, IgG₂, IgG₃, orIgG₄) that is responsible for increasing the in vivo serum half-life ofthe IgG molecule.

11) Immunoconjugates

The invention also pertains to immunoconjugates or antibody-drugconjugates (ADC), comprising an antibody conjugated to a cytotoxic agentsuch as a chemotherapeutic agent, toxin (e.g., an enzymatically activetoxin of bacterial, fungal, plant, or animal origin, or fragmentsthereof), or a radioactive isotope (i.e., a radioconjugate). Such ADCmust show an acceptable safety profile.

The use of ADCs for the local delivery of cytotoxic or cytostaticagents, e.g., drugs to kill or inhibit tumor cells in the treatment ofcancer [Syrigos and Epenetos, Anticancer Research 19: 605-14 (1999);Niculeascu-Duvaz and Springer, Adv. Drug Del. Rev. 26: 151-72 (1997);U.S. Pat. No. 4,975,278] theoretically allows targeted delivery of thedrug moiety to tumors, and intracellular accumulation therein, wheresystemic administration of these unconjugated drug agents may result inunacceptable levels of toxicity to normal cells as well as the tumorcells sought to be eliminated (Baldwin et al., Lancet, 603-05 (1986);Thorpe, (1985) Antibody Carriers Of Cytotoxic Agents In Cancer Therapy:A Review, in Monoclonal Antibodies '84: Biological And ClinicalApplications, A. Pinchera et al. (eds), pp. 475-506). Maximal efficacywith minimal toxicity is sought thereby. Both polyclonal antibodies andmonoclonal antibodies have been reported as useful in these strategies(Rowland et al., Cancer Immunol. Immunother. 21:183-87 (1986)). Drugsused in these methods include daunomycin, doxorubicin, methotrexate, andvindesine. Toxins used in antibody-toxin conjugates include bacterialtoxins such as diphtheria toxin, plant toxins such as ricin, smallmolecule toxins such as geldanamycin (Mandler et al. J. Nat. CancerInst. 92(19):1573-81 (2000); Mandler et al., Bioorganic & Med. Chem.Letters 10:1025-28 (2000); Mandler et al. Bioconjugate Chem. 13: 786-91(2002)), maytansinoids (EP 1391213; Liu et al., Proc. Natl. Acad. Sci.USA 93: 8618-23 (1996)), and calicheamicin (Lode et al., Cancer Res.58:2928 (1998); and Hinman et al., Cancer Res. 53:3336-42 (1993)). Thetoxins may exert their cytotoxic and cytostatic effects by mechanismsincluding tubulin binding, DNA binding, or topoisomerase inhibition.Some cytotoxic drugs tend to be inactive or less active when conjugatedto large antibodies or protein receptor ligands.

Chemotherapeutic agents useful in the generation of suchimmunoconjugates have been described above, and include BCNU,streptozoicin, vincristine, vinblastine, adriamycin and 5-fluorouracil.

Enzymatically active toxins and fragments thereof that can be usedinclude diphtheria A chain, nonbinding active fragments of diphtheriatoxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain,abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordiiproteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII,and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonariaofficinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin,enomycin, and the tricothecenes. A variety of radionuclides areavailable for the production of radioconjugated antibodies. Examplesinclude ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, and ¹⁸⁶Re. Conjugates of the antibodyand cytotoxic agent are made using a variety of bifunctionalprotein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol)propionate (SPDP), iminothiolane (IT), bifunctional derivatives ofimidoesters (such as dimethyl adipimidate HCl), active esters (such asdisuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azidocompounds (such as bis(p-azidobenzoyl) hexanediamine), bis-diazoniumderivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine),diisocyanates (such as toluene 2,6-diisocyanate), and bis-activefluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Forexample, a ricin immunotoxin can be prepared as described in Vitetta etal., Science, 238: 1098 (1987). Carbon-14-labeled1-isothiocyanatobenzyl-3-methyldiethylene triamine-pentaacetic acid(MX-DTPA) is an exemplary chelating agent for conjugation ofradionucleotide to the antibody. See, for example, WO 1994/11026.

Conjugates of the antibody and cytotoxic agent are made using a varietyof bifunctional protein-coupling agents such asN-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane(IT), bifunctional derivatives of imidoesters (such as dimethyladipimidate HCL), active esters (such as disuccinimidyl suberate),aldehydes (such as glutareldehyde), bis-azido compounds (such asbis(p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such asbis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such astolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin canbe prepared as described in Vitetta et al., Science, 238: 1098 (1987).Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent forconjugation of radionucleotide to the antibody. See WO94/11026. Thelinker may be a “cleavable linker” facilitating release of the cytotoxicdrug in the cell. For example, an acid-labile linker,peptidase-sensitive linker, dimethyl linker or disulfide-containinglinker (Chari et al., Cancer Res. 52:127-131 (1992)) may be used.

Additionally, the small molecule toxins such as calicheamicin,maytansine (U.S. Pat. No. 5,208,020), trichothene and CC1065 are alsocontemplated as conjugatable toxins for use with the inventiveformulation. In one embodiment, the full length antibody or antigenbinding fragments thereof can be conjugated to one or more maytansinoidmolecules (e.g., about 1 to about 10 maytansinoid molecules per antibodymolecule). Maytansinoids are mitotic inhibitors which act by inhibitingtubulin polymerization. Maytansinoids, isolated from natural sources orprepared synthetically, including maytansine, maytansinal andderivatives and analogues thereof have been described, see e.g., U.S.Pat. No. 5,208,020 and references cited therein (see col. 2, line 53 tocol. 3, line 10) and U.S. Pat. Nos. 3,896,111 and 4,151,042. Methods ofpreparing antibody-maytansinoid conjugates are also described in U.S.Pat. No. 5,208,020. In a preferred embodiment, a maytansinoid is linkedto the antibody via a disulfide or other sulfur-containing linker group.Maytansine may, for example, be converted to May-SS-Me, which may bereduced to May-SH3 and reacted with modified antibody to generate amaytansinoid-antibody immunoconjugate. Chari et al., Cancer Res. 52:127-131 (1992). The antibody can be modified by known methods and theantibody containing free or protected thiol groups is then reacted witha disulfide containing maytansinoid to produce the conjugate. Thecytotoxicity of the antibody-maytansinoid conjugate can be measured invitro or in vivo by known methods and the IC₅₀ determined.

Calicheamicin is another immunoconjugate of interest. The calicheamicinfamily of antibiotics are capable of producing double-stranded DNAbreaks at sub-picomolar concentrations. Structural analogues ofcalicheamicin which may be used include, but are not limited to, γ₁ ¹,α₂ ¹, α₃ ¹, N-aceytl-yl, PSAG and θ¹ ₁ (Hinman et al., Cancer Res.53:3336-3342 (1993) and Lode et al., Cancer Res. 58:2925-2928 (1998)).Other anti-tumor drugs that the antibody can be conjugated to includeQFA which is an antifolate. Both calicheamicin and QFA haveintracellular sites of actions and do not readily cross the plasmamembrane. Therefore, cellular uptake of these agents through antibodymediated internalization greatly enhances their cytotoxic effects.

Immunoconjugates formed between an antibody and a compound withnucleolytic activity (e.g., a ribonuclease or DNA endonuclease such asdeoxyribonuclease, DNase) are also contemplated.

In the ADCs of the invention, an antibody (Ab) is conjugated to one ormore drug moieties (D), e.g. about 1 to about 20 drug moieties perantibody, through a linker (L). The ADC of Formula I may be prepared byseveral routes, employing organic chemistry reactions, conditions, andreagents known to those skilled in the art, including: (1) reaction of anucleophilic group of an antibody with a bivalent linker reagent, toform Ab-L, via a covalent bond, followed by reaction with a drug moietyD; and (2) reaction of a nucleophilic group of a drug moiety with abivalent linker reagent, to form D-L, via a covalent bond, followed byreaction with the nucleophilic group of an antibody.

Ab-(L-D)_(p)  Formula I

Nucleophilic groups on antibodies include, but are not limited to: (i)N-terminal amine groups, (ii) side-chain amine groups, e.g. lysine,(iii) side-chain thiol groups, e.g. cysteine, and (iv) sugar hydroxyl oramino groups where the antibody is glycosylated. Amine, thiol, andhydroxyl groups are nucleophilic and capable of reacting to formcovalent bonds with electrophilic groups on linker moieties and linkerreagents including: (i) active esters such as NHS esters, HOBt esters,haloformates, and acid halides; (ii) alkyl and benzyl halides such ashaloacetamides; and (iii) aldehydes, ketones, carboxyl, and maleimidegroups. Certain antibodies have reducible interchain disulfides, i.e.cysteine bridges. Antibodies may be made reactive for conjugation withlinker reagents by treatment with a reducing agent such as DTT(dithiothreitol). Each cysteine bridge will thus form, theoretically,two reactive thiol nucleophiles. Additional nucleophilic groups can beintroduced into antibodies through the reaction of lysines with2-iminothiolane (Traut's reagent) resulting in conversion of an amineinto a thiol.

ADCs of the invention may also be produced by modification of theantibody to introduce electrophilic moieties, which can react withnucleophilic substituents on the linker reagent or drug. The sugars ofglycosylated antibodies may be oxidized, e.g. with periodate oxidizingreagents, to form aldehyde or ketone groups that may react with theamine group of linker reagents or drug moieties. The resulting imineSchiff base groups may form a stable linkage, or may be reduced, e.g. byborohydride reagents to form stable amine linkages. In one embodiment,reaction of the carbohydrate portion of a glycosylated antibody witheither galactose oxidase or sodium meta-periodate may yield carbonyl(aldehyde and ketone) groups in the protein that can react withappropriate groups on the drug (Domen et al., J. Chromatog., 510:293-302 (1990)). In another embodiment, proteins containing N-terminalserine or threonine residues can react with sodium meta-periodate,resulting in production of an aldehyde in place of the first amino acid(Geoghegan and Stroh, Bioconjugate Chem. 3:138-46 (1992); U.S. Pat. No.5,362,852). Such aldehyde can be reacted with a drug moiety or linkernucleophile.

Likewise, nucleophilic groups on a drug moiety include, but are notlimited to: amine, thiol, hydroxyl, hydrazide, oxime, hydrazine,thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groupscapable of reacting to form covalent bonds with electrophilic groups onlinker moieties and linker reagents including: (i) active esters such asNHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl andbenzyl halides such as haloacetamides; and (iii) aldehydes, ketones,carboxyl, and maleimide groups.

Alternatively, a fusion protein comprising the antibody and cytotoxicagent may be made, e.g., by recombinant techniques or peptide synthesis.The length of DNA may comprise respective regions encoding the twoportions of the conjugate either adjacent one another or separated by aregion encoding a linker peptide that does not destroy the desiredproperties of the conjugate.

In yet another embodiment, the antibody may be conjugated to a“receptor” (such streptavidin) for utilization in tumor pre-targetingwherein the antibody-receptor conjugate is administered to the patient,followed by removal of unbound conjugate from the circulation using aclearing agent and then administration of a “ligand” (e.g., avidin) thatis conjugated to a cytotoxic agent (e.g., a radionucleotide).

The ADCs herein are optionally prepared with cross-linker reagents:BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB,SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB,sulfo-SMCC, and sulfo-SMPB, and SVSB(succinimidyl-(4-vinylsulfone)benzoate), which are commerciallyavailable (e.g., Pierce Biotechnology, Inc., Rockford, Ill.).

The antibody may also be conjugated to a highly radioactive atom. Avariety of radionuclides are available for the production ofradioconjugated antibodies. Examples include At²¹¹, Bi²¹², I¹³¹, In¹³¹,Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, P³² and Pb²¹² and radioactive isotopes of Lu.When the conjugate is used for diagnosis, it may comprise a radioactiveatom for scintigraphic studies, for example Tc⁹⁹ or I¹²³, or a spinlabel for nuclear magnetic resonance (nmr) imaging (also known asmagnetic resonance imaging, mri), such as iodine-123, iodine-131,indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium,manganese or iron.

The radio- or other labels may be incorporated in the conjugate in knownways. For example, the peptide may be biosynthesized or may besynthesized by chemical amino acid synthesis using suitable amino acidprecursors involving, for example, fluorine-19 in place of hydrogen.Labels such Tc⁹⁹ or I¹²³, Re¹³⁶, Re¹⁸⁸ and In¹¹¹ can be attached via acysteine residue in the peptide. Yttrium-90 can be attached via a lysineresidue. The IODOGEN® method can be used to incorporate iodine-123,Fraker et al., Biohem. Biophys. Res. Commun. 80:49-57 (1978). Othermethods of conjugating radionuclides are described in “MonoclonalAntibodies in Immunoscintigraphy,” (Chatal, CRC Press 1989).

Alternatively, a fusion protein comprising the antibody and thecytotoxic agent may be made by recombinant techniques or peptidesynthesis. The length of DNA may comprise respective regions encodingthe two portions of the conjugate either adjacent to one another orseparated by a region encoding a linker peptide which does not destroythe desired properties of the conjugate.

In another embodiment, the antibody may be conjugated to a “receptor”(such as streptavidin) for utilization in tumor pretargeting wherein theantibody-receptor conjugate is administered to the patient, followed byremoval of unbound conjugate from the circulation using a clearing agentand then administration of a “ligand” (e.g., avidin) that is conjugatedto a cytotoxic agent (e.g., a radionucleotide).

12) Other Amino Acid Sequence Modifications

Amino acid sequence modification(s) of the antibodies described hereinare contemplated. For example, it may be desirable to improve thebinding affinity and/or other biological properties of the antibody.Amino acid sequence variants of the antibody are prepared by introducingappropriate nucleotide changes into the antibody nucleic acid, or bypeptide synthesis. Such modifications include, for example, deletionsfrom, and/or insertions into and/or substitutions of, residues withinthe amino acid sequences of the antibody. Any combination of deletion,insertion, and substitution is made to arrive at the final construct,provided that the final construct possesses the desired characteristics.The amino acid changes also may alter post-translational processes ofthe antibody, such as changing the number or position of glycosylationsites.

A useful method for identification of certain residues or regions of theantibody that are preferred locations for mutagenesis is called “alaninescanning mutagenesis” as described by Cunningham and Wells in Science,244:1081-1085 (1989). Here, a residue or group of target residues areidentified (e.g., charged residues such as arg, asp, his, lys, and glu)and replaced by a neutral or negatively charged amino acid (mostpreferably alanine or polyalanine) to affect the interaction of theamino acids antigen. Those amino acid locations demonstrating functionalsensitivity to the substitutions then are refined by introducing furtheror other variants at, or for, the sites of substitution. Thus, while thesite for introducing an amino acid sequence variation is predetermined,the nature of the mutation per se need not be predetermined. Forexample, to analyze the performance of a mutation at a given site, alascanning or random mutagenesis is conducted at the target codon orregion and the expressed antibody variants are screened for the desiredactivity.

Amino acid sequence insertions include amino- and/or carboxyl-terminalfusions ranging in length from one residue to polypeptides containing ahundred or more residues, as well as intrasequence insertions of singleor multiple amino acid residues. Examples of terminal insertions includean antibody with an N-terminal methionyl residue or the antibody fusedto a cytotoxic polypeptide. Other insertional variants of the antibodymolecule include the fusion to the N- or C-terminus of the antibody toan enzyme (e.g. for ADEPT) or a polypeptide which increases the serumhalf-life of the antibody.

Another type of variant is an amino acid substitution variant. Thesevariants have at least one amino acid residue in the antibody moleculereplaced by a different residue. The sites of greatest interest forsubstitutional mutagenesis include the hypervariable regions, but FRalterations are also contemplated. Conservative substitutions are shownin the Table A below under the heading of “preferred substitutions”. Ifsuch substitutions result in a change in biological activity, then moresubstantial changes, denominated “exemplary substitutions” in Table A,or as further described below in reference to amino acid classes, may beintroduced and the products screened.

TABLE A Amino Acid Substitutions Exemplary Preferred Original ResidueSubstitutions Substitutions Ala (A) val; leu; ile val Arg (R) lys; gln;asn lys Asn (N) gln; his; asp, lys; arg gln Asp (D) glu; asn glu Cys (C)ser; ala ser Gln (Q) asn; glu asn Glu (E) asp, gln asp Gly (G) ala alaHis (H) asn; gln; lys; arg arg Ile (I) leu; val; met; ala; phe;norleucine leu Leu (L) norleucine; ile; val; met; ala; phe ile Lys (K)arg; gln; asn arg Met (M) leu; phe; ile leu Phe (F) leu; val; ile; ala;tyr tyr Pro (P) Ala ala Ser (S) Thr thr Thr (T) Ser ser Trp (W) tyr; phetyr Tyr (Y) trp; phe; thr; ser phe Val (V) ile; leu; met; phe; ala;norleucine leu

Substantial modifications in the biological properties of the antibodyare accomplished by selecting substitutions that differ significantly intheir effect on maintaining (a) the structure of the polypeptidebackbone in the area of the substitution, for example, as a sheet orhelical conformation, (b) the charge or hydrophobicity of the moleculeat the target site, or (c) the bulk of the side chain. Naturallyoccurring residues are divided into groups based on common side-chainproperties:

(1) hydrophobic: norleucine, met, ala, val, leu, ile;

(2) neutral hydrophilic: cys, ser, thr;

(3) acidic: asp, glu;

(4) basic: asn, gln, his, lys, arg;

(5) residues that influence chain orientation: gly, pro; and

(6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one ofthese classes for another class.

Any cysteine residue not involved in maintaining the proper conformationof the antibody also may be substituted, generally with serine, toimprove the oxidative stability of the molecule and prevent aberrantcrosslinking. Conversely, cysteine bond(s) may be added to the antibodyto improve its stability (particularly where the antibody is an antibodyfragment such as an Fv fragment).

A particularly preferred type of substitutional variant involvessubstituting one or more hypervariable region residues of a parentantibody (e.g. a humanized or human antibody). Generally, the resultingvariant(s) selected for further development will have improvedbiological properties relative to the parent antibody from which theyare generated. A convenient way for generating such substitutionalvariants involves affinity maturation using phage display. Briefly,several hypervariable region sites (e.g. 6-7 sites) are mutated togenerate all possible amino substitutions at each site. The antibodyvariants thus generated are displayed in a monovalent fashion fromfilamentous phage particles as fusions to the gene III product of M13packaged within each particle. The phage-displayed variants are thenscreened for their biological activity (e.g. binding affinity) as hereindisclosed. In order to identify candidate hypervariable region sites formodification, alanine scanning mutagenesis can be performed to identifyhypervariable region residues contributing significantly to antigenbinding. Alternatively, or additionally, it may be beneficial to analyzea crystal structure of the antigen-antibody complex to identify contactpoints between the antibody and IgE. Such contact residues andneighboring residues are candidates for substitution according to thetechniques elaborated herein. Once such variants are generated, thepanel of variants is subjected to screening as described herein andantibodies with superior properties in one or more relevant assays maybe selected for further development.

Another type of amino acid variant of the antibody alters the originalglycosylation pattern of the antibody. By altering is meant deleting oneor more carbohydrate moieties found in the antibody, and/or adding oneor more glycosylation sites that are not present in the antibody.

Glycosylation of antibodies is typically either N-linked or O-linked.N-linked refers to the attachment of the carbohydrate moiety to the sidechain of an asparagine residue. The tripeptide sequencesasparagine-X-serine and asparagine-X-threonine, where X is any aminoacid except proline, are the recognition sequences for enzymaticattachment of the carbohydrate moiety to the asparagine side chain.Thus, the presence of either of these tripeptide sequences in apolypeptide creates a potential glycosylation site. O-linkedglycosylation refers to the attachment of one of the sugarsN-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, mostcommonly serine or threonine, although 5-hydroxyproline or5-hydroxylysine may also be used.

Addition of glycosylation sites to the antibody is convenientlyaccomplished by altering the amino acid sequence such that it containsone or more of the above-described tripeptide sequences (for N-linkedglycosylation sites). The alteration may also be made by the additionof, or substitution by, one or more serine or threonine residues to thesequence of the original antibody (for O-linked glycosylation sites).

Nucleic acid molecules encoding amino acid sequence variants of theanti-IgE antibody are prepared by a variety of methods known in the art.These methods include, but are not limited to, isolation from a naturalsource (in the case of naturally occurring amino acid sequence variants)or preparation by oligonucleotide-mediated (or site-directed)mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlierprepared variant or a non-variant version of the anti-IgE antibody.

13) Other Antibody Modifications

The antibodies of the present invention can be further modified tocontain additional nonproteinaceous moieties that are known in the artand readily available. Preferably, the moieties suitable forderivatization of the antibody are water-soluble polymers. Non-limitingexamples of water-soluble polymers include, but are not limited to,polyethylene glycol (PEG), copolymers of ethylene glycol/propyleneglycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleicanhydride copolymer, polyaminoacids (either homopolymers or randomcopolymers), and dextran or poly(n-vinyl pyrrolidone)polyethyleneglycol, polypropylene glycol homopolymers, polypropylene oxide/ethyleneoxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinylalcohol, and mixtures thereof. Polyethylene glycol propionaldehyde mayhave advantages in manufacturing due to its stability in water. Thepolymer may be of any molecular weight, and may be branched orunbranched. The number of polymers attached to the antibody may vary,and if more than one polymer is attached, they can be the same ordifferent molecules. In general, the number and/or type of polymers usedfor derivatization can be determined based on considerations including,but not limited to, the particular properties or functions of theantibody to be improved, whether the antibody derivative will be used ina therapy under defined conditions, etc. Such techniques and othersuitable formulations are disclosed in Remington: The Science andPractice of Pharmacy, 20th Ed., Alfonso Gennaro, Ed., PhiladelphiaCollege of Pharmacy and Science (2000).

C. Pharmaceutical Formulations

Therapeutic formulations are prepared for storage by mixing the activeingredient having the desired degree of purity with optionalpharmaceutically acceptable carriers, excipients or stabilizers(Remington: The Science and Practice of Pharmacy, 20th Ed., LippincottWilliams & Wiklins, Pub., Gennaro Ed., Philadelphia, Pa. 2000).Acceptable carriers, excipients, or stabilizers are nontoxic torecipients at the dosages and concentrations employed, and includebuffers, antioxidants including ascorbic acid, methionine, Vitamin E,sodium metabisulfite; preservatives, isotonicifiers, stabilizers, metalcomplexes (e.g. Zn-protein complexes); chelating agents such as EDTAand/or non-ionic surfactants.

When the therapeutic agent is an antibody fragment, the smallestinhibitory fragment which specifically binds to the binding domain ofthe target protein is preferred. For example, based upon the variableregion sequences of an antibody, antibody fragments or even peptidemolecules can be designed which retain the ability to bind the targetprotein sequence. Such peptides can be synthesized chemically and/orproduced by recombinant DNA technology (see, e.g., Marasco et al., Proc.Natl. Acad. Sci. USA 90: 7889-7893 [1993]).

Buffers are used to control the pH in a range which optimizes thetherapeutic effectiveness, especially if stability is pH dependent.Buffers are preferably present at concentrations ranging from about 50mM to about 250 mM. Suitable buffering agents for use with the presentinvention include both organic and inorganic acids and salts thereof.For example, citrate, phosphate, succinate, tartrate, fumarate,gluconate, oxalate, lactate, acetate. Additionally, buffers may becomprised of histidine and trimethylamine salts such as Tris.

Preservatives are added to retard microbial growth, and are typicallypresent in a range from 0.2%-1.0% (w/v). Suitable preservatives for usewith the present invention include octadecyldimethylbenzyl ammoniumchloride; hexamethonium chloride; benzalkonium halides (e.g., chloride,bromide, iodide), benzethonium chloride; thimerosal, phenol, butyl orbenzyl alcohol; alkyl parabens such as methyl or propyl paraben;catechol; resorcinol; cyclohexanol, 3-pentanol, and m-cresol.

Tonicity agents, sometimes known as “stabilizers” are present to adjustor maintain the tonicity of liquid in a composition. When used withlarge, charged biomolecules such as proteins and antibodies, they areoften termed “stabilizers” because they can interact with the chargedgroups of the amino acid side chains, thereby lessening the potentialfor inter and intra-molecular interactions. Tonicity agents can bepresent in any amount between 0.1% to 25% by weight, preferably 1 to 5%,taking into account the relative amounts of the other ingredients.Preferred tonicity agents include polyhydric sugar alcohols, preferablytrihydric or higher sugar alcohols, such as glycerin, erythritol,arabitol, xylitol, sorbitol and mannitol.

Additional excipients include agents which can serve as one or more ofthe following: (1) bulking agents, (2) solubility enhancers, (3)stabilizers and (4) and agents preventing denaturation or adherence tothe container wall. Such excipients include: polyhydric sugar alcohols(enumerated above); amino acids such as alanine, glycine, glutamine,asparagine, histidine, arginine, lysine, ornithine, leucine,2-phenylalanine, glutamic acid, threonine, etc.; organic sugars or sugaralcohols such as sucrose, lactose, lactitol, trehalose, stachyose,mannose, sorbose, xylose, ribose, ribitol, myoinisitose, myoinisitol,galactose, galactitol, glycerol, cyclitols (e.g., inositol),polyethylene glycol; sulfur containing reducing agents, such as urea,glutathione, thioctic acid, sodium thioglycolate, thioglycerol,α-monothioglycerol and sodium thio sulfate; low molecular weightproteins such as human serum albumin, bovine serum albumin, gelatin orother immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone; monosaccharides (e.g., xylose, mannose, fructose,glucose; disaccharides (e.g., lactose, maltose, sucrose); trisaccharidessuch as raffinose; and polysaccharides such as dextrin or dextran.

Non-ionic surfactants or detergents (also known as “wetting agents”) arepresent to help solubilize the therapeutic agent as well as to protectthe therapeutic protein against agitation-induced aggregation, whichalso permits the formulation to be exposed to shear surface stresswithout causing denaturation of the active therapeutic protein orantibody. Non-ionic surfactants are present in a range of about 0.05mg/ml to about 1.0 mg/ml, preferably about 0.07 mg/ml to about 0.2mg/ml.

Suitable non-ionic surfactants include polysorbates (20, 40, 60, 65, 80,etc.), polyoxamers (184, 188, etc.), PLURONIC polyols, TRITON®,polyoxyethylene sorbitan monoethers (TWEEN®-20, TWEEN®-80, etc.),lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenatedcastor oil 10, 50 and 60, glycerol monostearate, sucrose fatty acidester, methyl celluose and carboxymethyl cellulose. Anionic detergentsthat can be used include sodium lauryl sulfate, dioctyle sodiumsulfosuccinate and dioctyl sodium sulfonate. Cationic detergents includebenzalkonium chloride or benzethonium chloride.

In order for the formulations to be used for in vivo administration,they must be sterile. The formulation may be rendered sterile byfiltration through sterile filtration membranes. The therapeuticcompositions herein generally are placed into a container having asterile access port, for example, an intravenous solution bag or vialhaving a stopper pierceable by a hypodermic injection needle.

The route of administration is in accordance with known and acceptedmethods, such as by single or multiple bolus or infusion over a longperiod of time in a suitable manner, e.g., injection or infusion bysubcutaneous, intravenous, intraperitoneal, intramuscular,intraarterial, intralesional or intraarticular routes, topicaladministration, inhalation or by sustained release or extended-releasemeans.

The formulation herein may also contain more than one active compound asnecessary for the particular indication being treated, preferably thosewith complementary activities that do not adversely affect each other.Alternatively, or in addition, the composition may comprise a cytotoxicagent, cytokine or growth inhibitory agent. Such molecules are suitablypresent in combination in amounts that are effective for the purposeintended.

The active ingredients may also be entrapped in microcapsules prepared,for example, by coascervation techniques or by interfacialpolymerization, for example, hydroxymethylcellulose orgelatin-microcapsules and poly-(methylmethacylate) microcapsules,respectively, in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nano-particles andnanocapsules) or in macroemulsions. Such techniques are disclosed inRemington's Pharmaceutical Sciences 18th edition, supra.

Stability of the proteins and antibodies described herein may beenhanced through the use of non-toxic “water-soluble polyvalent metalsalts”. Examples include Ca²⁺, Mg²⁺, Zn²⁺, Fe²⁺, Fe³⁺, Cu²⁺, Sn²⁺, Sn⁴⁺,Al²⁺ and Al³⁺. Example anions that can form water soluble salts with theabove polyvalent metal cations include those formed from inorganic acidsand/or organic acids. Such water-soluble salts have a solubility inwater (at 20° C.) of at least about 20 mg/ml, alternatively at leastabout 100 mg/ml, alternatively at least about 200 mg/ml.

Suitable inorganic acids that can be used to form the “water solublepolyvalent metal salts” include hydrochloric, acetic, sulfuric, nitric,thiocyanic and phosphoric acid. Suitable organic acids that can be usedinclude aliphatic carboxylic acid and aromatic acids. Aliphatic acidswithin this definition may be defined as saturated or unsaturated C₂₋₉carboxylic acids (e.g., aliphatic mono-, di- and tri-carboxylic acids).For example, exemplary monocarboxylic acids within this definitioninclude the saturated C₂₋₉ monocarboxylic acids acetic, proprionic,butyric, valeric, caproic, enanthic, caprylic pelargonic and capryonic,and the unsaturated C₂₋₉ monocarboxylic acids acrylic, propriolicmethacrylic, crotonic and isocrotonic acids. Exemplary dicarboxylicacids include the saturated C₂₋₉ dicarboxylic acids malonic, succinic,glutaric, adipic and pimelic, while unsaturated C₂₋₉ dicarboxylic acidsinclude maleic, fumaric, citraconic and mesaconic acids. Exemplarytricarboxylic acids include the saturated C₂₋₉ tricarboxylic acidstricarballylic and 1,2,3-butanetricarboxylic acid. Additionally, thecarboxylic acids of this definition may also contain one or two hydroxylgroups to form hydroxy carboxylic acids. Exemplary hydroxy carboxylicacids include glycolic, lactic, glyceric, tartronic, malic, tartaric andcitric acid. Aromatic acids within this definition include benzoic andsalicylic acid.

Commonly employed water soluble polyvalent metal salts which may be usedto help stabilize the encapsulated polypeptides of this inventioninclude, for example: (1) the inorganic acid metal salts of halides(e.g., zinc chloride, calcium chloride), sulfates, nitrates, phosphatesand thiocyanates; (2) the aliphatic carboxylic acid metal salts (e.g.,calcium acetate, zinc acetate, calcium proprionate, zinc glycolate,calcium lactate, zinc lactate and zinc tartrate); and (3) the aromaticcarboxylic acid metal salts of benzoates (e.g., zinc benzoate) andsalicylates.

D. Methods of Treatment:

For the prevention or treatment of disease, the appropriate dosage of anactive agent, will depend on the type of disease to be treated, asdefined above, the severity and course of the disease, whether the agentis administered for preventive or therapeutic purposes, previoustherapy, the patient's clinical history and response to the agent, andthe discretion of the attending physician. The agent is suitablyadministered to the patient at one time or over a series of treatments.

A preferred method of treatment is the treatment of IgE-mediateddisorders. IgE mediated disorders includes atopic disorders, which arecharacterized by an inherited propensity to respond immunologically tomany common naturally occurring inhaled and ingested antigens and thecontinual production of IgE antibodies. Specific atopic disordersinclude allergic asthma, allergic rhinitis, atopic dermatitis andallergic gastroenteropathy. Atopic patients often have multipleallergies, meaning that they have IgE antibodies to, and symptoms from,many environmental allergens, including pollens, fungi (e.g., molds),animal and insect debris and certain foods.

However disorders associated with elevated IgE levels are not limited tothose with an inherited (atopic) etiology. Other disorders associatedwith elevated IgE levels, that appear to be IgE-mediated and aretreatable with the formulations of this present invention includehypersensitivity (e.g., anaphylactic hypersensitivity), eczema,urticaria, allergic bronchopulmonary aspergillosis, parasitic diseases,hyper-IgE syndrome, ataxia-telangiectasia, Wiskott-Aldrich syndrome,thymic alymphoplasia, IgE myeloma and graft-versus-host reaction.

Allergic rhinitis, also known as allergic rhinoconjunctivitis or hayfever, is the most common manifestation of an atopic reaction to inhaledallergens, the severity and duration of which is often correlative withthe intensity and length of exposure to the allergen. It is a chronicdisease, which may first appear at any age, but the onset is usuallyduring childhood or adolescence. A typical attack consists of profusewatery rhinorrhea, paroxysmal sneezing, nasal obstruction and itching ofthe nose and palate. Postnasal mucus drainage also causes sore throat,throat clearing and cough. There can also be symptoms of allergicblepharoconjunctivitis, with intense itching of the conjunctivae andeyelids, redness, tearing, and photophobia. Severe attacks are oftenaccompanied by systemic malaise, weakness, fatigue, and sometimes,muscle soreness after intense periods of sneezing.

Asthma, also known as reversible obstructive airway disease, ischaracterized by hyperresponsiveness of the tracheobronchial tree torespiratory irritants and bronchoconstrictor chemicals, producingattacks of wheezing, dyspnea, chest tightness, and cough that arereversible spontaneously or with treatment. It is a chronic diseaseinvolving the entire airway, but varies in severity from occasional mildtransient episodes to severe, chronic, life-threatening bronchialobstruction. Asthma and atopy may coexist, but only about half ofasthmatics are also atopic, and an even smaller percentage of atopicpatients also have asthma. However, atopy and asthma are not entirelyindependent in that asthma occurs more frequently among atopic thanamongst nonatopic individuals, especially during childhood. Asthma hasfurther been historically broken down into two subgroups, extrinsicasthma and intrinsic asthma.

Extrinsic asthma, also known as allergic, atopic or immunologic asthma,is descriptive of patients that generally develop asthma early in life,usually during infancy or childhood. Other manifestations of atopy,including eczema or allergic rhinitis often coexist. Asthmatic attackscan occur during pollen seasons, in the presence of animals, or onexposure to house dust, feather pillows, or other allergens. Skin testsshow positive wheal-and-flare reactions to the causative allergens.Interestingly, total serum IgE concentrations are frequently elevated,but are sometimes normal.

Intrinsic asthma, also known as nonallergic or idopathic asthma,typically first occurs during adult life, after an apparent respiratoryinfection. Symptoms include chronic or recurrent bronchial obstructionunrelated to pollen seasons or exposure to other allergens. Skin testsare negative to the usual atopic allergens, serum IgE concentration isnormal. Additional symptoms include sputum blood and eosinophilia. Otherschemes for classifying asthma into subgroups, like aspirin-sensitive,exercise-induced, infectious and psychologic merely define externaltriggering factors that affect certain patients more so than others.

Finally, it is important to note that while some classifications havehistorically associated only allergic asthma with IgE dependency, thereis now strong statistically significant data showing a correlationbetween IgE and asthma (both allergic and non-allergic). Chapter 27,“The Atopic Diseases”, A. I. Terr in Medical Immunology, 9th Ed., Simonand Schuster, Stites et al., Ed. (1997). As a result, the term“IgE-mediated disorders”, for purposes of this patent application,includes both allergic and non-allergic asthma.

Physical signs of an asthma attack include tachypnea, audible wheezing,and use of the accessory muscles of respiration. Rapid pulse andelevated blood pressure are also typically present, as are elevatedlevels of eosinophils in the peripheral blood and nasal secretions.Pulmonary functions show a decrease in flow rates and 1 second forcedexpiratory volume (FEV₁). The total lung capacity and functionalresidual capacity are typically normal or slightly increased, but may bedecreased with extreme bronchospasm.

The pathology of asthma can be distinguished by early phase and latephase reactions. The early phase is characterized by smooth musclecontraction, edema and hypersecretion, while the late phase reactionsare characterized by cellular inflammation. Asthma can be induced byvarious non-specific triggers including infections (e.g., viralrespiratory infections), physiologic factors (e.g., exercise,hyperventilation, deep breathing, psychologic factors), atmosphericfactors (e.g., sulfur dioxide, ammonia, cold air, ozone, distilled watervapor), ingestants (e.g., propranolol, aspirin, nonsteroidalanti-inflammatory drugs), experimental inhalants (e.g., hypertonicsolutions, citric acid, histamine, methacholine, prostaglandin F_(2α))and occupational inhalants (e.g., isocyanates). Various additionaloccupational or environmental allergens that cause allergic asthma caninclude animal products, insect dusts, sea creatures, plant products,fruits, seeds, leaves and pollens, organic dyes and inks, microbialagents, enzymes, therapeutic agents, sterilizing agents, and inorganicand organic chemicals.

Atopic dermatitis, also known as eczema, neurodermatitis, atopic eczemaor Besnier's prurigo, is common chronic skin disorder specific to asubset of patients with the familial and immunologic features of atopy.The essential feature is a pruritic dermal inflammatory response, whichinduces a characteristic symmetrically distributed skin eruption withpredilection for certain sites. There is also frequent overproduction ofIgE by B lymphocytes. While atopic dermatitis is classified as acutaneous form of atopy because it is associated with allergic rhinitisand asthma and high IgE levels, the severity of the dermatitis, however,does not always correlate with exposure to allergens on skin testing,and desensitization (unlike other allergic diseases) is not effectivetreatment. While high serum IgE is confirmatory of a diagnosis ofallergic asthma, normal levels do not preclude it. Onset of the diseasecan occur at any age, and lesions begin acutely with erythematousedematous papule or plaque with scaling. Itching leads to weeping andcrusting, then to chronic lichenification. On the cellular level, acutelesion is edemous and the dermis is infiltrated with mononuclear cells,CD4 lymphocytes. Neutrophils, eosinophils, plasma cells and basophilsare rare, but degranulated mast cells are present. Chronic lesionsfeature epidermal hyperplasia, hyperkeratosis and parakeratosis, and thedermis is infiltrated with mononuclear cells, Langerhans' cells and mastcells. There may also be focal areas of fibrosis, including involvementof the perineurium of small nerves.

Allergic gastroenteropathy, also known as eosinophilicgastroenteropathy, is an unusual atopic manifestation in which multipleIgE food sensitivities are associated with a local gastrointestinaltract mucosal reaction. It is rare in adults, but more common, buttransient, in infants. The condition results when ingested foodallergens react with local IgE antibodies in the jejunal mucosa liberatemast cell mediators, resulting in gastrointestinal symptoms shortlyafter the meal. Continued exposure produced chronic inflammation,resulting in gastrointestinal protein loss and hypoproteinemic edema.Blood loss through the inflamed intestinal mucosa may be significantenough to cause iron deficiency anemia. The allergic reaction occurslocally in the upper gastrointestinal mucosa following allergenexposure, but resolves with allergen avoidance.

Anaphylaxis and urticaria are clearly IgE-mediated, but they lackgenetic determinants, and have no predilection for atopic individuals.Anaphylaxis is an acute, generalized allergic reaction with simultaneousinvolvement of several organ systems, usually cardiovascular,respiratory, cutaneous and gastrointestinal. The reaction isimmunologically mediated, and it occurs on exposure to an allergen towhich the subject has been previously sensitized. Urticaria andangioedema refers to the physical swelling, erythema and itchingresulting from histamine stimulated receptor in superficial cutaneousblood vessels, and is the hallmark cutaneous feature of systemicanaphylaxis. Systemic anaphylaxis is the occurrence of an IgE-mediatedreaction simultaneously in multiple organs resulting from drug, insectvenom or food. It is caused suddenly by allergen induced, mast cellloaded IgE, resulting in profound and life-threatening alteration in thefunctioning of various vital organs. Vascular collapse, acute airwayobstruction, cutaneous vasodilation and edema, and gastrointestinal andgenitourinary muscle spasm occur almost simultaneously, although notalways to the same degree.

The pathology of anaphylaxis includes angioedema and hyperinflatedlungs, with mucous plugging of airways and focal atelectasis. On acellular level, the lungs appear similarly as during an acute asthmaattack, with hypersecretion of bronchial submucosal glands, mucosal andsubmucosal edema, peribronchial vascular congestion and eosinophilia inthe bronchial walls. Pulmonary edema and hemorrhage may be present.Bronchial muscle spasm, hyperinflation, and even rupture of alveoli mayalso be present. Important features of human anaphylaxis include edema,vascular congestion, and eosinophilia in the lamina propria of thelarynx, trachea, epiglottis and hypopharynx.

Exposure to the allergen may be through ingestion, injection, inhalationor contact with skin or mucous membrane. The reaction begins withinseconds or minutes after exposure to the allergen. There may be aninitial fright or sense of impending doom, followed rapidly by symptomsin one or more target organ systems: cardiovascular, respiratory,cutaneous or gastrointestinal.

The allergens responsible for anaphylaxis differ from those commonlyassociated with atopy. Foods, drugs, insect venoms or latex are thecommon sources. Food allergens includes those found in crustaceans,mollusks (e.g., lobster, shrimp, crab), fish, legumes (e.g., peanuts,peas, beans, licorice), seeds (e.g. sesame, cottonseed, caraway,mustard, flaxseed, sunflower), nuts, berries, egg whites, buckwheat andmilk. Drug allergens include those found in heterologous proteins andpolypeptides, polysaccharides and haptenic drugs. Insect allergensinclude Hymenopterainsects, including the honeybee, yellow jacket,hornet, wasp and fire ant.

While epinephrine is the typical treatment for anaphylaxis,antihistamine or other histamine blockers are typically prescribed forless severe urticaria or angioedemic reaction.

E. Combination Therapies

The method of the invention can be combined with known methods oftreatment for IgE-mediated disorder, either as combined or additionaltreatment steps or as additional components of a therapeuticformulation.

For example, antihistamines, especially non-sedating antihistamines maybe administered before, prior to, or commensurate with the anti-IgEantibodies of the invention. Suitable antihistamines include those ofthe alkylamine (e.g., chlorpheniramine), ethanolamine (e.g.,diphenhydramine) and phenothiazine (e.g., promethazine). While manyantihistamines antagonize the pharmacological effects of histamine byblocking its receptor sites on the effector cells, other commonantihistamine drugs operate by blocking histamine release from mastcells that have been sensitized and armed with allergen-specific IgE(e.g., cromolyn sodium). Example antihistamines include astemizole,azatadine maleate, bropheniramine maleate, carbinoxamine maleate,cetirizine hydrochloride, clemastine fumarate, cyproheptadinehydrochloride, dexbrompheniramine maleate, dexchlorpheniramine maleate,dimenhydrinate, diphenhydramine hydrochloride, doxylamine succinate,fexofendadine hydrochloride, terphenadine hydrochloride, hydroxyzinehydrochloride, loratidine, meclizine hydrochloride, tripelannaminecitrate, tripelennamine hydrochloride, triprolidine hydrochloride.

Particular symptoms of IgE-mediated disorders (e.g., early phasereactions) can be ameliorated with sympathomimetics or drugs havingbronchodialator effect. Epinephrine is a broad acting alpha andbeta-adrenergic often administered subcutaneously in a dose of 0.2-0.5mL of 1:100 aqueous solution. A longer acting form of epinephrine (i.e.,terbutaline) in 1:200 suspension is also used when a longer durationeffect is desired. Suitable additional beta-adrenergics includealbuterol, pirbuterol, metaproterenol, salmeterol, isoetharine andformeterol for administration nasally (e.g., hand-held nebulizer,intermittent positive-pressure breathing device, or metered-dosepressurized inhalers) or orally.

Bronchodilation can also be achieved through administration ofxanthines, especially when they are administered in combination with theabove sympathomimetic drugs. Example xanthines include aminophylline(iv. 250-500 mg) and theophylline (oral, 10-20 μg/ml serumconcentration).

Other symptoms from various IgE-mediated disorders (e.g., late phasereactions) can be attenuated by treatment with glucocorticoids or otherdrugs having anti-inflammatory effects. Prednisone (30-60 mg daily) isadministered systemically for severe attacks, while beclomethasonedipropionate, triamcinolone acetonide and flunisolide are administeredin aerosolized form as long-term maintenance therapy. Additionalcorticosteroids that have anti-inflammatory effects include:betamethasone, budesonide, dexamethasone, fludrocortisone acetate,flunisolide, fluticasone propionate, hydrocortisone, methylprednisolone,prednisolone, prednisone, triamcinolone.

Non-steroidal anti-inflammatory drugs that may also be used incombination with the therapeutic methods of the invention include,acetaminophen, aspirin, bromfenac sodium, diclofenac sodium, diflunisal,etodolac, fenoprofen calcium, flurbiprofen, ibuprofen, indomethacin,ketoprofen, meclofenamate sodium, mefenamic acid, nabumetone, naproxen,naproxen sodium, oxyphenbutazone, phenylbutzone, piroxicam, sulindac,tolmetin sodium.

Additionally, the maximum therapeutic benefit may also be achieved withthe administration of decongestants (e.g., phenylephrine,phenylpropanolamine, pseudoephadrin), cough suppressants (e.g.,dextromethorphan, codeine, or hydrocodone) or analgesic (e.g.,acetaminophen, aspirin).

Allergen desensitization is a treatment form in which allergens areinjected into the patient for the purpose or reducing or eliminating theallergic response. It is also known as allergen immunotherapy,hyposensitization or allergy injection therapy. It is often used incombination with other allergy treatments, but not often as a primarytreatment. It has been successfully employed when allergen avoidance isimpossible. A typical allergen desensitization treatment incorporatessubcutaneous injection of sterile allergen in increasing doses once ortwice a week until a dose is achieved that produces a transient smalllocal area of inflammation at the injection site. The dose is then givenon a maintenance schedule once every 2-4 weeks. Allergic desensitizationis most often used in the treatment of allergic asthma and allergicrhinitis, although it has had success in treating anaphylaxis.Desensitization has also been effectively used through the use ofadjuvants, such as incomplete Freund's adjuvant, which is an emulsion ofaqueous antigen in mineral oil. The physiological effect creates aninsoluble liquid depot from which droplets of allergen are graduallyreleased. Another form of allergen desensitization is to polymerizemonomeric allergens with glutaraldehyde to create a molecule withrelatively low allergenicity (i.e., causes allergic response), whileretaining an effective degree of immunogenicity.

F. Pharmaceutical Dosages:

Dosages and desired drug concentration of pharmaceutical compositions ofthe present invention may vary depending on the particular useenvisioned. The determination of the appropriate dosage or route ofadministration is well within the skill of an ordinary artisan. Animalexperiments provide reliable guidance for the determination of effectivedoses for human therapy. Interspecies scaling of effective doses can beperformed following the principles laid down by Mordenti, J. andChappell, W. “The Use of Interspecies Scaling in Toxicokinetics,” InToxicokinetics and New Drug Development, Yacobi et al., Eds, PergamonPress, New York 1989, pp. 42-46.

When in vivo administration of the polypeptides or antibodies describedherein are used, normal dosage amounts may vary from about 10 ng/kg upto about 100 mg/kg of mammal body weight or more per day, preferablyabout 1 mg/kg/day to 10 mg/kg/day, depending upon the route ofadministration. Guidance as to particular dosages and methods ofdelivery is provided in the literature; see, for example, U.S. Pat. No.4,657,760; 5,206,344; or 5,225,212. It is within the scope of theinvention that different formulations will be effective for differenttreatments and different disorders, and that administration intended totreat a specific organ or tissue may necessitate delivery in a mannerdifferent from that to another organ or tissue. Moreover, dosages may beadministered by one or more separate administrations, or by continuousinfusion. For repeated administrations over several days or longer,depending on the condition, the treatment is sustained until a desiredsuppression of disease symptoms occurs. However, other dosage regimensmay be useful. The progress of this therapy is easily monitored byconventional techniques and assays.

G. Administration of the Formulation

The formulations of the present invention, including but not limited toreconstituted formulations, are administered to a mammal in need oftreatment with the protein, preferably a human, in accord with knownmethods, such as intravenous administration as a bolus or by continuousinfusion over a period of time, by intramuscular, intraperitoneal,intracerobrospinal, subcutaneous, intra-articular, intrasynovial,intrathecal, oral, topical, or inhalation routes.

In preferred embodiments, the formulations are administered to themammal by subcutaneous (i.e. beneath the skin) administration. For suchpurposes, the formulation may be injected using a syringe. However,other devices for administration of the formulation are available suchas injection devices (e.g. the INJECT-EASE™ and GENJECT™devices);injector pens (such as the GENPEN™); auto-injector devices, needlelessdevices (e.g. MEDIJECTOR™ and BIOJECTOR™); and subcutaneous patchdelivery systems.

In a specific embodiment, the present invention is directed to kits fora single dose-administration unit. Such kits comprise a container of anaqueous formulation of therapeutic protein or antibody, including bothsingle or multi-chambered pre-filled syringes. Exemplary pre-filledsyringes are available from Vetter GmbH, Ravensburg, Germany.

The appropriate dosage (“therapeutically effective amount”) of theprotein will depend, for example, on the condition to be treated, theseverity and course of the condition, whether the protein isadministered for preventive or therapeutic purposes, previous therapy,the patient's clinical history and response to the protein, the type ofprotein used, and the discretion of the attending physician. The proteinis suitably administered to the patient at one time or over a series oftreatments and may be administered to the patient at any time fromdiagnosis onwards. The protein may be administered as the sole treatmentor in conjunction with other drugs or therapies useful in treating thecondition in question.

Where the protein of choice is an antibody, from about 0.1-20 mg/kg isan initial candidate dosage for administration to the patient, whether,for example, by one or more separate administrations. However, otherdosage regimens may be useful. The progress of this therapy is easilymonitored by conventional techniques.

Uses for an anti-IgE formulation (e.g., rhuMAbE-25, rhMAbE-26, Hu-901)include the treatment or prophylaxis of IgE-mediated allergic diseases,parasitic infections, interstitial cystitis and asthma, for example.Depending on the disease or disorder to be treated, a therapeuticallyeffective amount (e.g. from about 1-15 mg/kg) of the anti-IgE antibodyis administered to the patient.

H. Articles of Manufacture

In another embodiment of the invention, an article of manufacture isprovided which contains the formulation and preferably providesinstructions for its use. The article of manufacture comprises acontainer. Suitable containers include, for example, bottles, vials(e.g. dual chamber vials), syringes (such as single or dual chambersyringes) and test tubes. The container may be formed from a variety ofmaterials such as glass or plastic. The container holds the formulation.The label, which is on, or associated with the container may indicatedirections for reconstitution and/or use. The label may further indicatethat the formulation is useful or intended for subcutaneousadministration. The container holding the formulation may be a multi-usevial, which allows for repeat administrations (e.g. from 2-6administrations) of the reconstituted formulation. The article ofmanufacture may further comprise a second container comprising asuitable diluent (e.g. BWFI). Upon mixing of the diluent and thelyophilized formulation, the final protein concentration in thereconstituted formulation will generally be at least 50 mg/ml. Thearticle of manufacture may further include other materials desirablefrom a commercial and user standpoint, including other buffers,diluents, filters, needles, syringes, and package inserts withinstructions for use.

The invention will be more fully understood by reference to thefollowing examples. They should not, however, be construed as limitingthe scope of the invention. All citations throughout the disclosure arehereby expressly incorporated by reference.

In another embodiment, the invention provides for an article ofmanufacture comprising the formulations described herein foradministration in an auto-injector device. An auto-injector can bedescribed as an injection device that upon activation, will deliver itscontents without additional necessary action from the patient oradministrator. They are particularly suited for self-medication oftherapeutic formulations when the delivery rate must be constant and thetime of delivery is greater than a few moments.

Example 1 Isolation of Primate IgE

Human IgE was cloned from the human IgE myeloma cell line U266 (ATCC,Manassas, Va., TIB #196). Rhesus and cyno IgE sequences were determinedby cloning and sequencing the IgE from cDNA derived from rhesus and cynoperipheral blood mononuclear cells that had been stimulated to generatedIgE-switched cells (PBMC). Forward and reverse primers (shown below)were designed from the human IgE sequences. An upstream forward primerwas designed just upstream of the CH2 domain. The reverse primer wasdesigned at the end of the transmembrane domain. Rhesus and Cyno PBMCwas obtained from the California National Primate Research Center(Davis, Calif.). 5×10⁶ PBMC were cultured with IL-4 (100 ng/ml) andCD40L (3 μg/ml) (R&D Systems, Minneapolis, Minn., #204-IL and #617-CLrespectively) for 4 days. Cells were then harvested, RNA was prepared(RNeasy Mini Kit, #74106, Qiagen, Valencia, Calif.), and cDNA made usingBD Sprint Powerscript oligo dT priming kit (BD Biosciences, San Jose,Calif., #639558). RT-PCR was then performed [94° C. 2 minutes; 94° C. 15seconds; 60° C. 30 seconds; 68° C. 2 minutes; 30 cycles; 68° C. 10minutes]. Taq polymerase was added (10 minutes 72° C.) after theindicated cycles to add A overhangs for TA cloning (Invitrogen,Carlsbad, Calif., #45-0641). PCR products were cloned by TOPO-TA cloningand clones were then sequence verified (Genentech, Inc.). Human, Rhesusand Cyno sequences were aligned using in house analysis programs(Genentech, Inc.). The following homologies are for sequences betweenthe CH2 and transmembrane domains. Between Rhesus (432 amino acids) andCyno (431 amino acids) there were 6 differences which is approximately98.6% homology. Between human and Rhesus there were 53 differencesequaling 87.7% homology. Human and Cyno there was 56 differencesequaling 87% homology (See FIG. 1).

Primers Used for Cloning:

Forward primers upstream of CH2 sequence:

5′-ccgcccaccgtgaagatcttacagtc (SEQ ID NO:63)Reverse primer at the end of the transmembrane domain:

(SEQ ID NO:64) 5′-cggctcgagactaggcgtggggctggaggacgttg

Example 2 Isolation of anti-IzE/M1′ Abs Generation of the CH3−CH4−M1′/FcFusion Protein

The human IgE CH3−CH4−M1′/Fc fusion protein was generated by PCRamplification of the human IgE CH3−CH4−M1′ domains, plus an additional15 amino acids immediately downstream of the M1′ domain from cDNAprepared from U266 cells (ATTC Manassas, Va., TIB#196). RNA was preparedfrom U266 cells (RNeasy Mini Kit, #74106, Qiagen, Valencia, Calif.) andcDNA made using BD Sprint Powerscript oligo dT priming (BD Biosciences,San Jose, Calif., #639558). RT-PCR was performed, and the PCR productcloned by TOPO-TA cloning (Invitrogen, Carlsbad, Calif., #45-0641). AnN-terminal signal sequence was added by PCR mutagenesis for expressionin mammalian cells, and the signal sequence+CH3+CH4+M1′+15 amino acidswas cloned into an expression vector (pRK huIgG1 Fc; Genentech) togenerated a C-terminal fusion with the human IgG1 Fc region. Thesequence of the final protein, including signal sequence and human IgG1Fc is as follows:

(SEQ ID NO:65) MGWSCIILFLVATATGVHSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGLAGGSAQSQRAPDRVLCHSGQQQGLPRAAGGSVPHPRCHCGAGRADWPGPPELDVCVEEAEGEAPWRAQVTDKAAHYTLCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

The protein was produced by transient transfection of CHO cells(Genentech), and protein was purified from cell culture supernatantusing standard Protein A sepharose column chromatography techniques.

Immunization and Creation of Hybridomas

A panel of pan-specific antibodies that selectively bind the M1′ portionof human IgE-M1′ were generated using the CH3−CH4−M1′/Fc protein. Eachhind footpad of a BALB/c mouse was injected with 1 μg CH3−CH4−M1′/Fcresuspended in monophosphoryl-lipid A and trehalose dicorynomycolate(MPL™+TDM) adjuvant (Corixa, Hamilton, Mont.) at 3- to 4-day intervals.Serum was taken after 8 boosts and titered by enzyme-linkedimmunosorbant assay (ELISA) and fluorescence-activated cell sorting andflow cytometry (FACS screening, see next section) to ensure that themouse had a good immune response to CH3−CH4−M1′/Fc. Three days after thefinal boost, popliteal node cells were fused with the mouse myeloma cellline P3X63Ag.U.1 (see, for example, Chuntharapai et al., 1997, MethodsEnzymol. 288:15-27). Fused hybridoma cells were selected from unfusedpopliteal node or myeloma cells using hypoxanthin-aminopterin-thymidine(HAT) selection in Medium D from the ClonaCell® hybridoma selection kit(StemCell Technologies, Inc., Vancouver, BC, Canada), resulting thegeneration of 4224 clones.

Screening for Pan-Specific Anti-Human M1′ Antibodies

Hybridoma clones generated as previously described were screened forproduction of monoclonal antibodies binding to the M1′ region of theCH3−CH4−M1′/Fc protein, the M1′ region of human IgE-M1′ stably expressedon the surface of the A20 mouse B-cell lymphoma cell line (IgE-M1′/A20),and the M1′ region of human IgE-M1′ stably expressed on the surface ofthe BJAB human B-cell lymphoma cell line (IgE-M1′/BJAB). Negativecontrols included human CD-4/Fc, human IgE stably expressed on thesurface of the A20 mouse B-cell lymphoma cell line (IgE/A20), A20 mouseB-cell lymphoma cell line (A20), human IgE stably expressed on thesurface of the BJAB human B-cell lymphoma cell line (IgE/BJAB), and BJABhuman B-cell lymphoma cell line (BJAB).

ELISA Screening

To screen the 4224 clones, enzyme-linked immunosorbant assay (ELISA) wasperformed generally as described in Baker et al., 2002, TrendsBiotechnol., 20:149-156. Assays were performed in both 384- and 96-wellplates. Briefly, a 384-(or a 96-) well plate was coated with 50 μl ofgoat anti-human IgG Fc (MP Biomedicals, Irvine, Calif.) at aconcentration of 2 μg/ml in coating buffer (0.05 M carbonate buffer, pH9.6), sealed, and stored overnight at 4° C. After removing the coatingsolution, 80 μl (or 200 μl for a 96-well plate) of assay/blockingsolution containing 0.5% bovine serum albumin and 0.05% Tween®-20 in PBS(pH 7.4) (ELISA diluent) was added to each well, and plates wereincubated at room temperature for one hour with agitation. Wells werethen washed three times with 100 μl (or 300 μl for a 96-well plate)0.05% Tween®-20 in PBS (wash buffer).

After the washing step, 50 μl (or 100 μl for a 96-well plate) of antigensolution containing 0.4 μg/ml of CH3−CH4−M1′/Fc or human CD-4/Fc inELISA diluent was added to each well, and plates were incubated at roomtemperature for one hour with agitation. The wells were washed threetimes with wash buffer as before. Supernatant from individual hybridomaclones was added such that one well with CH3−CH4−M1′/Fc and one wellwith human CD-4/Fc each received 50 μl (or 100 μl for a 96-well plate)of supernatant from a single hybridoma clone. Plates were incubated atroom temperature for one hour with agitation, and the wells were washedthree times with wash buffer as before.

After washing, 50 μl (or 100 μl for a 96-well plate) of a 1:1000dilution of sheep anti-mouse IgG coupled to horseradish peroxidase (nocross-reactivity to human IgG (MP Biomedicals)) in ELISA diluent wasadded to each well. Plates were incubated at room temperature for onehour with agitation, washed three times with wash buffer as before, andpatted dry. Wells were developed by adding 50 μl (or 100 μl for a96-well plate) of tetramethylbenzidine (TMB) microwell peroxidasesubstrate (BioFX Laboratories, Owing Mills, Md., catalog #TMBW-0100-01)to each well and incubating at room temperature for 5-10 minutes oruntil a good color change was observed. Development was stopped byadding 50 μl (or 100 μl for a 96-well plate) of TMB Stop Solution (BioFXLaboratories catalog #BSTP-0100-01) to each well. Plates were analyzedwith a Sunrise plate reader (Tecan US, Inc., Research Triangle Park,N.C.) at 650 nm.

Prebleed and polysera were used as controls. Prebleed samples containedmouse sera prior to immunization, and polysera samples contained mouseanti-sera obtained after 10 immunizations.

FACS Screening

To screen 3221 clones generated in Example 1, fluorescence-activatedcell sorting (FACS) was performed using IgE-M1′/A20 and IgE-M1′/BJABcell lines. IgE/A20, IgE/BJAB, A20, and BJAB cell lines served asnegative controls. Cells were resuspended and centrifuged at 500 g for 5minutes at 4° C. Media was aspirated and cells were resuspended in 4° C.FACSFlow (BD Biosciences, San Jose, Calif.) buffer with 1% fetal bovineserum (cell staining buffer). Cells were centrifuged as before, mediaaspirated, and cells were resuspended at 2×10⁶ cells/ml of cell stainingbuffer at 4° C. Cells were added to 96-well round bottom plates at 50μl/well (1×10⁵ cells/well), and 100 μl of supernatant from individualhybridoma clones was added to each well such that each hybridomasupernatant was incubated with one well containing each cell line. Theplate was incubated on ice for 30 minutes. The plate was centrifuged at500 g for 5 minutes at 4° C. and supernatants were aspirated. Each wellwas resuspended in 200 μl cell staining buffer at 4° C., and the plateswere centrifuged as before. Cell staining buffer was aspirated.

After the washing step, cells in each well were resuspended in 100 μl ofa 1:1000 dilution of goat anti-mouse IgG Fc coupled to R-phycoerythrin(Jackson Immunoresearch, West Grove, Pa.) in cell staining buffer at 4°C., and plates were incubated in the dark on ice for 30 minutes. Theplate was centrifuged at 500 g for 5 minutes at 4° C. and supernatantswere aspirated. Each well was resuspended in 200 μl cell staining bufferat 4° C., and the plates were centrifuged as before. Cell stainingbuffer was aspirated. Cells in each well were resuspended in 200 μl cellstaining buffer at 4° C. and transferred to 1.2 ml micro titertubes(Quality Scientific Plastics, Petaluma, Calif.). FACS was performed on aFACScan or FACSCalibur (BD Biosciences).

N-Terminal Sequencing/Isolation of RNA/Sequencing and Cloning

The antibodies were purified from the supernatant of anti-IgE/M1′hybridomas, and were analyzed for N-terminal sequencing for clonalitydetermination in phosphate buffered saline. Each antibody was separatedon a Precast 4-20% Tris HCl SDS-PAGE (Invitrogen, Carlsbad, Calif.)under reducing condition. The resolved heavy chain (HC) and light chain(LC) were each subjected to N-terminal sequencing using a Procise 494N-terminal sequencer (Applied Biosystems, Foster City, Calif.) using the20-min cycle as described by Henzel et al. Analytical Biochemistry 267,148-160 (1999). The first 25 residues were sequenced to establishmonoclonality. When the HC or LC chain of the Ab was blocked with apyroglutamyl group that made the N-terminal amino acid inaccessible toEdman sequencing, removal of the blocking group was performed prior tosequencing. The pyroglutamyl group was removed with the pyroglutamateaminopeptidase enzyme (PGAP, Sigma, St Louis, Mo.) using the protocoldescribed by Pham et al. Electrophoresis 2005, 26 4243-4251.

The sequence of the heavy chain (HC) and light chain (LC) M1′ antibodies7A6, 1C11, 47H4, 26A11, 45C1 and 28E9 were determined to be thefollowing:

7A6 HC QVQLQQSGAELVRPGASVTLSCKAS (SEQ ID NO:66) LCDIVMSQSPSSLTVSVGEKVTLSCKS (SEQ ID NO:67) 1C11 HCQVQLQQSGAELVRPGASVTLSCKAS (SEQ ID NO:68) LC DIVMSQSPSSLAVSVGEKVTMSCKS(SEQ ID NO:69) 47H4 HC EVKLVESGGGLVQPGGSRKLSCAAS (SEQ ID NO:70) LCDVVLTQTPLSLPVSLGDQASI (SEQ ID NO:71) 26A11 HC EVQLQQSGPELVKPGASVKMSCKAS(SEQ ID NO:72) LC DIQMTQTTSSLSASLGDRVTITCRS (SEQ ID NO:73) 45C1 HCQIQLVQSGPELKKPGETVK (SEQ ID NO:74) LC DVVMTQTPLTLSVTIGQPASISCK (SEQ IDNO:75) 28E9 HC EVKLVESGGGLVQPGGSLRLSCATS (SEQ ID NO:76) LCDIQMTQSPASLSVSVGETVTFTCR (SEQ ID NO:77)In order to determine the full length sequences, 5′ degenerate primerswere designed from the N terminal amino acid sequences and known Ig genesegments, and PCR was performed with degenerate downstream heavy andlight chain conserved sequences.

Forward Primers

7A6 HC FOR.BsiWI 5′-tcgacgtacgctcaggttcagctgca gcaatctggggctgagctgg (SEQID NO:78) LC FOR.EcoRV 5′-gatcgatatcgtgatgtcccagtctc cctcctccctaac (SEQID NO:79) 1C11 HC FOR.BsiWI 5′-tcgacgtacgctcaggttcaattgcagcagtctggggctgagctgg (SEQ ID NO:80) LC FOR.EcoRV5′-gatcgatatcgtaatgtctcagtctc cttcctccctagc (SEQ ID NO:81) 47H4 HC9.1HCF.BsiWI 5′-tcgacgtacgctgaggtgaagttggt ggagtctgggggaggcttag (SEQ IDNO:82) LC 47H4LCF.EcoRV 5′-gatcgatatcgtgctgactcagactc cactctccctgcc (SEQID NO:83) 26A11 HC C7F7HCF.BsiWI 5′-tcgacgtacgctgaggtccagctccagcagtctggacctgagc (SEQ ID NO:84) LC 2B4LCF.EcoRV5′-gatcgatatccagatgacccaaacta catcctccctg (SEQ ID NO:85) 45C1 HC2G6HCF.BsiWI 5′-tcgacgtacgctcagatccagttggt gcagtctggacctgagctg (SEQ IDNO:86) LC 9C10LCF.EcoRV 5′-gatcgatatcgtgatgacgcagactc cactcactttgtcgg(SEQ ID NO:87) 28E9 HC 9.1HCFBsiWI 5′-tcgacgtacgctgaggtgaagctggtggagtctgaaggaggcttgg (SEQ ID NO:88) LC 5E10.LCF.EcoRV5′-gatcgatatccagatgacccagtctc cagcctccctatc (SEQ ID NO:89)

Reverse Primers

Heavy Chain Primer (HCR) (SEQ ID NO:90)5′-ctggacagggatccagagttccaggtcactgtcactggctcaggg Light Chain Primer(LCR) (SEQ ID NO:91) 5′-ctgtaggtgctgtctttgctgtcctgatcagtccaactg

RNA was harvested from anti-IgE/M1′ hybridomas (RNeasy Mini Kit, #74106,Qiagen, Valencia, Calif.) and cDNA was prepared using BD SprintPowerscript oligo dT priming kit (BD Biosciences, San Jose, Calif.,#639558). PCR was performed using the above primers and PCR productswere cloned using the TOPO-TA kit (Invitrogen, Carlsbad, Calif.,#45-0641). PCR was done using Platinum Pfx High Fidelity Polymerase(Invitrogen, Carlsbad, Calif., # 11708-039) with PCR conditions [94° C.2 minutes; 94° C. 15 seconds; 60° C. 30 seconds; 68° C. 2 minutes; 30cycles; 68° C. 10 minutes]. Clones were screened for inserts andmultiple clones were sequenced (Genentech, Inc.) to verify originalanti-IgE/M1′ heavy chain and light chain gene sequence.

Anti-M1′ antibody variable domains were subcloned into expressionvectors with different Fc regions to generate chimeric antibodies withdifferent species and/or isotype Fc's. Primers were designed to clonethe variable domain (CDR+framework) into mouse IgG2a, mouse IgG2a-DANA,and human IgG1 Fc regions.

Primers were designed to incorporate restriction sites with heavy andlight chain sequence. Heavy chains were cloned using BsiWI and ApaI.Light chains were cloned using EcoRV and KpnI. New PCR products werethen digested and ligated into mIgG2a (LPG10), mIgG2a-DANA(pErk-E27DANA), or huIgG1 for heavy chain, or mKappa (LPG2) or huKappaexpression vectors (Genentech, Inc.). Final clones were sequenceverified (Genentech, Inc.).

3′ primers and forward and reverse primer combinations for cloning ofVariable CDR sequences are as follows:

Reverse Primers

7A6 HC REV.ApaI (SEQ ID NO:92) 5′-accgatgggcccttggtggaggctgaagagactgtgagLC REV.KpnI (SEQ ID NO:93)5′-ccttggtaccccctccgaacgtgtacggatagctataatattg 1C11 HC REV.ApaI (SEQ IDNO:94) 5′-gaccgatgggcccttggtggaggctgaggagactgtg LC REV.KpnI (SEQ IDNO:95) 5′-ccttggtaccccctccgaacgtgtacggatagctataa 47H4 HC 47H4HCR.ApaI(SEQ ID NO:96) 5′-tgggcccttggtggaggctgaggagacggtgactgag LC 47H4LCR.KpnI(SEQ ID NO:97) 5′-ttccaacttggtacctccacc 26A11 HC 7G8HCR.ApaI (SEQ IDNO:98) 5′-gaccgatgggcccttggtggargctgcagagacagtgaccagag LC 47H4LCR.KpnI(SEQ ID NO:99) 5′-ttccaacttggtacctccacc 45C1 HC 45C1HCR.ApaI (SEQ IDNO:100) 5′-cgatgggcccttggtggargckgaggagacggtgagaatg LC 5C2LCR.KpnI (SEQID NO:101) 5′-agcttggtaccccctccg 28E9 HC 28E9.HC.REV.ApaI (SEQ IDNO:102) 5′-cgatgggcccttggtggaggctgaggagacggcgactgag LC 1D5.2LCR,KpnI(SEQ ID NO:103) 5′-ttccaacttggtacccgagccg

Primer Combinations:

Forward Reverse 7A6: HC 7A6.FOR.BsiWI - - - 7A6.REV.ApaI LC7A6.FOR.EcoRV - - - 7A6.REV.KpnI 1C11: HC 1C11.FOR.BsiWI - - -1C11.REV.ApaI LC 1C11.FOR.EcoRV - - - 1C11.REV.KpnI 47H4: HC9.1.HCF.BsiWI - - - 7H4HCR.ApaI LC* 47H4.LCF.EcoRV - - - 47H4.LCR.KpnI26A11 HC C7F7.HCF.BsiWI - - - 7G8.HCR.ApaI LC 2B4.LCF.EcoRV - - -47H4.LCR.KpnI 45C1 HC 2G6.HCF.BsiWI - - - 45C1.HCR.ApaI LC9C10.LCF.EcoRV - - - 5C2.LCR.KpnI 28E9 HC 9.1.HCF.BsiWI - - -28E9.HCR.ApaI LC 5E10.LCF.EcoRV - - - 1D52.LCR.KpnI

The 47H4 light chain had an internal KpnI site that precluded directcloning into the mKappa and huKappa expression vectors. The internalKpnI site was mutated using the Quick Change XL Site DirectedMutagenesis Kit (Stratagene, Cedar Creek, Tex., #200517-5) [95° C. 1minute; 95° C. 50 seconds; 60° C. 50 seconds; 68° C. 4.5 minutes; 68° C.7 minutes]. Primers were designed according to requirements of the kitto mutate a single nucleotide within the KpnI site that did not changethe amino acid sequence. TAC was mutated to TAT which conserved thetyrosine (Y) at that position. Final clones were sequence verified(Genentech, Inc.).

Primers Used for Mutagenesis Were:

(SEQ ID NO:104) FOR 5′-cc tat tta cat tgg tat ctg cag aag cca ggc c (SEQID NO:105) REV 5′-ggc ctg gct tct gca gat acc aat gta aat agg

Example 2A Humanization of Anti-IgE/M1′ Antibodies

This example describes the humanization of the murine anti-IgE/M1′antibodies 26A11, 7A6 and 47H4.

Materials and Methods

The M1′ domain of membrane associated human IgE was expressed as an Fcfusion in CHO cells and purified by conventional means. Hybridomasexpressing the antibodies 26A11, 7A6 and 47H4 were obtained byimmunizing mice with the recombinant M1′-Fc fusion protein andidentified by ELISA using plates coated with M1′-Fc. Functionalantibodies were identified by their ability to bind to M1′ expressingcells and promote apoptosis.

Cloning of murine 26A11, 7A6 and 47H4 variable domains—Total RNA wasextracted from hybridoma cells producing 26A11, 7A6 or 47H4 usingstandard methods. The variable light (VL) and variable heavy (VH)domains were amplified using RT-PCR with degenerate primers to the heavyand light chains. The forward primers were specific for the N-terminalamino acid sequence of the VL and VH regions. Respectively, the LC andHC reverse primers were designed to anneal to a region in the constantlight (CL) and constant heavy domain 1 (CH1), which are highly conservedacross species. The polynucleotide sequence of the inserts wasdetermined using routine sequencing methods. The 26A11, 7A6 and 47H4 VLand VH amino acid sequences are shown in FIGS. 6A and 6D, 6B and 6E, and6C and 6F, respectively.Direct hypervariable region grafts onto the acceptor human consensusframework—The phagemid used for this work is a monovalent Fab-g3 displayvector and consists of 2 open reading frames under control of a singlephoA promoter. The first open reading frame consists of the stII signalsequence fused to the VL and CH1 domains of the acceptor light chain andthe second consists of the stII signal sequence fused to the VH and CH1domains of the acceptor heavy chain followed by the minor phage coatprotein P3.

The VL and VH domains from murine 26A11, 7A6 or 47H4 antibodies(mu26A11, mu7A6 or mu47H4) were aligned with the human VL kappa I (huKI)and human VH subgroup III (huIII) consensus sequences. To make the CDRgrafts, hypervariable regions from mu26A11, mu7A6 or mu47H4 were graftedinto the huKI and huIII consensus acceptor frameworks to generate thedirect CDR-graft (26A11.v1, 7A6.v1 or 47H4.v1) (FIGS. 6A-6F). In the VLdomain the following regions were grafted to the human consensusacceptor: positions 24-34 (L1), 50-56 (L2) and 89-97 (L3). In the VHdomain, positions 26-35 (H1), 49-65 (H2) and 94-102 (H3) were grafted.MacCallum et al. [MacCallum et al. J. Mol. Biol. 262: 732-745 (1996))]have analyzed antibody and antigen complex crystal structures and foundposition 49 and 94 of the heavy chain to be part of the contact regionthus it seems reasonable to include these positions in the definition ofCDR-H2 and CDR-H3 when humanizing antibodies.

Humanized anti-IgE/M1′ antibodies 26A11.v1, 7A6.v1 and 47H4.v1 weregenerated as IgG antibodies by Kunkel mutagenesis of LC and HCexpression vectors using separate oligonucleotides for eachhypervariable region. Amino acid changes to increase stability were alsomade using Kunkel mutagenesis. Kunkel et al., J. Biol. Chem. 263(29):14784-14789 (1988). Correct clones were identified by DNA sequencing.

IgG Production—For screening purposes, IgG variants were initiallyproduced in 293 cells. Vectors coding for VL and VH (25 μg) weretransfected into 293 cells using the FuGene system. 500 μl of FuGene wasmixed with 4.5 ml of DMEM media containing no FBS and incubated at roomtemperature for 5 min. Each chain (25 μg) was added to this mixture andincubated at room temperature for 20 min and then transferred to fiveT-150 flasks for transfection overnight at 37° C. in 5% CO₂. Thefollowing day the media containing the transfection mixture is removedand replaced with 23 ml PS04 media with 0.1 ml/L trace elements (A0934)and 10 mg/L insulin (A0940). Cells were incubated for an additional 5days after which the media was harvested at 1000 rpm for 5 min andsterile filtered using a 0.22 μm low protein-binding filter. Samplescould be stored at 4° C. after addition of 2.5 ml 0.1% PMSF for every125 ml of media.Affinity determinations—Affinity determinations were performed byScatchard analysis, a cell binding ELISA and by surface plasmonresonance using a BIAcore™-2000 or A100.Scatchard analysis—Daudi-human, Rhesus and Cyno IgE/M1′ cells wereprepared for binding in cold Binding buffer composed of base media, with10 mM HEPES pH 7.4, and 2% FBS as well as 40 ug/ml human IgG. Cells arediluted to concentration of 1.7×10⁶ cells/ml, and kept on ice until theyare added to the assay. The proteins/antibodies are iodinated withIodogen method. Various concentrations of cold protein are prepared intriplicate, using a 1:2 dilution starting with the saturationconcentration and ending at a concentration of zero, with a total of 14concentrations. Hot protein of a single concentration is added to alldilutions to compete with the cold protein. Lastly the cells are addedto the hot and cold protein mixture, 250,000 cells per sample were used.Assay is kept at 4° C. for 4 hours, shaking. Each sample is thencollected and filtered on membrane, washed at least 3 times with bindingbuffer, allowed to dry and then counted for 1 minute using Perkin ElmerWizard 1470 Auto Gamma Counter.Competitive electrochemilluminescent cell binding assay—Relative bindingaffinities of humanized variants were measured using a competitiveelectrochemilluminescent cell binding assay. Transfected BJAB cellsexpressing IgE-M1′ (BJAB-IgE/M1′) (long) or control transfected cellsnot expressing M1′ (BJAB-IgE) (short) were washed withphosphate-buffered saline (PBS) and seeded at 25,000 cells/well in 25 μlPBS on 96-well MULTI-ARRAY High Bind plates (Meso Scale Discovery).Cells were incubated on the plates for one hour at room temperature toallow cell attachment to the wells. To block non-specific binding, 25 μlof 30% FBS in PBS was added to each well. The plates were then incubatedat room temperature for 30 minutes with mild shaking. Blocking solutionwas decanted and serial dilutions of humanized variants (0.022-1333 nM)supplemented with a fixed amount of biotinylated anti-IgE M1′ antibody(33.3 nM 26A11 or 47H4) in 25 μl PBS containing 2% FBS (assay buffer)were added. After one hour incubation at room temperature with mildagitation, the plates were washed three times with PBS (300 μl/well),using a microplate washer (ELx405 Select, Bio-Tek Instruments, Inc.,Winooski, Vt.). Bound antibodies were detected by adding 25 μl of 0.25μg/ml ruthenium-labeled streptavidin in assay buffer. After a one hourincubation at room temperature, plates were washed and Tris-based ReadBuffer T (1×, without surfactant) (Meso Scale Discovery) was added (150μl/well). Electrochemilluminescent signals were recorded using SectorImager 6000 reader (Meso Scale Discovery).Biacore 2000—Two orientations were used; either M1′-Fc or a particularantibody variant were immobilized (approximately 100 RU, in 10 mM SodiumAcetate pH 4.8 on a CM5 sensor chip) and the corresponding ligand(antibody variant or M1′ Fc, respectively) served as the analyte(injected at a flow rate of 30 μL/min, using a 2-fold serial dilution of0.5 to 1000 nM in PBST). Each sample was analyzed with 3-minuteassociation and 10-minute disassociation. After each injection the chipwas regenerated using 10 mM Glycine pH 1.7.Biacore A-100-M1′—was immobilized (approximately 100 RU, in 10 mM SodiumAcetate pH 4.8 on a CM-5 sensor chip) and the antibody variant served asthe analyte (injected at a flow rate of 30 μL/min, using a 2-fold serialdilution of 0.5 to 1000 nM in PBST). Each sample was analyzed with5-minute association and 5-minute disassociation. After each injectionthe chip was regenerated using 10 mM Glycine pH 1.7.

Binding response was corrected by subtracting a control flow cell from18F7 variant IgG flow cells. A 1:1 Languir model of simultaneous fittingof k_(on) and k_(off) was used for kinetics analysis.

Results and Discussion

CDR grafts of 26A11, 7A6 and 47H4—The human acceptor framework used forhumanization is based on the consensus human kappa I VL domain and theconsensus human subgroup III VH domain. The VL and VH domains ofmu26A11, mu7A6 and mu47H4 were aligned with the human kappa I andsubgroup III domains; each complementarity determining region (CDR) wasidentified and grafted into the human acceptor framework to generate aCDR graft that could be expressed as an IgG (FIGS. 6A-6F).Affinity Evaluation—26A11.v1, 7A6.v1 and 47H4.v1 were evaluated using acell binding ELISA and by surface plasmon resonance (Table 1). Theseassays indicated that the CDR grafts had affinities very similar totheir respective hybridoma antibodies.Elimination of potential deamidation and iso-aspartic acid forming sitesin CDR-L1 of 26A11 and 47H4—To avoid potential manufacturing issues,potential iso-aspartic acid forming sites Asn₂₈-Gly₂₉ in CDR-L1 of47H4.v1 and Asn₃₁-Ser₃₂ in CDR-L1 of 26A11.v1 were eliminated bysampling residues found in other antibodies at these positions (FIG. 6A,6C, Table I). Changing Gly₂₉ to Ala₂₉ in CDR-L1 of 47H4.v1 (47H4.v2 and47H4.v5), and Ser₃₂ to Tyr₃₂ in CDR-L1 of 26A11 (26A11.v3 and 26A11.v6)or Ala₃₂ (26A11.v2 or 26A11.v5) were found to be a suitablereplacements. In addition, changing Asn₃₁ to either Ser₃₁ (26A11.v13 or26A11.v15) or Gln₃₁ (26A11.v14 or 26A11.v16) also served to eliminatepotential deamidation and iso-aspartic acid formation and providedcandidates with affinities similar to their respective hybridomaantibodies.

Potential oxidation of Met₃₄ in CDR-H1 of either 26A11.v1 or 47H4.v1 wasavoided by changing this residue to Ile₃₄ in both antibodies withoutaffecting M1′ binding.

Example 3 Specificity of Anti-M1′ Abs

The specificity of anti-IgE/M1′ antibody clones was tested on human Bcell line BJAB (ATCC Manassas, Va., #HB-136) transfected with IgE withthe M1′ sequence (“long form”) or IgE lacking the M1′ sequence (“shortform”). IgE BJAB cell lines were generated by retroviral transduction ofBJAB cells using a pMSCV expression vector (Washington University, St.Louis, Mo.). cDNA of the full length heavy and light chains of human IgEB cell receptor were obtained from the human IgE myeloma cell line U266(ATCC, Manassas, Va., TIB#196) and were subcloned into the retroviralvector in combination with an IRES (Internal Ribosomal Entry Sequence)to allow for bicistronic co-transfection and co-expression of theantibody heavy and light chains. Further description of the method ofretroviral transduction is provided below.

PG13 packaging cells (ATCC CRL-10686) were seeded on a 10 cm tissueculture plate at 2×10⁶ cells per plate (DMEM high glucose, 10% FBS,penicillin, streptomycin, 2 mM L-glutamine) for 24 hours. Cells weretransfected with pMSCV DNA constructs using FuGENE 6 and cultured for 2days at 37° C., 5% CO2. Cell culture supernatant containing retroviralparticles was harvested and filtered through a 0.4 micron filter.Sterile protamine sulfate was added to a final concentration of 10μg/ml, and 4 ml of supernatant was used to infect approximately 1×10⁶BJAB cells by spin infection at 32° C. for 90 minutes, followed bycontinued culture in retroviral supernatant for 3-4 hours at 37° C. in5% CO₂. Infected BJAB cells were recovered, transferred to RPMI cellculture medium (RPMI, 10% FBS (Hyclone, Logun, Utah, #SH30071.03),penicillin, streptomycin, 2 mM L-glutamine), and expanded for sorting.Positively transfected cells were identified by flow cytometry usingMAE11 (Genentech) anti-human IgE antibody to detect surface IgE.

Anti-IgE/M1′ antibodies are specific for the long form and not the shortform of membrane IgE, as determined by flow cytometry staining of BJABIgE short and long form cell lines. Anti-human IgE (Mae11) antibody(Genentech, Inc.) was used as a positive control for its ability to bindboth the long and short form of IgE. Anti-gp120 mIgG1 or anti-ragweedmIgG2a antibodies were used as isotype controls (Genentech, Inc).

BJAB cells are grown in RPMI 10% FBS (Hyclone, Logun, Utah,#SH30071.03), Penicillin/Streptomycin, 2 mM L-Glutamine (Genentech,Inc.). 0.5×10⁶ BJAB-Long or BJAB-short cells were blocked with mouse (10μl) (VWR, #RLD108-0100) and human serum (10 μl) (Sigma, St. Louis, Mo.,#S-2257) for 15 minutes on ice in 100 μl of FACs Wash Buffer (2% FBS in1×PBS (Genentech, Inc.). Cells were then stained with 1 μg/ml of eachanti-M1′ antibody for another 20 minutes on ice and then washed with 1ml of FACs wash buffer and centrifuged at 1200 rpm for 5 minutes. Cellswere resuspended in 100 μl of FACs Wash Buffer and then stained withgoat anti-mouse IgG-PE (5 μl) (Caltag/Invitrogen, Carlsbad, Calif.,#M30004-4) on ice for 20 minutes. Cells were washed as before andresuspended in 1 ml of FACs wash buffer for analysis on the FACs Caliburmachine (BD, Inc, Franklin Lakes, N.J.). All antibodies tested werespecific for the long form of IgE and did not bind BJAB-IgE/short cellsabove isotype control. We observed a wide range of relative affinitiesbased on staining intensities.

We also assessed anti-M1′ antibody binding to the U266 cell line (ATCC,Manassas, Va., #TIB196) which naturally expresses a low level of humanIgE containing M1′ on the cell surface. U266 cells are maintained athigh density (1-2×10⁶/ml) in hybridoma medium [RPMI 1640, 15% Fetalbovine serum, 2 mM L-glutamine, 10 mM HEPES, 4.5 g/L glucose, 1.5 g/Lbicarbonate]. U266 cells were stained with anti-M1′ antibodies at 1μg/ml. 47H4, 47G4 and 42A5 stained U266 at levels similar to Mae11.Antibodies 42H4, 45C1 and 28E9 stained U266 at very low levels. 7A6,1C11, 26A11, 51D2, and 26B11 did not stain U266. (FIG. 2C)

Example 3A Murine Anti-IbE/M1′ Binding Specificity

FIGS. 2D-F show the binding of murine anti-IgE/M1′ antibodies 47H4,26A11 and 7A6 to a collection of cell lines that express human Rhesus orCyno IgE/M1′.

The specificity of anti-IgE/M1′ antibody clones was tested on the humanB cell line BJAB (ATCC Manassas, Va., #HB-136) and Daudi (ATCC #CCL-213)infected by retrovirus to express the long form of IgE with the M1′sequence or the short form of IgE lacking the M1′ sequence. BJAB cellsare grown in RPMI 10% FBS (Hyclone, Logun, Utah, #SH30071.03),Penicillin/Streptomycin, 2 mM L-Glutamine (Genentech, Inc.). 0.5×10⁶BJAB-Long or BJAB-short cells were blocked with mouse (10 μl) (VWR,#RLD108-0100) and human serum (10μl) (Sigma, St. Louis, Mo., #S-2257)for 15 minutes on ice in 100μl of FACs Wash Buffer (2% FBS in 1×PBS(Genentech, Inc.)). Cells were then stained with 1 μg/ml of eachanti-M1′ antibody for another 20 minutes on ice and then washed with 1ml of FACs wash buffer and centrifuged at 1200 rpm for 5 minutes. Cellswere resuspended in 100 μl of FACs Wash Buffer and then stained withgoat anti-mouse IgG-PE (5 μl) (Caltag/Invitrogen, Carlsbad, Calif.,#M30004-4) on ice for 20 minutes. Cells were washed as before andresuspended in 1 ml of FACs wash buffer for analysis on the FACs Caliburmachine (BD, Inc, Franklin Lakes, N.J.). All antibodies tested werespecific for the long form of IgE and did not bind BJAB-IgE/short cellsabove isotype control. We observed a wide range of relative affinitiesbased on staining intensities.

The specificity of anti-IgE/M1′ antibody clones was tested on the humanB cell line Daudi infected by retrovirus to express membrane IgE withthe M1′ sequence (long form) or a membrane IgE lacking the M1′ sequence(short form). Anti-IgE/M1′ antibodies (47H4, 26A11, 7A6) are specificfor the long form and not the short form (FIG. 2D). An anti-gp120 mIgG1antibody was used an isotype control (Genentech, Inc).

The human B cell line Daudi was transduced with the retroviruscontaining the human IgE/primate M1′ cassette for either rhesus or cynoor the human IgE/M1′. Following transduction cells expressing human,rhesus, or cyno IgE/M1′ were sorted by FACs sorter to >98% purity overthe course of 3-4 sorts.

FIG. 2F demonstrates the ability of anti-IgE/M1′ antibodies to bindRhesus and Cyno M1′. 47H4 and 7A6 bind both Rhesus and Cyno M1′, whereas26A11 binds only Rhesus M1′.

In addition to the Daudi transfectant cell lines, we assessedanti-IgE/M1′ antibody binding to U266, a human IgE myeloma cell line(ATCC, Manassas, Va., #TIB196). U266 cells are maintained at highdensity (1-2×10⁶/ml) in hybridoma medium [RPMI 1640, 15% Fetal bovineserum, 2 mM L-glutamine, 10 mM HEPES, 4.5 g/L glucose, 1.5 g/Lbicarbonate]. U266 cells were stained with anti-M1′ antibodies at 1μg/ml. anti-IgE/M1′ antibody 47H4 bound U266 while 26A11 and 7A6 did not(FIG. 2E).

Example 3B Humanized Anti-IgE/M1′ Binding Specificity

Example 3B shows the binding of humanized anti-IgE/M1′ antibodies to acollection of cell liens that express human, rhesus or cyno IgE/M1′.

Using the same Daudi or BJAB human B cell lines overexpressing human,rhesus and cyno M1′ discussed in Example 3A, the specificity ofhumanized anti-IgE/M1′ antibody clones was tested on the human B cellline Daudi infected by retrovirus to express the long form of IgE withthe M1′ sequence or the short form of IgE lacking the M1′ sequence.Humanized anti-IgE/M1′ antibodies (47H4v5, 26A11v6, 7A6v1) are specificfor the long form and not the short form (no M1′) [FIG. 2G]. HERCEPTIN®anti-Her2 MAb huIgG1 was used as an isotype control (Genentech, Inc.).In addition, humanized anti-IgE/M1′ antibodies (47H4v5 and 26A11v6) bindto U266 cell lines (FIG. 2H).

FIG. 2I shows the ability of humanized anti-IgE/M1′ antibodies to bindboth rhesus and cyno M1′. The antibodies 47H4v5 and 7A6v1 bind bothrhesus and cyno M1′, whereas 26A11v6 only binds only rhesus M1′.

Example 4 Relative Binding Affinity of anti-M1′ Antibodies

We observed a wide range of anti-IgE/M1′ antibody binding intensities at1 μg/ml. To assess the relative affinities of these antibodies for theIgE-long receptor, we stained BJAB-Long cells with a dilution series ofanti-M1′ antibody (1, 0.1, 0.01, 0.001 μg/ml). BJAB-Long cells wereblocked with mouse and human serum (10 μl) for 20 minutes on ice. Cellswere stained with the appropriate amount of anti M1′-antibody, oranti-gp120 mIgG1 or anti-ragweed mIgG2a isotype controls for another 20minutes. Cells were then washed in FACs wash buffer (1 ml), centrifuged(1200 rpm for 5 minutes) and then resuspended in 100 μl of FACs Washbuffer with goat anti-mouse IgG-PE antibody (5 μl) (CALTAG/Invitrogen,Carlsbad, Calif. #M30004-4) for detection. Cells were washed again asabove and then analyzed on a FACs Calibur machine (BD, Inc, FranklinLakes, N.J.). Voltage settings were based on the 0.001 μg/ml isotypecontrol. From these results anti-IgE/M1′ antibody candidates were rankedaccording to relative binding affinity:

-   -   42H4>7A6, 47H4, 47G4>42A5, 26A11, 45C1>51D2, 26B11>1C11>28E9

In addition to relative affinity determinations by antibody titrationand FACs detection, we also determined affinities of selected anti-M1′antibodies to BJAB cell lines expressing IgE long form using Scatchardanalysis. BJAB-Long cells were prepared for binding in cold Bindingbuffer composed of base media, with 10 mM HEPES pH 7.4, and 2% FBS aswell as 40 μg/ml human IgG. Cells were diluted to a concentration of1.7×10⁶ cells/ml, and kept on ice until added to the assay. Theantibodies were iodinated with Iodogen method. Various concentrations ofunlabelled antibody were prepared in triplicate, using a 1:2 dilutionstarting with the saturation concentration and ending at a concentrationof zero, with a total of 14 concentrations. Iodinated antibody of asingle concentration was added to all dilutions of the competitorunlabelled antibody. Lastly 250,000 BJAB-Long cells were added to eachmixture of iodinated and unlabelled antibody. The samples were incubatedat 4° C. for 4 hours, shaking. Each sample was then collected andfiltered on a membrane, washed at least 3 times with binding buffer,allowed to dry and then measured for 1 minute using a Perkin ElmerWizard 1470 Auto Gamma Counter.

Example 4A Scatchard Affinity of Murine Anti-IgE/M1′ Antibodies

The BJAB or Daudi cells expressing various forms of IgE with or withoutM1′ (Human, Rhesus, Cyno) were prepared for binding in cold Bindingbuffer composed of base media, with 10 mM HEPES pH 7.4, and 2% FBS aswell as 40 ug/ml human IgG. Cells are diluted to concentration of1.7×10⁶ cells/ml, and kept on ice until they are added to the assay. Theproteins/antibodies are iodinated with the Iodogen method. Variousconcentrations of cold protein are prepared in triplicate, using a 1:2dilution starting with the saturation concentration and ending at aconcentration of zero, with a total of 14 concentrations. Hot protein ofa single concentration is added to all dilutions compete with the coldprotein. Lastly the cells are added to the hot and cold protein mixture,250,000 cells per sample were used. Assay is kept at 4° C. for 4 hours,shaking. Each sample is then collected and filtered on membrane, washedat least 3 times with binding buffer, allowed to dry and then countedfor 1 minute using Perkin Elmer Wizard 1470 Auto Gamma Counter.

FIG. 3O summarizes the affinities of murine anti-M1′ antibodies measuredby Scatchard analysis. Murine antibody 47H4 mIgG1 bound human, Rhesus,Cyno M1′ with affinities of 0.79, 0.77 and 0.97 nM, respectively. Murineantibodies 26A11 mIgG1 and 7A6 mIgG1 bound human M1′ with affinities of2.3 and 0.64 nM, respectively.

FIG. 3P summarizes the binding affinities of humanized anti-IgE/M1′antibodies to human, rhesus and cyno M1′. Humanized antibody 47H4v5huIgG1 bound human, rhesus and cyno M1′ with affinities of 1.5, 1.3 and2.5 nm, respectively. Humanized antibodies 47H4 v2, 47H4v1, 26A11v6,26A11v14 and 26A11v1 bound human M1′ with affinities of 0.54, 0.37,1.85, 1.5 and 1.06, respectively.

Example 5 Anti-IgE/M1′ Epitope Binding/Blocking Studies

Blocking studies were performed between anti-IgE/M1′ antibody candidatesto determine overlapping or distinct binding epitopes. When the blockingand detecting antibodies were of different isotype (i.e., IgG1 vs.IgG2a), these isotype differences were exploited to determine the extentof blocking by detecting with an isotype-specific secondary antibody(CALTAG/Invitrogen, Carlsbad, Calif., Goat anti-mouse IgG1-PE #32004, orGoat anti-mouse IgG2a #M32204). When the blocking and binding antibodyantibodies were of the same isotypes, the antibodies were conjugated toBiotin (Pierce, Rockford, Ill., EZ-link-sulfo-NHS-LC-Biotin#CAS127062-220) and detected with Streptavidin-PE (BD #554061), orconjugated to Alexa-647 (Molecular Probes/Invitrogen, Carlsbad, Calif.,#A20173). Initially blocking and detection antibodies were used at a 1:1ratio (10 μg/ml) (FIGS. 4A-4B). Antibody combinations that initiallygave no block or only partial block were further tested using a 10:1blocking to detection antibody ratio. BJAB-Long cells were blocked withmouse and human serum (as described above), and then stained with theblocking antibody (10 μg/ml) in FACs Wash Buffer (2% FBS/1×PBS) for 20minutes on ice. Cells were washed in FACs Wash Buffer and then stainedwith the detection antibody at the 1:1 (10 μg/ml) or 10:1 ratio (1μg/ml) for 20 minutes on ice. Cells were washed again as above and thenanalyzed on a FACS Calibur machine (BD, Inc, Franklin Lakes, N.J.).Stained cells were compared to an isotype control antibody eitheranti-gp120 mIgG1 (Genentech, Inc.) or anti-Ragweed mIgG2a (Genentech,Inc.) (FIG. 4C). For comparison, complete blocking was determined bystaining with the same antibody unconjugated when possible.

The blocking studies revealed three major binding groups A and B and C.Group A was further divided into two groups A1 (47H4, 47G4, 42H4, 42A5),and A2 (45C1, 51D2, 26A11) based on partial overlapping epitopes (FIG.4D). Group C (26B11) had very little overlap with other antibodycandidates. Three candidates overlapped more broadly than the others.1C11 appeared to have overlapping binding with group A1 and A2, and wasonly partially blocked by group B (28E9). 7A6 primarily belongs to groupA1 but had partial interaction with group A2 candidates. 28E9 belongs ina group all to itself. 28E9 had only partial interaction with group A2candidates.

Example 5A Epitope Mapping

FIGS. 5A-E show epitope binding studies performed using anti-IgE/M1′antibodies. Murine antibodies 47H4, 7A6 and 26A11 are shown in FIGS. 5Band 5D, while humanized variants 47H4v5, 7A6v1 and 26A11v6 are shown inFIGS. 5C and 5E.

Epitope Mapping Studies: Murine Candidates

15 peptides were generated spanning the sequence surrounding andincluding human M1′ (Clifford Quan) (FIG. 5A). Peptides were resuspendedin either dH20 or 50% DMSO. Peptides were coated on 96 well plates (NUNCMaxisorp high protein-binding capacity ELISA plates #44-2404) at 1 μg/mlin Coating Buffer (0.05M Carbonate/bicarbonate (pH9.6) (100 μl perwell). The M1′-Fc fusion protein was used as a positive control forbinding. Negative controls included wells coated with human IgE (U266)and non-coated wells. Peptides were allowed to coat overnight at 4° C.The following morning Plates were washed 3 times with wash buffer(PBS/0.05% Tween-20 (pH 7.4)). Plates were then blocked in Blockingbuffer (PBS, 0.5% BSA (pH 7.4)) for 1 hour with gentle agitation.Dilutions of the antibodies (40 ng/ml and 1 ng/ml) to be tested (47H4mIgG1, 47H4v5 huIgG1, 26A11 mIgG1, 26A11v6 huIgG1, 7A6 mIgG1, 7A6v1huIgG1) were made in Magic Buffer [PBS (pH7.4), 0.5% BSA. 0.05%Tween-20, 10 ppm Proclin., 0.2% BgG, 0.25% Chaps, 5 mM EDTA, 0.35MNaCl]. Anti-gp120 mIgG1 and HERCEPTIN® huIgG1 antibodies were used ascontrols for murine and human anti-IgE/M1′ antibodies respectively. Onceplates were sufficiently blocked (0.5% BSA/1×PBS), plates were washed 3times, and then antibodies were added to the plate in triplicate (100 μlper well). Plates were then incubated for 2 hours at room temperature.Murine antibody plates were washed 3 times and then anti-mouseIgG1-Biotin (BD Biosciences (A85-1) #553441) was added (1:10,000, 100 μlper well) and incubated for 1 hour at RT. Following 3 washes, SA-HRP (BDBiosciences #554066) was added (1:20,000, 100 μl per well) and incubatedfor 1 hour. Human IgG1 antibody plates were washed as before andanti-huIgG.Fc-HRP (Jackson ImmunoResearch (#109-036-098)) was added(1:10,000, 100 μl per well) and incubated for 1 hour at RT. Oncesecondary incubations were complete, plates were washed 6 times and TMBsubstrate (BD OptEIA #555214) was added (100 μl per well). Thesubstrate-HRP reaction was stopped with 1M H3PO4 after ˜4 minutes.Plates were then read at 450/650. Data was represented as relative OD(OD450/CD650).

FIGS. 5B and 5D illustrate the binding of murine 47H4, 26A11 and 7A6anti-IgE/M1′ candidates to M1′ peptides. Binding of these candidatescorrelate with epitope groupings defined antibody blocking studies. 47H4mIgG1 bound peptide 4 (SAQSQRAPDRVLCHS) (SEQ ID NO:8). 7A6 mIgG1 boundpeptides 4 (SAQSQRAPDRVLCHS) (SEQ ID NO:8) and 5 (RAPDRVLCHSGQQQG) (SEQID NO:9). 26A11 mIgG1 bound peptides 7 (GQQQGLPRAAGGSVP) (SEQ ID NO:11)and 8 (PRAAGGSVPHPRCH) (SEQ ID NO:12).

FIGS. 5C and 5E illustrate the binding of humanized anti-IgE/M1′antibodies to M1′ peptides. The epitope mapping was performed asdescribed above for the corresponding murine antibodies, except that adifferent secondary antibody was used. Human IgG1 antibody plates werewashed as before and anti-IgG.Fc-HRP secondary antibody (JacksonImmunoResearch (#109-036-098) was added (1:10,000, 100 μl per well) andincubated for 1 hour at RT. Epitope binding parallels that observed withthe parental murine antibodies. 47H4 v5 binds peptide 4(SAQSQRAPDRVLCHS) (SEQ ID NO:8). 7A6v1 bound peptides 4(SAQSQRAPDRVLCHS) (SEQ ID NO:8) and 5 (RAPDRVLCHSGQQQG) (SEQ ID NO:9).26A11 mIgG1 bound peptides 7 (GQQQGLPRAAGGSVP) (SEQ ID NO:11) and 8(PRAAGGSVPHPRCH) (SEQ ID NO:12).

Example 6 Induction of Apoptosis by Murine Anti-IzE/M1′ inDaudi-IgE/Long Cells

Daudi-Long (IgE/M1′) cells were used to test the effect of crosslinkingsurface IgE on the induction of apoptosis. Daudi cells (ATCC, Manassas,Va., #CCL-213) are a human Burkitt Lymphoma cell line known to besusceptible to apoptosis in response to BCR crosslinking. Daudi cellsexpressing the long form of IgE were generated by retroviraltransduction of the U266 heavy and light chains of IgE with M1′, asdescribed above for the generation of BJAB IgE long cells. Flowcytometry analysis of Daudi-IgE/Long cells using antibodies againstendogenous IgM and transfected IgE B cell receptor indicate higherexpression of IgM than IgE. Apoptosis of Daudi-IgE/Long cells wasstudied in cells cultured to a density of 0.2×10⁶/1.5 ml in culturemedium [RPMI, 10% FBS (Hyclone, Logun, Utah, #SH30071.03),Penicillin/Streptomycin (Gibco/Invitrogen, Carlsbad, Calif. #15140-122),2 mM Glutamine (Genentech, Inc.), 10 mM HEPES (7.2) (Genentech, Inc.), 1mM NaPyruvate (Gibco/Invitrogen, Carlsbad, Calif. #11360), 1.59 g/Lsodium bicarbonate solution (Gibco/Invitrogen, Carlsbad, Calif.#25080-094)]. Prior to the start of the apoptosis assay, dead cells wereremoved over a ficoll gradient (GE Healthcare #17-1440-03) to reducebackground levels of cell death in the assay. 0.2×10⁶ cells werecultured in triplicate with and without anti-M1′ antibodies or controlantibodies in solution for 72 hours. Cells were then harvested andanalyzed for levels of apoptosis using the Annexin V-FITC ApoptosisDetection Kit I (BD Biosciences, San Jose, Calif. #556547). Cells werewashed twice in cold PBS (Genentech, Inc.) and then resuspended in 100μl 1× binding buffer (0.1 M Hepes/NaOH (pH7.4), 1.4 M NaCl, 25 mM CaCl₂)(BD Biosciences, San Jose, Calif., #51-66121E). Cells were then stainedwith 2.5 μl of Annexin V-FITC antibody (BD Biosciences, San Jose, Calif.#51-65874X) and 5 μl of Propidium Iodide (PI) (BD Biosciences, San Jose,Calif. #51-66211E) in the dark. After 15 minutes, 400 μl of 1× bindingbuffer was added to each tube and cells were analyzed on a FACs Caliburflow cytometry machine (BD, Inc. Franklin Lakes, N.J.). Approximately10-20,000 events were collected for each sample. Dying cells are definedas Annexin-V positive and PI negative. Dead cells are positive for bothAnnexin-V and PI. The percentage of each population (dead and dying) wascalculated using FlowJo FACs analysis software (Tree Star, Inc.,Ashland, Oreg.). Data in triplicate were averaged and standarddeviations calculated. Percent Apoptosis was calculated as the sum ofdead and dying cells and graphed using Excel (Microsoft, Inc.).

Camptothecin (Sigma-Aldrich, St. Louis, Mo., #C9911-100 mg) and anti-IgMantibody (JacksonImmuno Research, West Grove, Pa., #109-006-120) wereused as positive controls for inducing apoptosis in the Daudi-IgE/Longcell line. Anti-gp120 mIgG1 or anti-Ragweed mIgG1 antibodies (Genentech,Inc.) were used as negative controls for this assay. Daudi-IgE/Longcells were cultured with a range of Anti-IgE/M1′ or isotype controlantibodies concentrations (25, 10, 1, 0.1, 0.01, 0.001 μg/ml).Anti-IgE/M1′ antibodies tested were 7A6, 47H4, 47G4, 42A5, 42H4, 1C11,26A11, 51D2, 45C1, 26B11 and 28E9 (Genentech, Inc.). Anti-human IgEantibody (Mae11-mIgG1) was also used for comparison.

Isotype control anti-gp120 and anti-ragweed antibodies did not induceapoptosis above untreated cells. Background levels of apoptosis were inthe 10-15% range for each experiment. Anti-IgE/M1′ antibodies 7A6 (>10μg/ml), 47H4 (>10 μg/ml), and 47G4 (25 μg/ml) induced apoptosis of DaudiIgE long cells. 26A11 induced similar magnitudes of apoptosis (˜30-50%)but at much lower concentrations (>0.1 μg/ml). 42A5, 51D2, 45C1, 26B11,and 28E9 did not induce apoptosis above background levels. Mae11 alsodid not induce apoptosis above background levels.

We also performed the apoptosis assay in the presence of a goatanti-mouse IgG F(ab′)₂ secondary antibody (Jackson ImmunoResearch, WestGrove, Pa. #115-006-062) to supercrosslink the IgE B-cell receptor onthe Daudi cell line. Crosslinking experiments were done in the presenceof goat anti-mouse IgG F(ab′)₂ antibody (30 μg) (Jackson ImmunoResearch,West Grove, Pa., #115-006-062). With the exception of 26B11 (30%), allantibodies induced maximum apoptotic levels of 70-80% but at differentconcentrations. These antibodies can be classified into two groups. 7A6,1C11, 26A11, 51D2, 45C1, and 28E9 induced maximum apoptosis at thehighest concentrations. The other group 47H4, 47G4, 42A5, and 42H4, andMAE11 exhibited decreasing apoptosis at higher concentrations.

Example 6A Induction of Apoptosis of Humanized Anti-IzgE/M1′ Antibodiesin Daud/IgE-Long Cells

Daudi-Long (IgE/M1′) cells were used to test the effect of crosslinkingsurface IgE on the induction of apoptosis in this cell line. Daudi cells(ATCC, Manassas, Va., #CCL-213) are a human Burkitt Lymphoma cell lineknown to be susceptible to apoptosis in response to BCR crosslinking.Daudi-IgE/Long cells were cultured at a density of 0.2×10⁶/1.5 ml inculture medium [RPMI, 10% FBS (Hyclone, Logun, Utah, #SH30071.03),Penicillin/Streptomycin (Gibco/Invitrogen, Carlsbad, Calif. #15140-122),2 mM Glutamine (Genentech, Inc.), 10 mM HEPES (7.2) (Genentech, Inc.), 1mM NaPyruvate (Gibco/Invitrogen, Carlsbad, Calif. #11360), 1.59 g/Lsodium bicarbonate solution (Gibco/Invitrogen, Carlsbad, Calif.#25080-094)] the night before and then dead cells were removed over aficoll gradient (GE Healthcare #17-1440-03) the next day. This reducedbackground levels of cell death in the assay. 0.2×10⁶ cells werecultured in triplicate with and without anti-M1′ antibodies or controlantibodies in solution for 72 hours. Cells were then harvested andanalyzed for levels of apoptosis using the Annexin V-FITC ApoptosisDetection Kit I (BD Biosciences, San Jose, Calif. #556547). Cells werewashed twice in cold PBS (Genentech, Inc.) and then resuspended in100-μl 1× binding buffer (0.1 M Hepes/NaOH (pH7.4), 1.4 M NaCl, 25 mMCaCl₂) (BD Biosciences, San Jose, Calif., #51-66121E). Cells were thenstained with 2.5 μl of Annexin V-FITC antibody (BD Biosciences, SanJose, Calif. #51-65874X) and 5μl of Propidium Iodide (PI) (BDBiosciences, San Jose, Calif. #51-66211E) in the dark. After 15 minute4001 of 1× binding buffer was added to each tube and cells were analyzedon a FACs Calibur flow cytometry machine (BD, Inc. Franklin Lakes,N.J.). Approximately 10-20,000 events were collected for each sample.Dying cells are defined as Annexin-V positive and PI negative. Deadcells are positive for both Annexin-V and PI. The percentage of eachpopulation (dead and dying) was calculated using FlowJo FACs analysissoftware (Tree Star, Inc., Ashland, Oreg.). Data in triplicate wereaveraged and standard deviations calculated. Percent Apoptosis wascalculated as the sum of dead and dying cells and graphed using Excel(Microsoft, Inc.).

An Anti-IgM antibody (JacksonImmuno Research, West Grove, Pa.,#109-006-120) was used as a positive control for inducing apoptosis inthe Daudi-IgE/Long cell line. HERCEPTIN® huIgG1 (Genentech, Inc.) wasused as a negative control for this assay. Daudi-IgE/Long cells werecultured with a range of Anti-IgE/M1′ or isotype control antibodiesconcentrations (25, 10, 1, 0.1, 0.01, 0.001 μg/ml). Secondarycrosslinking experiments were done in the presence of goat anti-humanIgG F(ab′)₂ antibody (50 μg) (Biosource #AH11301). Anti-IgE/M1′antibodies tested were 47H4v5, 26A11v6, 7A6v1 huIgG1.

Isotype control HERCEPTIN® huIgG1 did not induce apoptosis above nontreated cells. Background levels of apoptosis were in the 10-15% rangefor each experiment. Anti-IgE/M1′ antibodies 47H4 v5, 26A11v6 and 7A6v1induced apoptosis in the range of 30-40% (FIG. 8A).

We repeated the same assays in the presence of a goat anti-human IgGF(ab′)2 secondary antibody (Biosource #AHI1301) to crosslink the IgEreceptor on the Daudi cell line. All antibodies induced maximumapoptotic levels of 70-90%, with some decrease in apoptotic activity athigh concentrations of primary anti-IgE/M1′ antibody (FIG. 8B).

Wildtype vs. Afucosylated 47H4v5 in Inducing Apoptosis Without SecondaryCrosslinking.

An afucosylate (AF) version of 47H4 v5 was produced using BIOWA celllines (Genentech, Inc.). Both WT and AF versions of 47H4 v5 were able toinduce apoptosis to similar levels (FIG. 8C).

TABLE 1 Humanized Anti-IgE/M1′ Binding Affinities Biacore 2000 ScatchardBJAB-IgE Biacore A100 M1′ IgG Sequence Changes cell binding M1′immobilized immobilized Immobilized L1-31/32 H1-34/35 KD (nM) IC50 (nM)IC50 (nM) KD (nM) KD (nM) KD (nM) mu26A11 NS MM 1.6 nM 12 25/26 0.3 5.126A11.v1 NS MM 15 19 0.2 1.7 9.0 26A11.v2 NA MM 18 0.3 26A11.v3 NY MM 1022 0.0 2.8 26A11.v4 NS IM 20 29 0.9 26A11.v5 NA IM 25 35 26A11.v6 NY IM11 23 2.6 8.3 26A11.v7 NS IH 890 very weak 26A11.v10 NS IN ~3300 106426A11.v11 NA IN ~540 21364 26A11.v12 NY IN ~1200 26A11.v13 SS MM 19 4.026A11.v14 QS MM 19 3.9 26A11.v15 SS IM 32 8.4 26A11.v16 QS IM 27 8.8L1-27e/28 H1-34 H3-100k mu47H4 NG M M 0.4 nM 62 57 5.6 12 1.5 47H4.v1 NGM M 12 18 7.8 3.1 47H4.v2 NA M M 38 7.4 2.8 47H4.v3 NG I L ~7600 6947H4.v4 NA I L >1300 56 47H4.v5 NA I M 60 23 47H4.v6 NA M L 170 54 H1-34H3-100k mu7A6 M M 0.6 nM 52 4.5 7A6.v1 M M 39 15 7A6.v2 I L ~370 571

Example 7 Induced Calcium Flux

We investigated the ability of anti-M1′ antibodies to induce calciumflux in Daudi-IgE/Long cells as evidence that these antibodies caninduce cellular signaling downstream of the IgE B-cell receptor. Daudicells (ATCC, Manassas, Va., #CCL-213) that overexpress the long form ofIgE/M1′ were cultured overnight at a light density of 0.2×10⁶/ml. Thenext morning dead cells were removed over a ficoll gradient (GEHealthcare #17-1440-03). Cells were loaded with Indo-1 in bulk to ensureeven loading among all stimuli. Cells were resuspended at 5×10⁶/ml inculture medium (RPMI-10% FBS (Hyclone), penicillin/streptomycin, 2 mML-Glutamine) and combined with the calcium detection dye Indo-1 (5 μM)(Molecular probes/Invitrogen, Carlsbad, Calif., #11223). The cells werethen washed in culture media and resuspended at 10⁶/ml. 10⁶ cells wereused per stimulus. Samples were warmed in a 37° C. water bath for 5minutes prior to running on a FACs Vantage machine (BD, Inc, FranklinLakes, N.J.). Samples were initially run for 1 minute to generate abaseline and then samples were stimulated with 20 μg of each antibody,except for anti-IgM (10 μg). Data was collected for 8-10 minutes.Kinetic analysis was performed on FlowJo FACs analysis software (TreeStar, Inc., Ashland, Oreg.). Data is reported as the ratio of Indo-1 405Bound/Indo-1 1530 Free. All anti-M1′ antibodies were compared to isotypecontrol anti-gp120 mIgG1 (20 μg). Anti-human IgM (JacksonImmuno-Research, West Grove, Pa., #109-005-129) and anti-IgE (Mae11,Genentech, Inc.) were used as positive controls. 7A6, 47H4, 47G4, 26A11,and 1C11 induced a calcium flux in Daudi IgE long cells. 28E9 and 42A5induced low levels of calcium flux. 45C1, 26B11, and 51D2 did not inducecalcium flux.

Example 8 Induction of ADCC by Anti-IgE/M1′ 47H4 v5 wt and Afucosylated

Antibody-dependent cell-mediate toxicity enables to cytotoxic cells tobind (through the antibody) to the antigen-binding target cell andsubsequently kill the target cell with cytotoxins. Anti-IgE/M1′antibodies possessing ADCC activity or enhanced ADCC activity may haveenhanced therapeutic value in the treatment of IgE-mediated disorders.

It has been discovered that antibodies produced in mammalian cells thatare afucosylated have enhanced ADCC activity. The following experimentdescribed the production of afuscosylated anti-IgE/M1′ antibody.

NK cells were isolated from 100 ml whole blood (RosetteSep #15065, StemCell Technologies). Purity of NK cells was determined by anti-human CD56staining. >70% pure CD56+ NK cell were used in each assay. Anti-IgE/M1′antibodies and HERCEPTIN® anti-Her2 MAb huIgG1 isotype control weretitrated serially. These antibodies (50 μl) were incubated with BJABcells overexpressing human IgE/M1′ on the cell surface for 30 minutes atroom temperature in RPMI-1640 (no phenol red) (BioWhitaker #12-918F)with 1% FBS (Cell line was generated as outlined above). NK cells (50μl) were then added to the cell line at a 15:1 ratio (150,000 NK cellsto 10,000 targets (BJAB-Long)). Assays were done in triplicate.BJAB-huLong, antibodies, and NK cells were then incubated for 4 hours at37° C. After culture, 96 well U bottom plates were spun down andsupernatants were harvested (100 μl). Supernatants were then tested forLDH release using the LDH reaction Assay (Roche #1644793). Target aloneand Target lysed were used to calculate the percent cytotoxicity.Superantants were incubated at an equal volume with the LDH reactionmixture as outlined by the manufacturer for 30-60 minutes. Plates werethen read at 490 nm. % cytotoxicity was calculated as follows: =(Expvalue−Target alone)/target lysed−Target alone). Data was plotted usingKaleidagraph and best fit curves were used to generate ED50 values.

In FIG. 10, the HERCEPTIN® huIgG1 isostype control antibody induced lowlevel cytotoxicity. Anti-IgE/M1′ antibodies induced specificcytotoxicity. The wildtype and afucosylated forms of Anti-IgE/M1′ 47H4v5induced similar maximal % cytoxicity (˜70-80%). The afucosylated 47H4v5was more potent than the wildtype form (the EC50 of the afucoylated47H4v5 was ˜0.83 nM; the EC50 of the wildtype 47H4v5 was ˜6.6 nM).

Example 9 Effect of Murine Anti-IgE/M1′ Antibodies in Atopic hu-SCIDMouse

FIGS. 12A and 13A demonstrate the ability of anti-IgE/M1′ antibodies(both murine and humanized, respectively) to inhibit the production ofserum IgE and IgE producing plasma cells in an atopic hu-SCID model.Experiment 1 (#07-0377) tested murine anti-IgE/M1′ candidates andexperiment 2 (#07-1232) tested a humanized anti-IgE/M1′ candidate.

Donors were screened for serum IgE levels from our in house Leukopackblood donor program. Two donors selected to provide cells for the Atopichu-SCID model self identified as having allergies and had serum IgElevels of 1696 and 1152 ng/ml. Normal donors typically have IgE rangingfrom <100 to 300 ng/ml.

The hu-SCID experiments are outlined in FIGS. 12A and 13A. PBMC wereisolated by Leukophoresis and ficoll density gradient (GE Healthcare#17-1440-03) and counted. 108 PBMC cells (10⁸ per 100 μl) were injectedi.p. into irradiated SCID-beige mice on day zero. To skew the responsetowards IgE production, mice were treated with anti-IFNγ (BDBiosciences, San Jose, Calif., #554698) and anti-IL12 antibodies (100μg/dose) (BD Biosciences, San Jose, Calif., #554659) on days 0 and 3;and rhIL-4 (100 ng/dose) (R&D Systems, Minneapolis, Minn., #204-IL-010)on days 2,3,4. Mice were treated with experimental antibodies (i.e.anti-IgE/M1′) three times per week (approximately every three days)starting on day 0 until the end of the study. Human cells were allowedto expand between 7 and 14 days upon which the mice were euthanized.Bleeds were taken on day 7 and at the end of the study. On the final dayof the experiment, mice were euthanized and spleen cells were isolated.Single cell suspensions were used for IgE Elispot assay and FACs todetermine extent of human cell reconstitution and IgE plasma celldepletion.

Data is expressed as the mean±Standard Deviation. P-values werecalculated using JMP statistics software. Dunnett's test compares groupmeans where all test groups are tested against a reference group. EachPair Student's t compares each group pair using Student's t-test. ABonferroni Correction is then applied to adjust the p-values of the EachPair Student's t to safeguard against pairwise comparisons. All p-valuethreshold is 0.05. Percent change in the data reported in FIGS. 12 A-Iand 13 A-H was calculated between treatment group and control group withno normalization to baseline levels.

Free IgE levels were determined using a human ELISA procedure in whichMaxisorp 384-well ELISA plates (Nalge Nunc International, Rochester,N.Y.) were coated with 1 μg/ml monoclonal antibody MAE 11 in 50 mMcarbonate buffer, pH 9.6, at 4° C. overnight and blocked with 0.5%bovine serum albumin, in PBS at room temperature for 1 hour. Standards(0.098-12.5 ng/ml) and threefold serial dilutions of samples (minimumdilution 1:10 to avoid any serum effect) in PBS containing 0.5% bovineserum albumin, 0.05% polysorbate 20, 10 parts per million Proclin 300(Supelco, Bellefonte, Pa.), 0.25% CHAPS (Sigma, St. Louis, Mo.), 0.2%bovine g globulins (Biocell, Rancho Dominguez, Calif.) and 5 mM EDTAwere incubated on the plates at room temperature for 1 hour. Bound IgEwas detected by incubating peroxidase labeled goat anti-human IgEantibody (Kirkegaard & Perry Laboratories, Gaithersburg, Md.) in thewells for 1 hour. The substrate 3,3′,5,5′-tetramethyl benzidine(Kirkegaard & Perry Laboratories, Gaithersburg, Md.) was added and thereaction was stopped by adding 1 M phosphoric acid. Plates were washedbetween steps. Absorbance was read at 450 nm on a Titertek stackerreader (ICN, Costa Mesa, Calif.). The standard curve was fitted using afour-parameter nonlinear regression curve-fitting program (developed atGenentech). Data points which fell in the linear range of the standardcurve were used for calculating the IgE concentration in samples.

The human immunoglobulin isotype panel was performed by taking mousemonoclonal antibody (mAb) to human IgG1 (clone 2C11, Abcam Inc.,Cambridge, Mass.) was diluted to 4 ug/ml in 0.05M sodium carbonatebuffer, pH 9.6, and coated on ELISA plates (384-well, high-bind plates,Greiner Bio One, Monroe, N.C.) during an overnight incubation at 4° C.After washing 3 times with wash buffer (PBS/0.05% Tween-20), the plateswere blocked with PBS/0.5% bovine serum albumin (BSA) for 1 to 2 hours.This and all other incubations were performed at room temperature on anorbital shaker. Mouse serum samples were diluted 1:100 followed byserial 1:3 dilutions using assay buffer (PBS/0.5% BSA/0.05% Tween20/0.25% CHAPS/5 mM EDTA/15PPM Proclin). Using the same buffer, serialdilutions of IgG1 were prepared for the standard curve (12.20-1560ng/ml). Pre-diluted frozen controls at the high, mid, and low regions ofthe standard curve were thawed. After the blocking step, the plates werewashed and the samples, standards, and controls were added to the 384well plates and incubated for 2 hours. The plates were washed andbiotinylated mouse mAb to human IgG1 (Zymed Laboratories, South SanFrancisco, Calif.) was diluted 1:500 in assay buffer and added to thewashed plates for 1 hr incubation. Streptavidin-horse radish peroxidase(SA-HRP) (GE Healthcare, Piscataway, N.J.) was diluted 1:40,000 in assaybuffer and added to the plates after washing. Following a 30 minincubation and a final wash step, tetramethyl benzidine (TMB)(Kirkegaard & Perry Laboratories, Gaithersburg, Md.) was added and colorwas developed for 10 to 15 minutes. The reaction was stopped by adding1M phosphoric acid. The optical density was obtained using a microplatereader (450 nm, 650 nm reference wavelengths), and the sampleconcentrations were calculated from 4-parameter fits of the standardcurves. The minimum quantifiable concentration of human IgG1 in themouse serum samples was 1.22 ug/ml.

This overall ELISA method described above was also used for the analysisof the other Ig isotypes.

IgG2

Mouse anti-human IgG2 mAb (Y2 chain specific) (Southern Biotech,Birmingham, Ala.) was coated on ELISA plates at 4 ug/ml. The human IgG2standard curve range was 12.20-1560 ng/ml. Biotinylated mouse anti-humanIgG2 mAb (Y 2 chain specific) (Southern Biotech) was diluted to 0.5μg/ml and used as the detection antibody. SA-HRP was added to the 384well plates at a 1:10,000 dilution. The minimum quantifiableconcentration of human IgG2 in the mouse serum samples was 1.22 μg/ml.

IgG3

Mouse anti-human IgG3 mAb (Zymed Laboratories) was diluted to 1 μg/mland coated onto ELISA plates. The human IgG3 standard curve range was0.78-100 ng/ml. Biotinylated mouse anti-human IgG3 mAb (γ₃ chainspecific) (Southern Biotech) was diluted to 0.1 μg/ml and used as thedetection antibody. SA-HRP was added to the 384 well plates at a1:20,000 dilution. The minimum quantifiable concentration of human IgG3in the mouse serum samples was 78.1 ng/ml.

IgG4

Purified mouse anti-human IgG4 mAb (BD Pharmingen, San Jose, Calif.) wasdiluted to 0.25 ug/ml and coated onto ELISA plates. The human IgG4standard curve range was 0.20-25 ng/ml. Biotin-conjugated mouseanti-human IgG4 mAb (BD Pharmingen) was diluted to 0.25 μg/ml and usedas the detection antibody. SA-HRP was added to the 384 well plates at a1:20,000 dilution. The minimum quantifiable concentration of human IgG4in the mouse serum samples was 39.1 ng/ml.

IgA

Purified mouse anti-human IgA₁/A₂ mAb (BD Pharmingen) was diluted to 2μg/ml and coated onto ELISA plates. The human IgA standard curve rangewas 0.20-25 ng/ml. Biotin-conjugated mouse anti-human IgA₁/A₂ mAb (BDPharmingen) was diluted to 1 μg/ml and used as the detection antibody.SA-HRP was added to the 384 well plates at a 1:80,000 dilution. Theminimum quantifiable concentration of human IgA in the mouse serumsamples was 39.1 ng/ml.

IgM

Purified mouse anti-human IgM mAb (BD Pharmingen) was diluted to 0.5ug/ml and coated onto ELISA plates. The human IgM standard curve rangewas 0.78-100 ng/ml. Biotin-conjugated mouse anti-human IgM mAb (BDPharmingen) was diluted to 0.5 μg/ml and used as the detection antibody.SA-HRP was added to the 384 well plates at a 1:40,000 dilution. Theminimum quantifiable concentration of human IgM in the mouse serumsamples was 156 ng/ml.

Hu-SCID splenocytes, mouse splenocytes or lymph node cells were countedusing Fluoresbrite YG microspheres (Polysciences, Inc. #18862) on a FACsCalibur Flow Cytometer (BD (San Jose, Calif.)).

Elispot assays were used to determine the frequency of IgE producingplasma cells in hu-SCID mice following treatment with rhuIL-4,anti-IFNγ, and anti-IL-12 antibodies for 15 days. Elispot plates(Millipore, Billerica, Mass., #MSIPS4510, clear) were coated with a1:500 dilution of primary unconjugated anti-human IgE antibody (AXXORA,San Diego, Calif., #BET-A80-108A) in coating buffer [Genentech, Inc.(A3323)] at 100 μl/well overnight at 4° C. The primary antibody solutionwas then decanted and plates were washed twice with wash buffer (1×PBS,0.05% Tween-20). Membranes were blocked with 200μl/well of 0.5% BSA in1×PBS for 0.5-1 hour at 37° C. Blocking solution was removed andpositive control cells or hu-SCID splenocytes were added to the plate.The human Myeloma IgE producing U266 cell line (ATCC, Manassas, Va.,#TIB196) was used as a positive control for the assay. U266 cells wereadded to the plate starting at a concentration 3000 cells/0.1 ml(=0.032×10⁶/ml) of hybridoma medium [RPMI 1640, 15% Fetal bovine serum,2 mM L-glutamine, 10 mM HEPES, 4.5 g/L glucose, 1.5 g/L bicarbonate]then seven serial dilutions (1:2) from performed. Whole spleen singlecell suspensions were resuspended in 1 ml media. 100 μl was added to thefirst well. Seven 1:2 serial dilutions were then performed. U266hybridoma and spleen cells were incubated overnight at 37° C. Thefollowing day plates were washed three times with wash buffer (1XPBS,0.05% Tween-20) and then 100 μl/well of the secondary antibody,anti-human IgE-Alkaline Phosphatase conjugated (Sigma, St. Louis, Mo.,A-3525), was added at 1:2000 in 0.5% BSA/1×PBS to each well andincubated at 37° C. for 2 hours. Plates were washed three times and thenrinsed once with ddH₂0 (Genentech, Inc.). 100 μl/well of BCIP/NBTsolution (R&D Systems, Minneapolis, Minn., Elispot Blue Color Module,#SEL002) was added to each well and incubated in the dark for 30minutes. The plates were then rinsed with ddH20 once and the plate wasallowed to dry at room temperature. Plates were sent to BD Biosciencesfor counting (BD, Inc., Franklin Lakes, N.J.). The number of plasmacells was calculated using the number of spots detected, fold dilution(cell input), and the total spleen cell count.

Human plasma cells were prepared by removing spleens on day 15 fromantibody treated hu-SCID mice. Single cell suspensions were prepared andfiltered. 5×10⁶ cells were blocked with human (Sigma, St. Louis, Mo.,#S-2257) and mouse sera (VWR, #RLD108-0100), and then stained withanti-human CD38 PE (BD Biosciences, San Jose, Calif., #555460) andanti-human PC FITC (Dakocytomation, Glostrup, Denmark, #K2311)antibodies in FACs wash buffer (2% FBS, 1×PBS) on ice for 20 minutes.Cells were then washed and analyzed on a FACs Calibur machine (BD, Inc.,Franklin Lakes, N.J.). Human CD38 expression was used as a positivecontrol for successful human PBMC transfer. Plasma cells were defined asCD38 high, PC+.

In experiment #07-0377 (FIG. 12A), three anti-IgE/M1′ antibodies (47H4,26A11, and 7A6) were tested against isotype control anti-gp120-muIgG1.Isotype control treated mice generated high levels of human IgE by day9. Treatment with anti-IgE/M1′ candidates reduced IgE levels by 65-84%(FIG. 12 B-C). Anti-IgE/M1′ treatment also reduced IgE producing cellsin vivo by 19-69% (FIG. 12 D-E). Other serum Igs were relativelyunaffected by anti-IgE/M1′ treatment (reductions of ˜30% were observedwith some anti-M1′ antibodies for huIg1, IgG3 and IgG4 (FIG. 12 F-G). Noreduction in the percentage of total plasma cells of the spleen wasobserved with anti-IgE/M1′ treatment (FIG. 12 H-I).

In experiment #07-1232 (FIG. 13A), a humanized anti-IgE/M1′ (47H4v5) wastested against isotype control antibody HERCEPTIN®-huIgG1. Isotypecontrol treated mice generated high levels of serum IgE by day 8.Treatment with anti-IgE/M1′ huIgG1 reduced IgE levels by 79% (FIG. 13B-D) and IgE producing plasma cells by 75% (FIG. 13 C-D). No reductionin other serum Igs (IgG1, IgG2, IgG3, IgG4, IgM, IgA) (FIG. 13 E-F) orthe percentage of total plasma cells in the spleen was observed (FIG. 13G-H). These studies demonstrate that anti-IgE/M1′ antibodiesspecifically reduce serum IgE and IgE-producing cells, but notimmunoglobulins of other isotypes.

Example 10 Human M1′ Transgenic Mice

Generation of huM1′ Transgenic “Knockin” Mice

Since mice do not normally express an M1′ domain similar to humans, wegenerated mice with the human M1′ domain “knocked into” the mouse IgElocus (FIG. 14A). The human M1′ sequence uses the mouse M1′ spliceacceptor site upstream and is then fused to the mouse M1 sequencedownstream (FIG. 14B). An IRES-EGFPpA—Neo cassette was also knocked in3′ of the mouse M2 sequence. This knockin will allow for expression ofmouse IgE with the human M1′ domain on the surface of IgE+ B cells. TheM1′ sequence will not be expressed on secreted IgE.

Screening of M1′ Knockin Lines (PCR)

Human M1′ knockin mice were genotyped by PCR using primers specific forthe mouse IgE locus and human M1′ sequence. Primers used were asfollows:

WT FOR 5′-GGCCAAAGACCCTAAGACAGTC (SEQ ID NO:106) huMi′ FOR5′-GGGCTGGCTGGCGGCTCCGC (SEQ ID NO:107) WT REV 5′-CTATGCCCTGGTCTGGAAGATG(SEQ ID NO:108)Purified genomic DNA was analyzed with the above primers using 32 cyclesof the following program [94° C. 4 min; 94° C. 1 min; 60° C. 30 sec; 72°C. 1 min (30 cycles); 72° C. 10 min]. PCR products were then run out ona 2% agarose 0.5×TBE gel. Wildtype PCR genotype gave a 668 bp productand the hu-M1′ knockin generated a 457 bp product (FIG. 14C).

Screening of M1′ Knockin Lines (Southern)

huM1′ knockin ES cells and final mouse lines were screened and verifiedby Southern blot. 10 μg of purified ES cell or Tail genomic DNA wasdigested with HindIII for the left arm or BamHI for the right armovernight. Digested DNA was then run out on a 0.8% Agarose 1×TAE gel.DNA was then transferred to a nylon membrane (Roche #1417240) usingdenaturation buffer (1.5M NaCl; 0.5M NaOH) overnight. The membrane wasrinsed, UV crosslinked, and then soaked in DIG Easy Hyb solution (Roche#1585762) for 4 hours with rotation at 46° C. Probes were generated byPCR using the PCR DIG probe Synthesis Kit as directed by themanufacturer (Roche #11636090910).

Primers for the Left Arm Were:

FOR 5′-TGTCTGGTGGTGGACCTGGAAAGCG (SEQ ID NO:109) Rev5′-TCCTCGCTCTCCTCCTCTGGTGGTG (SEQ ID NO:110)

Primers for the Right Arm Were:

FOR 5′-CCATGCAACCTAGTATCCTATTCTC (SEQ ID NO:111) Rev5′-CTTTATACAGGAGAACCTAGCCCAG (SEQ ID NO:112)

Probes were tested against unlabeled PCR product to ensure increasedsize and good DIG-labeling. Blots were then probes overnight with boiledprobe overnight at 46° C. with rotation. The following day blots werethen washed and developed with anti-DIG antibody according tomanufactures directions. Blots were exposed to film for 15-20 minutes.FIG. 14D illustrates with southern results. Wildtype mice generate aleft arm 7.4 kB HindIII fragment which becomes a 3 kB fragment in thehu-M1′ knockin allele. Wildtype mice generate a right arm 14.1 kB BamHIfragment which becomes a 18.1 kB fragment in the hu-M1′ knockin allele.Wildtype and heterozygous mice are shown (FIG. 14D).

Example 11 Hu-M1′ Transgenic Model: TNP-OVA Immunization

This Example illustrates the ability of anti-IgE/M1′ candidates toprevent the generation of IgE resulting stimulated by TNP-OVA in both animmune primary response (Exp. #07-0234F; FIGS. 15A-I) or memory response(Exp. #07-0234B; FIGS. 16A-K) immune response to TNP-OVA. TNP-OVA ortrinitrophenyl-ovalbumin is a high potent immunogen often used togenerate potent antibody immune responses.

Data is expressed as the mean±Standard Deviation. P-values werecalculated using JMP statistics software. Dunnett's test compares groupmeans where all test groups are tested against a reference group. EachPair Student's t compares each group pair using Student's t-test. ABonferroni Correction is then applied to adjust the p-values of the EachPair Student's t to safeguard against pairwise comparisons. All p-valuethreshold is 0.05. Percent change in the data reported for primaryresponse (FIGS. 15 A-I) and the memory immune response (Figures A-K) wascalculated by subtracting the uninfected or unimmunized group mean valuefrom each of the mouse values, group means were recalculated and percentchange was then calculated against the control group for each timepoint.

TNP-OVA immunization of human IgE/M1′ knockin mice (C57BL/6) induces abalanced Th1/Th2 response in vivo. Antigen specific IgE levels followingprimary immunization and challenge reach levels of 10-200 ng/ml. Inexperiment #07-0234F, huM1′ knockin mice (C57B1/6) were immunized withTNP-OVA (Biosearch Technologies, Novato, Calif.) (100 μg in 2 mg alumper mouse i.p.) on day 0 (FIG. 15A). Mice were then treated with 0.1mg/kg antibodies three times per week between days 0 and 28 (FIG. 15A).In experiment #07-0234B, huM1′ knockin mice (C57B1/6) were immunizedwith TNP-OVA/Alum on day 0 (as before) and then challenged with TNP-OVA(100 μg per mouse i.p.) on day 28 (FIG. 16A). Mice were treated with 10mg/kg antibodies between days 28 and 49 (FIG. 16A). Mice were bled overthe course of the immune response to monitor antigen specific serum IgEand IgG1 levels.

TNP-OVA specific IgE IgG1 was measured using ELISA plates (384 well withMaxiSorp™ surface, Nunc, Neptune, N.J.) coated for 12-18 hr at 2-8° C.with 25 μL/well TNP-OVA (TNP:OVA ratio of 13:1) (Biosearch Technologies,Novato, Calif.) diluted to 0.5 μg/mL in 50 mM sodiumcarbonate/bicarbonate, pH 9.6. The plates were then decanted and blotteddry. Block buffer (PBS, 0.5% BSA, pH 7.2, 50 μL/well) was added to theplates for 1-2 hr. This and all subsequent incubations were performed atroom temperature with gentle agitation. Samples were diluted 1/50 inassay diluent (PBS, 0.5% BSA, 0.05% Tween-20, 0.01% Proclin 300)followed by serial 1/3 dilutions over eleven points. The standards wereserially diluted two-fold in assay diluent over seven points, startingat 1 ng/ml for Anti-TNP OVA IgG1 and 3 ng/ml for Anti-TNP OVA IgE.Plates were washed three times with wash buffer (PBS, 0.05% Tween-20, pH7.2) and standards, samples and controls were added (25 μL/well) toduplicate plates for the separate detection of IgG1 and IgE isotypes.After a 1.5-2 hr incubation, plates were washed six times with washbuffer. Biotinylated rat anti-mouse IgG1 and IgE mAb (BD Biosciences,San Diego, Calif.) were diluted to 0.5 μg/mL for IgG1 or 1.0 μg/mL forIgE in assay diluent and added to the appropriate plates (25 μL/well).Plates were incubated for 1-1.5 hr and washed six times with washbuffer. Streptavidin-horseradish peroxidase conjugate (AMDEX, GEHealthcare, Piscataway, N.J.) was diluted 1/80,000 for IgG1 or 1/5,000for IgE and added to the plates (25 μL/well) for 30 min. After washingsix times with wash buffer, plates were developed by adding 25 μL/welltetramethyl benzidine (Kirkegaard & Perry Laboratories, Gaithersburg,Md.) and incubating for 15 min for IgG1 or 25 min for IgE. The reactionwas stopped by the addition of 25 μL/well 1M H₃PO₄, and the absorbancewas read at 450 nm with a 620 nm reference. The results of unknownsamples interpolated from 4-parameter fits of the standard curves.

Mouse plasma cells from the spleen or lymph notes were first identifiedby separating CD138+ cells. These IgE producing plasma cells werequantified by the Elispot method. For total IgE producing cells, ananti-IgE antibody (from BD OptEIA mIgE set #555248) was coated onMultiScreen HTS plates (Millpore #MSIPS4W10) at a dilution of 1:2 usingELISA coating buffer at 50 μl per well. Coating was performed at 4° C.overnight. The following morning plates were washed 5 times with 200 μlsterile PBS-tween 20 (0.05%) using a multichannel pipet in the tissueculture hood. Plates were then blocked in 300 μl PBS/5% BSA or cellculture medium (RPMI-1640, 10% FBS) for two hours at room temperature.Single cell suspensions were prepared from the spleen or lymph node andcells counted by FACS (as outlined above). Cells were prepared forplating, starting with 10⁷ cells followed by 3-4 fold dilutions forTNP-OVA immunization models, or 4×10⁶ cells followed by 2 fold dilutionsfor the Nippostrongylus infection models. The mouse A20 B cell line wasused as a negative control and the TIB-141 cell line was used as apositive control. Cell dilutions were prepared in cell culture medium(RPMI-1640+10% FBS). Following the blocking step plates were washed oncewith cell culture medium and aspirated. Cells were plated in 100 μl perwell. Plates were then incubated overnight at 37° C., 5% CO₂. Thefollowing day plates were washed 6 times using a SkanWasher 300(Molecular Devices (Sunnyvale, Calif.)) with PBS-tween 20 (0.05%). Abiotinylated secondary antibody from the BD OptETA mIgE set (#555248)was then used at the concentration noted by the manufacturer, usuallybetween 1:250-1:500 in 100 μl/well. The secondary antibody was preparedin PBS/1% BSA. Plates were then incubated for 1 hour at room temperatureand then washed 6 times using a SkanWasher300 with PBS-tween 20 (0.05%).Streptavidin AP (R&D #SEL002) was then added at a dilution of 1:60 in100 μl per well, again prepared in PBS/1% BSA, and incubated for 1 hourat room temperature. Plates were then washed as before 3 times and thenrinsed twice with DI water. Any remaining liquid was blotted away on apaper towel. The developing reagent, BCIP/NBT (100 μl/well) was thenadded, and the plates incubated for 30 minutes at room temperature inthe dark. The substrate was then decanted and plates rinsed twice withDI water. Plates were inverted to remove any excess water and allowed todry. Spots were quantified using a dissection microscope.

Experiment #07-0234F tested the ability of anti-IgE/M1′ to prevent anIgE response to TNP-OVA primary immunization. Anti-gp120 isotype controltreated mice generated serum IgE, reaching peak levels between day 8 to14 (˜25 ng/ml) (FIG. 15B). Anti-IgE/M1′ treatment prevented the increasein serum IgE by day 8 (98%) and 14 (99%) (FIG. 15 C-D). This reductionwas significantly different from isotype treated animals, and notsignificantly different from unimmunized mice (FIGS. 15 C-E). The levelsof antigen specific IgG1 were only modestly affected by anti-IgE/M1′through the 28 days of the experiment (FIGS. 15 F-I).

Experiment #07-0234B tested the ability of anti-IgE/M1′ to prevent asecondary/memory IgE response to TNP-OVA. The secondary IgE response toTNP-OVA boost on day 28 is more rapid, peaking after 4 days rather than8-9 days in the primary response (FIG. 16B). Treatment with anti-IgE/M1′candidates starting with the boost on day 28 diminished the increase inIgE between days 28 and 35 (FIG. 16B). Anti-IgE/M1′ treated IgE levelswere significantly reduced compared to isotype control, 59-75% by day 32and 90-93% by day 35 (FIGS. 16C-D). By day 35-42 IgE levels were notsignificantly different from unimmunized mice (FIG. 16E). Area under thecurve analysis of these treatment groups between days 28 and 49 furtherdemonstrates that anti-IgE/M1′ reduced serum IgE levels by 74-84%, andthe average daily level of antigen specific IgE was also reduced by74-83% (FIGS. 16 F-H). No significant reduction in antigen specific IgG1was observed following treatment with anti-IgE/M1′ (FIGS. 16 I-K).

Example 12 Hu-M1′ Transgenic Model: Nippostrongylus brasiliensisInfection Model

This Example illustrates the ability of anti-IgE/M1′ antibodies toprevent the production of IgE (FIGS. 17A-D), as well as therapeuticallyreduce the production of IgE in a previously induced Nippostrongylusbrasiliensis infection. The reduction in IgE production was evaluated byadministration of anti-IgE/M1′ antibodies both at peak IgE levels of theimmune response (FIGS. 18 A-I), and when applied late in the immuneresponse (FIGS. 19 A-G).

Nippostrongylus brasiliensis is a gastrointestinal nematode that infectsrats and mice. Its eggs hatch in feces and mature into the infectivestage larvae L3. L3 larvae enter host through skin and migrate to theblood vessels, and then travel to the lung after one to two days. Afterdeveloping into L4 stage larvae in the lung, they travel along thehost's tracheus and esophagus and reach the jejunum at day 2 to 3. Thelarvae mature into adult worms and mate, and produce eggs around day 5.N. brasiliensis eggs are excreted out of the hosts along with feces.

Mice infected with N. brasiliensis demonstrate an initial innate immuneresponse, followed by strong type 2 immunity to clear the infection.Complement and fibronectin deposition are found in the earlier stage ofthe infection to facilitate leukocyte recruitment and adherence.Effector cells, such as eosinophils, basophils, and CD4+ Th2 cells, arerecruited to the lung to fight against the infection. Th2 cytokines,IL-4 and IL-13, play essential role in sustaining the immune response inthe lung, and are required for worm clearance in the intestine. Type 2responses are characterized by high levels of antibody production,including IgE.

Human IgE/M1′ knockin mice (C57BL/6) generate a strong IgE response toN. brasiliensis infection peaking at day 15-20 (FIGS. 17B, 18B, 19B).Serum IgE levels then drop to a lower, but elevated sustained level.Mice were infected with Nippostrongylus brasiliensis on day 0. All threeN. brasiliensis infection experiments were treated with 10 mg/kganti-IgE/M1′ mIgG1 antibodies or anti-gp120 mIgG1 isotype control. Inthe preventative study (FIG. 17A), huM1′ knockin mice were treated threetimes per week starting on day 0 through day 21. In the peak productionstudy (FIG. 18A), huM1′ knockin mice were treated three times per weekbetween days 11 and 21. In the late intervention study (FIG. 19A), huM1′knockin mice were treated three times per week between days 41 and 62.

Data is expressed as the mean±Standard Deviation. P-values werecalculated using JMP statistics software. Dunnett's test compares groupmeans where all test groups are tested against a reference group. EachPair Student's t compares each group pair using Student's t-test. ABonferroni Correction is then applied to adjust the p-values of the EachPair Student's t to safeguard against pairwise comparisons. All p-valuethreshold is 0.05. Percent change in the data reported in thepreventative and peak production studies was calculated by subtractingthe uninfected or unimmunized group mean value from each of the mousevalues, group means were recalculated and percent change was thencalculated against the control group for each timepoint. In the lateintervention study, the percent change was calculated within eachtreatment group by comparing days 48 and 55 to day 41.

The IgE-producing plasma cells were defined and evaluated by Elispot asdescribed previously in Example 12.

The preventative study tested the ability of anti-IgE/M1′ to prevent theincrease in IgE in response to a primary Nippostrongylus infection.Control (isotype treated) mice reached high levels of IgE production byday 15 following infection (˜3000 ng/ml). Anti-IgE/M1′ treated mice hadreduced IgE production following infection (reduced 93-94% compared toanti-gp120 mIgG1) that was not significantly different from uninfectedmice (FIGS. 17 B-D).

The peak production study tested the ability of anti-IgE/M1′ to reduceIgE levels therapeutically at the peak of the IgE response to N.brasiliensis infection. All treatment groups reached high IgE levels(˜2000 ng/ml) by day 11 following Nippostrongylus infection (FIG. 18B).Anti-IgE/M1′ treatment started on day 11 at the peak of this response.Anti-IgE/M1′ mIgG1 candidates reduced serum IgE levels by 82-89% withinfour days of treatment (FIG. 18 C-D). By day 21 the IgE levels inanti-IgE/M1′ treated mice were reduced by 97-98%, reaching levels thatare not statistically different from the uninfected control group (FIG.18E). IgE producing plasma cells were quantified by anti-IgE Elispot. N.brasiliensis infection induced significant numbers of IgE producingcells in both the mesenteric lymph node (<30 cells per 4×10⁶; FIG. 18F)and spleen (˜10 cells per 4×10⁶; FIG. 18G). By day 21 anti-IgE/M1′treatment reduced IgE producing cells in the mesenteric lymphnode by88-94% and in the spleen by 57-66%. The frequency of total plasma cells(CD138+ cells) in the mesenteric lymph node and spleen was increased inall treatment groups compared with uninfected mice, and there was nosignificant change in total plasma cell frequency in either organ due totreatment with anti-IgE/M1′ (FIG. 18 H-I). These results demonstrate theability of anti-IgE/M1′ antibodies to reduce serum IgE to nominal levelsby depleting IgE producing cells in vivo, even when applied at the peaklevel of IgE production.

The late intervention study tested the ability of anti-IgE/M1′ to reducethe low level sustained IgE that is achieved late in the infectioncycle. All treatment groups reached the peak of IgE production aroundday 15. Upon initiation of anti-IgE/M1′ treatment on day 41, there weresome differences in serum IgE levels amongst treatment groups (FIGS. 19B-C), that was normalized by referencing the day 41 levels as 100% (FIG.19D). Anti-IgE/M1′ treatment significantly reduced serum IgE levelscompared to the anti-gp120 mIgG1 isotype control between days 48 and 55(FIG. 19 E-G). By day 48 and 55 IgE levels were reduced 64-75% and75-84%, respectively, compared with isotype control (anti-gp120 mIgG1)which decreased 20% and 37%, respectively (FIGS. 19 F-G). The differencein mean IgE levels between treatment groups was not significantlydifferent from the isotype control group (gp120) prior to commencementof anti-IgE/M1′ therapy (FIG. 19E). However, treatment with anti-IgE/M1′antibodies showed a more dramatic and significant decrease in serum IgElevels than that observed in the control group by day 48 (FIG. 19F) andDay 55 (FIG. 19G). Percent change and p-value (d41) were calculated bycomparing each treatment group days 48 or 55 to the same group startingvalue in day 41 prior to treatment.

Example 13 Expression of Anti-IgE/M1′ Antibody in Mammalian Cells

This example illustrates preparation of potentially glycosylated formsof the desired protein or antibody by recombinant expression inmammalian cells.

The vector, pRK5 (see EP 307,247, published Mar. 15, 1989), is employedas the expression vector. Optionally, DNA encoding the light and/orheavy chain of the anti-IgE/M1′ antibody is ligated into pRK5 withselected restriction enzymes to allow insertion such DNA using ligationmethods such as described in Sambrook et al., supra.

In one embodiment, the selected host cells may be 293 cells. Human 293cells (ATCC CCL 1573) are grown to confluence in tissue culture platesin medium such as DMEM supplemented with fetal calf serum andoptionally, nutrient components and/or antibiotics. About 10 μg if DNAencoding the anti-IgE/M1′ antibody ligated into pRK5 is mixed with about1 μg DNA encoding the VA RNA gene [Thimmappaya et al., Cell, 31:543(1982)] and dissolved in 500 μl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 MCaCl₂. To this mixture is added, dropwise, 500 μl of 50 mM HEPES (pH7.35), 280 mM NaCl, 1.5 mM NaPO₄, and a precipitate is allowed to formfor 10 minutes at 25° C. The precipitate is suspended and added to the293 cells and allowed to settle for about four hours at 37° C. Theculture medium is aspirated off and 2 ml of 20% glycerol in PBS is addedfor 30 seconds. The 293 cells are then washed with serum free medium,fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium isremoved and replaced with culture medium (alone) or culture mediumcontaining 200 Ci/ml ³⁵S-cysteine and 200 μCi/ml ³⁵S-methionine. After a12 hour incubation, the conditioned medium is collected, concentrated ona spin filter, and loaded onto a 15% SDS gel. The processed gel may bedried and exposed to film for a selected period of time to reveal thepresence of the anti-IgE/M1′ antibody. The cultures containingtransfected cells may undergo further incubation (in serum free medium)and the medium is tested in selected bioassays.

In an alternative technique, the anti-IgE/M1′ antibody may be introducedinto 293 cells transiently using the dextran sulfate method described bySomparyrac et al., Proc. Natl. Acad. Sci., 12:7575 (1981). 293 cells aregrown to maximal density in a spinner flask and 700 μg DNA encoding theanti-IgE/M1′ antibody ligated into pRK5 is added. The cells are firstconcentrated from the spinner flask by centrifugation and washed withPBS. The DNA-dextran precipitate is incubated on the cell pellet forfour hours. The cells are treated with 20% glycerol for 90 seconds,washed with tissue culture medium, and re-introduced into the spinnerflask containing tissue culture medium, 5 μg/ml bovine insulin and 0.1μg/ml bovine transferrin. After about four days, the conditioned mediais centrifuged and filtered to remove cells and debris. The samplecontaining the expressed anti-IgE/M1′ antibody can then be concentratedand purified by any selected method, such as dialysis and/or columnchromatography.

In another embodiment, the anti-IgE/M1′ antibody can be expressed in CHOcells. The DNA encoding the anti-IgE/M1′ antibody ligated into pRK5 canbe transfected into CHO cells using known reagents such as CaPO₄ orDEAE-dextran. As described above, the cell cultures can be incubated,and the medium replaced with culture medium (alone) or medium containinga radiolabel such as ³⁵S-methionine. After determining the presence ofthe anti-IgE/M1′ antibody, the culture medium may be replaced with serumfree medium. Preferably, the cultures are incubated for about 6 days,and then the conditioned medium is harvested. The medium containing theexpressed anti-IgE/M1′ antibody can then be concentrated and purified byany selected method.

Epitope-tagged variants of the anti-IgE/M1′ antibody may also beexpressed in host CHO cells. The DNA encoding the anti-IgE/M1′ antibodyligated into pRK5 may be subcloned out of the pRK5 vector. The subcloneinsert can undergo PCR to fuse in frame with a selected epitope tag suchas a poly-his tag into a Baculovirus expression vector. The poly-histagged DNA encoding the anti-IgE/M1′ antibody insert can then besubcloned into a SV40 driven vector containing a selection marker suchas DHFR for selection of stable clones. Finally, the CHO cells can betransfected (as described above) with the SV40 driven vector. Labelingmay be performed, as described above, to verify expression. The culturemedium containing the expressed poly-His tagged anti-IgE/M1′ antibodycan then be concentrated and purified by any selected method, such as byNi²⁺-chelate affinity chromatography.

The anti-IgE/M1′ antibody may also be expressed in CHO and/or COS cellsby a transient expression procedure or in CHO cells by another stableexpression procedure.

Stable expression in CHO cells is performed using the followingprocedure. The proteins are expressed as an IgG construct(immunoadhesin), in which the coding sequences for the soluble forms(e.g. extracellular domains) of the respective proteins are fused to anIgG1 constant region sequence containing the hinge, CH2 and CH2 domainsand/or is a poly-His tagged form.

Following PCR amplification, the respective DNAs are subcloned in a CHOexpression vector using standard techniques as described in Ausubel etal., Current Protocols of Molecular Biology, Unit 3.16, John Wiley andSons (1997). CHO expression vectors are constructed to have compatiblerestriction sites 5′ and 3′ of the DNA of interest to allow theconvenient shuttling of cDNA's. The vector used expression in CHO cellsis as described in Lucas et al., Nucl. Acids Res. 24:9 (1774-1779(1996), and uses the SV40 early promoter/enhancer to drive expression ofthe cDNA of interest and dihydrofolate reductase (DHFR). DHFR expressionpermits selection for stable maintenance of the plasmid followingtransfection.

Twelve micrograms of the desired plasmid DNA is introduced intoapproximately 10 million CHO cells using commercially availabletransfection reagents SUPERFECT® (Quiagen), DOSPER® or FUGENE®(Boehringer Mannheim). The cells are grown as described in Lucas et al.,supra. Approximately 3×10⁻⁷ cells are frozen in an ampule for furthergrowth and production as described below.

The ampules containing the plasmid DNA are thawed by placement intowater bath and mixed by vortexing. The contents are pipetted into acentrifuge tube containing 10 mLs of media and centrifuged at 1000 rpmfor 5 minutes. The supernatant is aspirated and the cells areresuspended in 10 mL of selective media (0.2 μm filtered PS20 with 5%0.2 μm diafiltered fetal bovine serum). The cells are then aliquotedinto a 100 mL spinner containing 90 mL of selective media. After 1-2days, the cells are transferred into a 250 mL spinner filled with 150 mLselective growth medium and incubated at 37° C. After another 2-3 days,250 mL, 500 mL and 2000 mL spinners are seeded with 3×10⁵ cells/mL. Thecell media is exchanged with fresh media by centrifugation andresuspension in production medium. Although any suitable CHO media maybe employed, a production medium described in U.S. Pat. No. 5,122,469,issued Jun. 16, 1992 may actually be used. A 3 L production spinner isseeded at 1.2×10⁶ cells/mL. On day 0, the cell number and pH isdetermined. On day 1, the spinner is sampled and sparging with filteredair is commenced. On day 2, the spinner is sampled, the temperatureshifted to 33° C., and 30 mL of 500 g/L glucose and 0.6 mL of 10%antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365Medical Grade Emulsion) taken. Throughout the production, the pH isadjusted as necessary to keep it at around 7.2. After 10 days, or untilthe viability dropped below 70%, the cell culture is harvested bycentrifugation and filtering through a 0.22 μm filter. The filtrate waseither stored at 4° C. or immediately loaded onto columns forpurification.

For the poly-His tagged constructs, the proteins are purified using aNi-NTA column (Qiagen). Before purification, imidazole is added to theconditioned media to a concentration of 5 mM. The conditioned media ispumped onto a 6 ml Ni-NTA column equilibrated at 4° C., in 20 mM Hepes,pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rateof 4-5 ml/min. After loading, the column is washed with additionalequilibration buffer and the protein eluted with equilibration buffercontaining 0.25 M imidazole. The highly purified protein is subsequentlydesalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column andstored at −80° C.

Immunoadhesin (Fc-containing) constructs are purified from theconditioned media as follows. The conditioned medium is pumped onto a 5ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Naphosphate buffer, pH 6.8. After loading, the column is washedextensively with equilibration buffer before elution with 100 mM citricacid, pH 3.5. The eluted protein is immediately neutralized bycollecting 1 ml fractions into tubes containing 275 μL of 1 M Trisbuffer, pH 9. The highly purified protein is subsequently desalted intostorage buffer as described above for the poly-His tagged proteins. Thehomogeneity is assessed by SDS polyacrylamide gels and by N-terminalamino acid sequencing by Edman degradation.

Deposit of Material

The following materials have been deposited with the American TypeCulture Collection, University Blvd., Manassas, Va. 20110-2209, USA(ATCC):

Material ATCC Dep. No. Deposit Date 7A6.18 PTA-8268 Mar. 21, 20071C11.10.20 PTA-8267 Mar. 21, 2007 47G4.6.2 PTA-8266 Mar. 21, 200747H4.12.10 PTA-8270 Mar. 21, 2007 42H4.6.9 PTA-8260 Mar. 21, 200742A5.20.11 PTA-8265 Mar. 21, 2007 26A11.6.5 PTA-8262 Mar. 21, 200751D2.22.15 PTA-8264 Mar. 21, 2007 45C1.6.14 PTA-8269 Mar. 21, 200726B11.3.12 PTA-8261 Mar. 21, 2007 28E9.12.9 PTA-8263 Mar. 21, 2007

These deposits were made under the provisions of the Budapest Treaty onthe International Recognition of the Deposit of Microorganisms for thePurpose of Patent Procedure and the Regulations thereunder (BudapestTreaty). This assures maintenance of a viable culture of the depositsfor thirty (30) years from the date of deposits, and at least five (5)years after the most recent request for a sample. The deposits will bemade available by ATCC under the terms of the Budapest Treaty, andsubject to an agreement between Genentech, Inc. and ATCC, which assurespermanent and unrestricted availability of the progeny of the culture ofthe deposit to the public upon issuance of the pertinent U.S. patent orupon laying open to the public of any U.S. or foreign patentapplication, whichever comes first, and assures availability of theprogeny to one determined by the U.S. Commissioner of Patents andTrademarks to be entitled thereto according to 35 USC § 122 and theCommissioner's rules pursuant thereto (including 37 CFR § 1.14 withparticular reference to 8860G 638).

The assignee of the present application has agreed that if a culture ofthe materials on deposit should die or be lost or destroyed whencultivated under suitable conditions, the materials will be promptlyreplaced on notification with another of the same. Availability of thedeposited material is not to be construed as a license to practice theinvention in contravention of the rights granted under the authority ofany government in accordance with its patent laws. The foregoing writtendescription is considered to be sufficient to enable one skilled in theart to practice the invention. The present invention is not to belimited in scope by the example presented herein. Indeed, variousmodifications of the invention in addition to those shown and describedherein will become apparent to those skilled in the art from theforegoing description and fall within the scope of the appended claims.

1. An anti-IgE/M1′ antibody that specifically binds the M1′ segment ofIgE and which induces apoptosis in IgE-expressing B-cells.
 2. Theantibody of claim 1, wherein the antibody binds IgE that is of human,rhesus monkey and cynomolgus monkey in origin.
 3. An anti-IgE/M1′antibody that specifically binds the M1′ segment of IgE and specificallydepletes IgE-producing B-cells when a therapeutically effective amountis administered in vivo to a mammal.
 4. The antibody of claim 3 thatreduces total serum IgE.
 5. The antibody of claim 4 that reduces freeserum IgE.
 6. The antibody of claim 4, wherein the IgE isallergen-specific.
 7. The antibody of claim 3 that is chimeric.
 8. Theantibody of claim 3 that is humanized.
 9. The antibody of claim 3 thatis human.
 10. An anti-IgE/M1′ antibody that specifically binds to thesame epitope as one bound by an antibody selected from the groupconsisting of: 47H4, 7A6, 26A11, 47H4v5, 7A6v1 and 26A11v6.
 11. Theantibody of claim 10 wherein the epitope corresponds to a peptideselected from the group consisting of: peptide 4 (SEQ ID NO:8), peptide5 (SEQ ID NO:9), peptide 7 (SEQ ID NO:11) or peptide 8 (SEQ ID NO:12).12. The antibody of claim 11, wherein the epitope corresponds to peptide4 (SEQ ID NO:8).
 13. A peptide selected from the group consisting of:peptide 4 (SEQ ID NO:8), peptide 5 (SEQ ID NO:9), peptide 7 (SEQ IDNO:11) or peptide 8 (SEQ ID NO:12).
 14. An anti-IgE/M1′ antibody thatspecifically binds to an M1′ segment of IgE with a Scatchard bindingaffinity that is equivalent to that of the murine anti-IgE/M1′ antibody47H4.
 15. The antibody of claim 14, wherein the affinity is between 0.30and 0.83 nm.
 16. An anti-IgE/M1′ antibody that specifically binds to anM1′ segment of IgE with a Scatchard binding affinity that is equivalentto that of humanized anti-IgE/M1′ antibody 47H4v5.
 17. The antibody ofclaim 16, wherein the affinity is about 1.5 nm.
 18. An anti-IgE/M1′antibody comprising the heavy chain and light chain HVRs of an antibodyor antigen-binding fragment thereof selected from the group consistingof: 26A11, 26A11 v.1-16, 7A6, 7A6v1, 47H4, 47H4v1-6.
 19. The antibody ofclaim 18 comprising variable regions of the heavy and light chains ofthe antibody or antigen-binding fragment thereof selected from the groupconsisting of: 26A11, 26A11 v.1-16, 7A6, 7A6v1, 47H4, 47H4v1-6.
 20. Theantibody of claim 18, comprising the heavy and light chain HVRs or anantibody or antigen-binding fragment thereof of 47H4v1-6.
 21. Theantibody of claim 18 that is afucosylated.
 22. A composition comprisingthe antibody of any of claims 1-21 in combination with at least onepharmaceutically acceptable carrier.
 23. A composition comprising theantibody of any of claims 1-21 in combination with at least onepharmaceutically acceptable carrier and one or more drugs selected fromthe group consisting of: anti-IgE antibody, antihistamine,bronchodilator, glucocorticoid, NSAID, TNF-antagonist, integrinantagonist, immunosuppressive agent, IL-4 antagonist, IL-13 antagonist,dual IL-4/IL-13 antagonist, DMARD, antibody that binds to a B-cellsurface marker and BAFF antagonist.
 24. An isolated nucleic that encodesan antibody or antigen-binding fragment thereof comprising the heavy andlight chain HVRs of an apoptotic anti-IgE/M1′ antibody orantigen-binding fragment thereof selected from the group consisting of:26A11, 26A11v1-16, 7A6, 7A6v1, 47H4, 47H4v1-6.
 25. The nucleic acid ofclaim 24, further comprising nucleic acid encoding the variable regionsof the heavy and light chains of the antibody sequence selected from thegroup consisting of: 26A11, 26A11v1-16, 7A6, 7A6v1, 47H4, 47H4v1-6. 26.The nucleic acid of claim 25, wherein the encoded antibody isafucosylated.
 27. A vector in which the nucleic acid of claim 25 isoperably linked.
 28. A host cell comprising the vector of claim
 27. 29.The host cell of claim 28 that is mammalian.
 30. The host cell of claim29 that is Chinese Hamster Ovary.
 31. A process for producing anapoptotic anti-IgE/M1′ antibody or functional fragment comprisingculturing the host cell of claim 28 under conditions suitable forexpression of the antibody or fragment, and recovering the antibody orfragment.
 32. An article of manufacture enclosing the composition ofclaim 22 and a package insert indicating use for the treatment of anIgE-mediated disorder.
 33. The article of claim 32 that is a vial. 34.The article of claim 32 that is a pre-filled syringe.
 35. The article ofclaim 34, further comprising an injection device.
 36. The article ofclaim 35 that is an auto-injector.
 37. A method for specificallydepleting IgE-producing B-cells, comprising administering to a mammal atherapeutically effective amount of an anti-IgE/M1′ antibody thatspecifically binds to the M1′ segment of IgE and induces apoptosis inIgE-expressing B-cells.
 38. The method of claim 37, wherein the antibodycomprises the heavy and light chain HVRs of the antibody selected fromthe group consisting of: 26A11, 26A11v1-16, 7A6, 7A6v1, 47H4, 47H4v1-6.39. The method of claim 38, further comprising the reduction of totalserum IgE.
 40. The method of claim 39, further comprising the reductionof free serum IgE.
 41. The method of claim 39, wherein the IgE isallergen-specific.
 42. The method of claim 38, wherein the antibody hasADCC activity.
 43. A method of treating an IgE-mediated disordercomprising administering a therapeutically effective amount of ananti-IgE/M1′ antibody that specifically binds to the M1′ segment of IgEinduces apoptosis of IgE-expressing B-cells.
 44. The method of claim 43,wherein the antibody specifically depletes IgE-expressing B-cells. 45.The method of claim 43, wherein the antibody reduces total serum IgE.46. The method of claim 45, wherein the antibody reduce free serum IgE.47. The method of claim 45, wherein the IgE is allergen-specific. 48.The method of claim 43, wherein the antibody comprises the heavy andlight chain HVRs or an antibody selected from the group consisting of26A11, 26A11v1-16, 7A6, 7A6v1, 47H4, 47H4v1-6.
 49. The method of claim43 wherein the IgE-mediated disorder is selected from the groupconsisting of: allergic rhinitis, allergic asthma, non-allergic asthma,atopic dermatitis, allergic gastroenteropathy, anaphylaxis, urticaria,food allergies, allergic bronchopulmonary aspergillosis, parasiticdiseases, interstitial cystitis, hyper-IgE syndrome,ataxia-telangiectasia, Wiskott-Aldrich syndrome, athymic lymphoplasia,IgE myeloma, graft-versus-host reaction and allergic purpura.
 50. Amethod of treating an IgE-mediated disorder comprising a therapeuticallyeffective amount of an anti-IgE/M1′ antibody that specifically binds tothe M1′ segment of IgE and that induces apoptosis of IgE-expressingB-cells in combination with a therapeutically effective amount of atleast one drug selected from the group consisting of: anti-IgE antibody,antihistamine, bronchodilator, glucocorticoid, NSAID, decongestant,cough suppressant, analgesic, TNF-antagonist, integrin antagonist,immunosuppressive agent, IL-4 antagonist, IL-13 antagonist, dualIL-4/IL-13 antagonist, DMARD, antibody that binds to a B-cell surfacemarker and BAFF antagonist. In a specific aspect, the antibodyspecifically depletes IgE-producing B-cells.
 51. A method of treating anIgE-mediated disorder comprising a combined treatment regimen ofadministering a therapeutically effective amount of an anti-IgE/M1′antibody that specifically binds to the M1′ segment of IgE and thatinduces apoptosis of IgE-expressing B-cells prior to, simultaneous withor after the administration of a known method of treatment for allergicdisorders.
 52. The method of claim 51, wherein the known treatment forallergic disorder comprises the administration of an anti-IgE antibodyantihistamine, a bronchodilator, a glucocorticoid, a non-steroidalanti-inflammatory drug, an immunosuppressant, a IL-4 antagonist, a IL-13antagonist, a dual IL-4/IL-13 antagonist, a decongestant, a coughsuppressant or an analgesic.
 53. The method of claim 51, wherein theknown treatment for allergic disorder comprises a treatment regimen ofallergen densitization.
 54. A method for preventing allergen-induced IgEproduction, comprising administering a therapeutically effective amountof an anti-IgE/M1′ antibody that that specifically binds to the M1′segment of IgE and induces apoptosis of IgE-expressing B-cells.
 55. Amethod for reducing allergen-induced IgE production, comprisingadministering a therapeutically effect give amount of an anti-IgE/M1′antibody that that specifically binds to the M1′ segment of IgE andinduces apoptosis of IgE-expressing B-cells.
 56. A murine hybridomadeposited at the ATCC on Mar. 21, 2007 selected from the groupconsisting of: PTA-8260, PTA-8261, PTA-8262, PTA-8263, PTA-8264,PTA-8265, PTA-8266, PTA-8267, PTA-8268, PTA-8269, PTA-8270.
 57. Anantibody that is secreted by the hybridoma of claim
 52. 58. A transgenicanimal that expresses the human M1′ segment of IgE.